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Abstract 
Jembrana disease is an acute disease of Bali cattle (Bos javanicus) in Indonesia 
caused by Jembrana disease virus (JDV), a lentivirus most closely related to Bovine 
immunodeficiency virus. Control of the disease in Bali cattle, which are important to 
the economy of Indonesia, is dependent on the continued availability of protein 
antigens for immunosurveillance procedures that have been developed. Further 
investigation is also required to characterise of the proteins of JDV and to provide 
methods of producing commercial quantities of recombinant proteins for vaccine 
manufacture. 
A problem with the large scale production of viral proteins using recombinant 
technology was that the proteins have been mainly produced as insoluble products 
within inclusion bodies in bacterial cells and in that insoluble format they were 
unsuitable for use as antigens. A method for solubilisation of the insoluble proteins 
was developed that involved solubilisation of the inclusion bodies with low 
concentrations of urea in an alkaline solution and the method could be performed 
easily and at low cost without any detectable loss of antigenicity. The solubilised 
protein was successfully renatured without the formation of aggregates by dilution of 
the urea in the presence of the reducing agent dithiothreitol. The method would be 
suitable for use during the large scale production of recombinant viral proteins for 
vaccine manufacture. 
To provide an additional reagent for diagnosis of the disease, mice were immunised 
with the recombinant capsid (CA) protein of JDV and a hybridoma was produced 
that secreted monoclonal antibodies reactive with the CA protein. This monoclonal 
antibody was effectively used in an immunoperoxidase assay to demonstrate virus 
in tissues. As an alternative to this technology, recombinant antibody fragments, 
scFv, reactive with the CA protein of JDV, were also produced by phage display 
technology. These scFv were expressed as soluble products in the periplasmic 
space of transfected host bacterial cells. The scFv reacted specifically with the CA 
protein in western immunoblots and although further optimisation of the methods of 
production of this scFv are required, the reagents developed can be for expression 
of the antibody when required, without the need for maintaining liquid nitrogen 
storage facilities that are necessary for storage of hybridomas. 
The size and nature of the glycosylation of the envelope proteins SU and TM of JDV 
harvested from infected cattle was determined. Two proteins of 75 and 60 kDa were 
initially identified in SDS-PAGE as the SU and TM, respectively. They were initially iii 
 
identified using a specific glycoprotein stain and then matrix-assisted laser 
desorption/ionisation-time of flight (MALDI-TOF) mass spectrometric (MS) analysis 
of the protein sequence. Further investigation on the unmatched mass value from 
MALDI-TOF/MS data suggested that post-translational glycosylation occurred on N-
linked glycosylation sites of the JDV-SU and on O-linked glycosylation sites of the 
JDV-TM. This is the first report of the characteristics of the envelope proteins of JDV 
and their identification will facilitate further studies of the nature of the immune 
response to JDV infection using immunoblotting procedures. iv 
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Chapter 1 
General introduction 
Cattle in Indonesia, and especially Bali cattle (Bos javanicus), contribute to poverty 
reduction by improving efficacy in integrated farming systems. They are used as 
draught animals for rice production, for meat production, for grazing on land otherwise 
not used, and via manure contribute to soil fertility.  The utilisation of cattle as draft 
power enables smallholder farmers to double food production from their available 
land.  While Bali cattle have a number of advantages under Indonesian conditions, 
and have been widely distributed throughout Indonesia, they have disadvantages.  
A major disadvantage is their unique susceptibility to Jembrana disease and this 
disease is therefore a major threat to the success of the various Bali cattle 
distribution programs and consequently to the attempts to increase food production 
in Indonesia. 
The discovery that Jembrana disease is caused by Jembrana disease virus (JDV) a 
lentivirus most closely related to Bovine immunodeficiency virus has led to the 
development of a variety of diagnostic reagents and a tissue-derived vaccine that in 
turn have led to better control of the disease. Molecular biological methods offer 
extensive promise for improvement in the initial diagnostic reagents and vaccines 
that were developed. The aims of the research reported in this thesis were to 
improve the methods developed previously for the production of recombinant 
proteins for antigens and for vaccine production, the development of monoclonal 
antibody (MAb) reagents for diagnostic techniques, and further characterisation of 
the envelope proteins of JDV that would enable enhanced diagnostic methods. As a 
background to these investigations, a review of Jembrana disease and JDV, and a 
review of literature related to the production of recombinant proteins, MAb and post-
translational glycosylation of viral proteins was undertaken and is incorporated in 
Chapter 2. 
Recombinant proteins of JDV have been produced for many years with a bacterial 
expression system but a major problem during their production by this system has 
been their production as insoluble proteins within inclusion bodies, and there has 
been minimal production of soluble protein, resulting in poor yields of protein. To 
increase yields, a method of solubilisation of the insoluble recombinant surface unit 
(SU) and capsid (CA) proteins of JDV was investigated, which would potentially 
increase the yield of these and other proteins produced by this expression system 2 
 
and enable their use as antigens in immunological assays and as experimental 
vaccines. The results of this investigation are reported in Chapter 3. 
A MAb against the CA protein of JDV has been produced previously and this has 
provided extremely useful reagents for the development of diagnostic assays for the 
detection of JDV. Unfortunately, maintenance of the hybridomas in Indonesia has 
been difficult due to lapses in the supply of liquid nitrogen and the hybridoma was 
lost.  It was also hypothesised that additional MAbs against the envelope 
glycoproteins (SU and TM) could provide a means of identifying the size of the 
glycosylated SU and TM glycoproteins of JDV in SDS-PAGE gels. Attempts were 
therefore made to produce additional MAb by conventional hybridoma technology 
and these results are reported in Chapter 4. Recent developments in combinatorial 
antibody libraries combined with the display of functional antibody fragments at the 
tips of filamentous phage, known as phage display system, allows direct selection of 
highly specific MAbs from naive combinatorial antibody libraries. It was 
hypothesised that this technology would lead to the selection of stable clones that 
could be used to express MAbs in a bacterial expression system and overcome 
problems of long-term storage of hybridomas. Attempts were therefore made to 
produce recombinant antibodies against the SU and CA protein of JDV using the 
Tomlinson I and J libraries, and these investigations are described in Chapter 5. 
Successful production of MAbs against the CA proteins was achieved but was not 
successful against the envelope proteins of JDV. Therefore, to identify these 
proteins in native JDV preparations, an attempt was made to characterise 2 
glycosylated proteins present in JDV by mass spectrometric analysis and these 
results are described in Chapter 6. Additional analysis of the mass spectrometric 
data for 2 glycosylated proteins of 75 and 60 kDa, that were identified as SU and 
TM, were undertaken to determine the nature of their polysaccharide moieties and 
these results are also reported in Chapter 6. 
A general discussion of the research results reported in the thesis and 
recommendations for future research related to these results are presented in 
Chapter 7. 3 
 
Chapter 2 
Review of the literature 
 
This Chapter contains a review of the literature relevant to the research undertaken 
and reported in this thesis, which concerns the development of reagents for the 
diagnosis and control of Jembrana disease and further characterisation of the 
envelope glycoproteins of the bovine lentivirus, Jembrana disease virus (JDV). This 
review is arranged into several sections: an initial section providing background 
information on the family Retroviridae (retroviruses); a section on the bovine 
lentiviruses including JDV and Bovine immunodeficiency virus (BIV); a section 
describing technical aspects of the production of soluble recombinant viral proteins; 
a section describing the technical aspects of the production of monoclonal antibody 
using conventional and recombinant techniques. 
 
2.1  Characteristics of the Retroviridae 
The family Retroviridae comprises a large group of viruses that have been detected 
in many vertebrate species.  They have shared structural and genomic features and 
similar modes of reproduction but vary considerably in the type of disease with 
which they are associated. 
All retroviruses have a genome consisting of 2 identical strands of single-stranded 
RNA enclosed within a protein coat (capsid) which is again enclosed by a lipid 
envelope.  The viral envelope is formed from the plasma membrane of the cell as 
the virus is released from the cell and it contains virus-encoded glycoproteins 
important in attachment and penetration of the virus into the cell (Temin & Mizutani, 
1970). 
The retroviruses are unique in that their replication requires a reversal of the normal 
flow of genetic information. In all living organisms and many viruses, genetic 
information is stored as DNA and later transcribed into RNA, which serves as a 
template for protein synthesis. In contrast, retroviruses store their genetic 
information as RNA and they also contain the unique enzyme, reverse transcriptase 
(RT) that catalyses the reverse transcription of the RNA genome into DNA. All 
retroviruses contain 3 major open reading frames designated, from the 5’– to 3’- 
ends of the genome, gag, pol and env genes that are translated as polyproteins: 4 
 
gag encoding the core proteins, which include the matrix (MA), the capsid (CA) and 
the nucleocapsid (NC), pol encoding the enzymatic proteins RT, integrase (IN) and 
protease (PR), and env encoding the envelope surface unit (SU) and 
transmembrane (TM) glycoproteins. The SU contains the determinants that interact 
with the host cell receptor and coreceptor, while TM not only anchors the SU/TM 
complex in the membrane but also contains domains that are critical for catalysing 
the membrane fusion reaction between viral and host lipid bilayers during virus 
entry. Human immunodeficiency virus (HIV) is one of the members of this family and 
a detailed understanding of the molecular biology of HIV is available in the review 
by Wang et al. (2000). 
The replication of retroviruses is divisible into early and late phases (Turner & 
Summers, 1999) as depicted in Figure 2.1. Retroviruses recognise potential host 
cells through specific interactions between a host cell receptor and the viral 
envelope membrane glycoprotein SU. The main receptor for HIV-1 and HIV-2 is 
CD4 on T lymphocytes whilst the main co-receptors are the α-chemokine CXCR4 
and the β-chemokine CCR5 (Dragic et al., 1996). After binding, fusion of the viral 
envelope with the cellular membrane occurs directly at the cell surface releasing the 
virus core into the cytoplasm of the cell (early phase). In the late phase of 
replication, the viral genome is reverse transcribed, via the action of RT, into 
double-stranded DNA and integrated into the genome of the host cell where it 
resides permanently as the “provirus”. Viral protein is expressed from spliced 
messenger RNA transcripts of the proviral DNA and some such as SU and TM 
require post-translational glycosylation; these glycoproteins are incorporated into 
regions within the plasma membrane where the viral RNA genome is packed into 
capsids that bud from the membrane along with the viral envelope proteins. The 
cell-free particles undergo a further maturation process before they are capable of 
productive infection in appropriate target cells. 
 5 
 
 
 
Figure 2.1. Schematic diagram illustrating the features of the retrovirus 
replication cycle. Following recognition of a specific cellular receptor by the viral 
envelope glycoprotein and adsorption of the virion to the cell surface, the viral 
core is released into the cell cytoplasm. The viral RNA is uncoated and reverse 
transcribed into a double-stranded DNA. The integrated provirus uses a 
combination of viral and cellular transcription factors to replicate new copies of 
its RNA genome. Some of these viral RNAs are exported to the cytoplasm to 
serve as new viral genomes, however a percentage of the viral RNA is spliced 
into smaller mRNA species that are translated by the host cell ribosomal 
machinery. The viral regulatory proteins Tat and Rev tightly control transcription 
and transport of viral mRNA to the cell cytoplasm and both proteins are 
essential for retrovirus replication. Figure from Turner & Summers (1999). 
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Taxonomy 
The retroviruses are subdivided into 7 genera: Alpharetrovirus, Betaretrovirus, 
Gammaretrovirus, Deltaretrovirus, Epsilonretrovirus, Spumavirus and Lentivirus 
(Table 2.1). Previously, these viruses were grouped according to the nature of the 
diseases they produced and their electron microscopic appearance within infected 
cells and the core in the mature virus: concentric nucleocapsids were attributed to 
alpharetroviruses, gammaretroviruses, deltaretroviruses and spumaviruses; a rod or 
truncated cone-shaped core was characteristic of lentiviruses and betaretroviruses. 
 
Table 2.1. Genera in the family Retroviridae and their principal hosts and associated 
disease. 
Genus  Type species  Hosts  Genome 
of type 
species 
Pathological 
features of disease 
References 
Alpharetrovirus  Avian leukosis 
virus (ALV) 
Avian  7200 bp 
 
Oncogenic  (Venugopal, 1999) 
Betaretrovirus  Mouse mammary 
tumor virus 
(MMTV) 
Mammalian  8805 bp 
 
Oncogenic  (Cardiff & 
Wellings, 1999) 
Gammaretrovirus  Murine leukemia 
virus (MLV) 
Mammalian  8256 bp  Oncogenic  (Chesterman 
et al., 1966) 
Deltaretrovirus  Bovine leukemia 
virus (BLV) 
Mammalian  8000 bp  Oncogenic  (Van der Maaten 
et al., 1982, 
Willems et al., 
2000) 
Epsilonretrovirus  Walleye dermal 
sarcoma virus 
(WDSV) 
Fish  12700 bp 
 
Oncogenic    (Holzschu et al., 
2003, Holzschu 
et al., 1995, 
Zhang et al., 
1996) 
Lentivirus  Human 
immunodeficiency 
virus (HIV) 
Humans  9869 bp 
 
Lymphocyte-tropic 
associated with 
immunosuppression 
Macrophage-tropic 
strains associated 
with arthritis, 
pneumonia, 
encephalitis, 
anaemia 
(Weber, 1989) 
Spumavirus  Human 
spumavirus 
Simians  13246 bp 
 
Subclinical 
infections 
(Kupiec et al., 
1991) 
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Pathogenicity 
The retroviruses may also be divided into 3 groups according to their pattern of 
pathogenicity: the oncogenic retroviruses or oncoviruses, many of which are 
associated with leukaemias and sarcomas; the spumaviruses that do not seem to 
be associated with any disease; lentiviruses, many of which are associated with 
immunodeficiencies, but some of which are associated with neurological lesions, 
some with arthritis and some with pneumonia (Weiss, 1996). 
Most retroviruses are transmitted laterally but the oncoviruses or cancer causing 
viruses may also be transmitted vertically by integration of the provirus into the 
genome of germ cells (Mims, 1981). The proviral form of these oncoviruses can be 
associated with transformation of the host cells into cells that have a tumour 
producing potential (Maeda et al., 2008). 
Retroviruses characteristically persist in infected animals for the life of the animal 
(Wells & Poiesz, 1990).  Some produce clinical disease only after prolonged 
incubation periods, some produce intermittent clinical disease associated with 
reactivation of virus and expression of clinical disease after periods of latency 
(Meiering & Linial, 2002).  During the periods of latency the virus may be detectable 
but it is often difficult to detect because it is present at only low levels, necessitating 
indirect means such as the detection of antibody for the recognition of virus 
infection. 
In the period of clinical latency following HIV infection, there is still detectable virus 
in the peripheral blood; it was suggested that this virus is derived from infected 
CD4+ lymphoblasts that have reverted to a resting memory state (Marcello, 2006). 
In FIV infection, it was suggested that CD4(+)CD25(-) cells provide latent viral 
reservoirs for FIV infection and CD4(+)CD25(+) represent ideal candidates for a 
productive FIV infection (Joshi et al., 2005a, Joshi et al., 2005b, Joshi et al., 2004). 
In Equine infectious anaemia virus (EIAV) infections, the proviral DNA was present 
in tissues regardless of disease status, particularly in macrophages that are the 
primary cellular reservoir and site of viral replication of EIAV (Oaks et al., 1998). 
Latency is not unique to retrovirus infections and is also seen in other virus types 
such as herpesviruses. However, the mechanism of latency or persistence of the 
virus in these groups differs from that in retroviruses.  Herpesviruses persist 
between periods of clinical disease in lymphoid cells or in ganglionic neurons of the 
peripheral nervous system.  For example, Bovine herpes virus type-1 (BHV-1) 
localises and persists in ganglionic neurons of the peripheral nervous system 8 
 
(Jones et al., 2006) and in germinal centres of pharyngeal tonsil (Winkler et al., 
2000). The virus within these sites exhibits limited replication: nested reverse 
transcription-PCR (RT-PCR) on latently infected cattle showed a few cells contained 
latency-related transcripts but not other immediate-early, and late transcripts 
(Winkler et al., 2000). Latency has also been detected in the circulating lymphocyte 
of Bovine papillomavirus-1 infected cattle (Campo et al., 1994) and in neoplastic 
and non-neoplastic tissues of horses (Carr et al., 2001). Reactivation of viral 
expression after periods of latency is often indicated by the appearance of infectious 
virus at the site of the initial infection in an immune host.  
 
Lentiviruses 
The lentiviruses can be divided into 4 groups (Table 2.2) on the basis of the host 
with which they have evolved: primate (including the 2 human virus types, HIV-1 
and HIV-2, and multiple Simian immunodeficiency virus [SIV] types), equine (EIAV), 
feline (Feline immunodeficiency [FIV]), ruminant lentiviruses including bovine 
(including BIV and JDV), and small ruminant lentiviruses infecting sheep (Maedi-
visna virus [MVV]) and goats (Caprine arthritis encephalitis virus [CAEV] (Clements 
& Zink, 1996). 
Lentiviruses, like other retroviruses, contain the obligatory major open reading 
frames gag, pol and env. The gag open reading frame encodes a precursor 
polyprotein (Gag) that is cleaved to form the non-glycosylated structural proteins 
MA, CA and NC.  The NC is associated with the viral RNA genome and required for 
packaging RNA into the virion (Coffin, 1979, Coffin, 1992).  NC is also essential for 
the 2 obligatory strand transfers during viral DNA synthesis via promotion of primer 
binding site homo-dimer (Egele et al., 2004, Huthoff & Berkhout, 2001).  The CA 
forms the core of the virion, it is the most immunodominant viral protein (Coffin, 
1979, Coffin, 1992) and the conserved C-terminus of the CA is important in virion 
assembly and release (Melamed et al., 2004). 
The pol open reading frame encodes 3 enzymatic proteins, RT, IN and PR that are 
utilised during the replication process. RT is essential for the transcription of the 
viral RNA genome to a dsDNA intermediate or provirus (Temin, 1993).  IN is an 
essential protein involved in incorporation of the provirus DNA into the host cell 
genome, and PR is vital for the cleavage of the viral polyproteins into individual 
subunit proteins during virus replication (Coffin, 1979, Coffin, 1992). 
Table 2.2. Principle distinguishing characteristic of viruses in the genus Lentivirus 9 
 
Group  Species  Host  Genome 
size/accessory 
genes 
Tropism/disease  Reference 
Primate 
group 
Human 
immunodeficiency 
virus (HIV) 
Humans  9869 bp 
 
Primarily 
lymphocyte-
tropic/acquired 
immunodeficiency 
syndrome 
(Weber, 
1989) 
  Simian 
immunodeficiency 
virus (SIV) 
Non-
human 
primates 
8816 bp  Primarily 
lymphocyte-
tropic/acquired 
immunodeficiency 
syndrome 
(Ringler 
et al., 
1988, 
Stephens 
et al., 
1997) 
Ruminant 
group 
Caprine arthritis-
encephalitis virus 
(CAEV) 
Goat  9065 bp  Macrophage-
tropic/arthritis, 
encephalitis and 
pneumonia  
(Olsen, 
2001) 
  Maedi-visna virus 
 
Sheep  9203 bp  monocyte/macro-
phage-tropic/ 
pneumonia, arthritis 
and mastitis 
(Sargan 
et al., 
1991) 
  Bovine 
immunodeficiency 
virus (BIV) 
Cattle  8482 bp  Lymphocyte and 
macrophage-
tropic/possible 
immunosuppression 
(Gonda 
et al., 
1994) 
  Jembrana 
disease virus 
(JDV) 
Cattle  7732 bp  Lymphocyte-
tropic/acute disease 
affecting  
(Wilcox 
et al., 
1995) 
Feline 
group 
Feline 
immunodeficiency 
virus (FIV) 
Domestic 
and large 
cats 
9891 bp  Primarily 
lymphocyte-
tropic/acquired 
immunodeficiency 
syndrome 
(Parodi et 
al., 1994, 
Pecon-
Slattery 
et al., 
2008) 
Equine 
group 
Equine infectious 
anaemia virus 
(EIAV) 
Horse   8249 bp 
- lacks gene 
encoding Vif, 
but contains 
gene S2 
Macrophage-tropic 
/intermittent 
anaemia 
(Olsen, 
2001, 
Yoon 
et al., 
2000) 
 
 
In lentiviruses, the polyprotein Env is translated and subsequently glycosylated in 
the endoplasmic reticulum where it also oligomerises (Chan et al., 1997). In the 
golgi, the attached oligosaccharides are processed and the glycoprotein is 
proteolytically cleaved into 2 subunits, the SU and TM, by a cellular PC6 protease of 10 
 
the subtilisin-like pro-protein convertase family. The glycoprotein complex is 
subsequently transported to the plasma membrane via the secretory pathway 
(Miranda et al., 2002). The TM subunit anchors the SU subunit to the viral surface 
via a disulphide bond and together they form a homotrimer, which is situated on the 
surface of viral particles. The external SU subunit determines receptor specificity 
while the TM subunit is responsible for the fusogenic process during entry (Eckert & 
Kim, 2001). 
The lentiviruses possess unique properties that differentiate them from other 
retroviruses, including their ability to infect both dividing and non-dividing cells 
(Lewis et al., 1992, Weinberg et al., 1991) and by their possession of additional 
accessory genes important in their replication.  In addition to the major open reading 
frames, lentiviruses have 2 regulatory genes and up to 4 accessory genes, the 
number varying with the species of lentivirus, making them the most complex 
members of the retroviruses. The regulatory and accessory genes are located 
mainly between the pol open reading frame and the 3’ end of the genome, and may 
include genes designated tat, rev, vif, nef, tmx, vpu, vpr, vpx, vpw, vpy, S2 and orfA.  
They collectively regulate viral transcription, translation, and aspects of viral 
pathogenicity (Cullen, 1991). 
The primate lentiviruses are the most complex of all retroviruses, possessing at 
least 6 accessory genes including tat, rev, vif, vpr, vpx or vpu and nef (Tristem et al., 
1992).  All lentiviruses possess tat and rev, which are expressed from multiply 
spliced transcripts, encode trans-acting regulatory proteins, and are essential for 
viral replication (Dorn et al., 1990, Gonda, 1992, Narayan, 1990).  Most lentiviruses 
also possess vif, which is expressed from a singly spliced transcript, and encodes a 
virion-associated protein also essential for viral replication (Schrofelbauer et al., 
2004, Volsky et al., 1995). 
 
2.2  Bovine lentiviruses 
2.2.1 Jembrana disease virus  
History 
Jembrana disease is an economically important infectious disease of Bali cattle that 
emerged for the first time in the latter months of 1964 in the Jembrana district of 
Bali, Indonesia (Pranoto & Pudjiastono, 1967). This outbreak spread throughout the 
island over the ensuing 12 months and then the prevalence waned, perhaps a 11 
 
consequence of herd immunity, and it was not reported again for several years.  
Second and the third outbreaks of Jembrana disease were subsequently detected 
that included one in the Tabanan district in 1972 and one in the Karangasem district 
in 1981 (Hardjosworo & Budiarso, 1973, Putra et al., 1983). Despite attempts to 
implement quarantine measures to prevent the movement of cattle from Bali, the 
disease has subsequently spread to some other Indonesian islands: Lampung 
province in South Sumatra (Soeharsono & Darmadi, 1976); the Banyuwangi district 
of East Java (Tranggono, 1988); the Sawahlunto district of West Sumatra (Tembok, 
1992); in the 1990s in South Kalimantan and then to West and East Kalimantan 
(Hartaningsih, personal communication). The initial occurrence of the disease in 
these areas was associated with high mortality rates and has since become 
endemic with lower mortality rates (Soeharsono, 1997). 
 
Clinical features of Jembrana disease  
The disease can be readily transmitted to naïve cattle by the inoculation of tissues, 
including blood and lymphoid tissues, from affected cattle; high titres of infectious 
virus are present in the plasma and spleen of affected animals during the course of 
the acute disease (Soeharsono et al., 1990).  Experimental transmission studies 
have confirmed field observations that the disease is an acute (transient) febrile 
condition with characteristic clinical findings during the acute disease process 
including anorexia, lethargy, fever, erosions of the oral mucous membranes and 
enlargement of superficial lymph nodes. Other clinical signs less consistently 
observed were hypersalivation, a nasal discharge, diarrhoea with blood in the 
faeces and pallor of the mucous membranes (Soeharsono et al., 1990, Soesanto et 
al., 1990).  In experimentally infected cattle housed indoors the case fatality rate 
associated with infection by the Tabanan/87 strain was 17% (Soesanto et al., 1990).  
Recovered cattle are viraemic for at least 2 years after infection, possibly for the life 
of the animal, and are therefore an important potential source of infection for other 
cattle.  However, in animals that recover there are no reports of the recurrence of 
disease suggesting that these animals develop a solid immunity to infection.  
Marked haematological changes are detected in affected Bali cattle: leukopenia as 
a result of a lymphopenia, eosinopenia and neutropenia, thrombocytopenia, 
anaemia, increased blood urea concentrations and diminished total plasma protein 
levels; these changes occur principally during the febrile period (Soesanto et al., 
1990). Gross pathological changes include vascular damage such as mild exudates 12 
 
and haemorrhages, but the most striking changes are lymphadenopathy and 
splenomegaly.  Lymphoid tissues of all organs, particularly in the enlarged lymph 
nodes and spleen, feature proliferating lymphoblastoid cells predominantly 
throughout parafollicular (T-cell) areas, and atrophy of follicles (B-cell areas).  A 
proliferative lymphoid infiltrate is also found in the parenchyma of most organs, 
particularly the liver and kidneys and an infiltrate containing proliferative 
macrophage-like cells is found in the lungs (Dharma, 1997). 
Jembrana disease virus appears to have a particular affinity for Bali cattle and it is 
only in this species that severe lesions and case fatalities appear to occur 
(Soeharsono et al., 1995a).  Other cattle types and buffalo, however, can be 
infected experimentally and become infected under field conditions.  Bos taurus, 
Bos indicus and crossbred Bali (Bos javanicus x Bos indicus) cattle and buffalo 
develop disease and a persistent viraemia (Soeharsono et al., 1995a).  The clinical 
changes and lesions that occur in these cattle types are consistent with those 
observed in Bali cattle, but they are much milder and would be more difficult to 
detect under field conditions (Wilcox et al., 1995). 
Although only limited studies of the disease in Bos taurus have been conducted, the 
studies have indicated that the effects of infection in Bos taurus are less severe than 
in Bos javanicus. Infection of Friesian cattle induced an acute disease after a short 
incubation period of about 4 days.  Clinical signs were fever and concurrent 
lymphadenopathy.  Haematological changes included leukopenia as a result of 
lymphopenia, neutropenia and thrombocytopenia (Soeharsono et al., 1995a).  
Increased blood urea concentration and signs of anaemia consistently detected in 
Bali cattle were not detected in Friesian cattle.  Histological lesions consistent with a 
mild form of Jembrana disease in Bali cattle were detected in some infected 
animals.  However, while there was follicular atrophy until 5 weeks after infection in 
the spleen and lymph nodes of Bali cattle  
 there was a marked follicular response in 
the spleen and lymph nodes of one Friesian animal in the immediate post-febrile 
period (Soeharsono et al., 1995a). Friesian cattle experimentally infected with JDV 
had no parafollicular proliferation of mononuclear cells in intestinal lymphoid tissue 
or haemorrhagic lesions (Soeharsono et al., 1995a). 
Since the first outbreak of Jembrana disease in 1964, there have been several 
hypotheses regarding the cause of the disease. The condition was initially 
considered to be caused by rinderpest virus (Adiwinata, 1968, Pranoto & 
Pudjiastono, 1967). Another theory was subsequently developed that the disease 
was caused by a rickettsia-like agent (Hardjosworo & Budiarso, 1973) and this 13 
 
persisted until the disease was demonstrated to be caused by a retrovirus (Wilcox 
et al., 1992) and subsequent sequence analysis confirmed it was a lentivirus, most 
closely related to BIV (Chadwick et al., 1995b, Lu et al., 2002a). 
 
Genome of JDV  
The genome of the Tabanan/87 strain of JDV, the only strain that has been 
completely sequenced, is 7732 bp.  A schematic representation of the genome of 
JDV is shown in Figure 2.2 and the molecular characteristics of the JDV proteins 
(Chadwick et al., 1995b) are shown in Table 2.3.  
 
Table 2.3. Predicted characteristics of protein products encoded by the JDV 
genome. Data sourced from Chadwick at al. (1995b).   
Coding area gene 
product 
Protein  Number of amino 
acid residues 
Predicted Mr 
(kDa) 
Gag  Matrix (MA)  125  14.3 
  Capsid (CA)  226  25.3 
  Nucleocapsid (NC)  85  9.2 
Gag/Pol 
Precursor 
  1432  163 
Pol precursor    1027  118 
Env  Surface unit (SU)  422  47.8 
  Transmembrane (TM)  359  41.1 
Vif    197  22.9 
Tat    97  10.7 
Rev    213  23.8 
Tmx    164  18.5 
 
The accessory genes of the bovine lentiviruses are less complex than that of the 
primate lentiviruses.  JDV contains 4 small putative accessory genes designated vif, 
tat, rev and tmx  that correspond to the accessory genes detected in BIV and are 
assumed to have similar functions in both viruses (Chadwick et al., 1995a).  While 
the functions of the HIV-1 accessory genes have been extensively investigated and 
reviewed (Cullen & Greene, 1990), in both bovine viruses their functions remain 
largely uncharacterised. It is known that JDV Tat is very potent and can strongly 
activate not only its own
 long terminal repeat (LTR) but also the HIV LTR. In 14 
 
contrast, HIV Tat cannot reciprocally activate
 the JDV LTR (Chen et al., 1999) and 
JDV Tat can functionally
 substitute for HIV Tat (Chen et al., 2000).  Like HIV Tat, 
JDV Tat 
 transactivates the HIV LTR at least partially in a TAR-dependent
 manner. 
However, the sequence in the loop region of TAR was not
 as critical for the function 
of JDV Tat as it was for HIV Tat (Chen et al., 2000).
  The BIV vif (Oberste & Gonda, 
1992) like the HIV-1 vif (Goncalves et al., 1996) facilitates the infectivity and spread 
of virus.  
 
Figure 2.2. The JDV genome resembles that of BIV and HIV type 1 with the 
typical 5’ to 3’ gag, pol and env gene organisation. It contains also the 
regulatory protein encoding genes between or overlapping the pol and env 
reading frames. From Burkala (2001). 
 
 
Immunological reagents for the detection of bovine lentiviruses 
There are no reports of the successful replication of JDV in cell culture and methods 
of preparation of JDV proteins for antigens have been reliant on the extraction of 
proteins from infected cattle tissues or the use of recombinant DNA techniques.  
The JDV CA with 226 amino acid (aa) residues is a small and highly basic protein 
with an estimated Mr of 25.3 kDa that is abundantly expressed, as detected by 
SDS-PAGE and western immunoblotting techniques, in infected cells and can be 15 
 
harvested from virus present in the plasma of infected animals during the acute 
febrile phase of the disease (Kertayadnya et al., 1993). 
The development of antigens able to differentiate BIV and JDV has been 
problematic.  The expression of antigenic and immunogenic JDV CA and TM 
proteins as fusion proteins to the glutathione-s-transferase (GST) in Escherichia coli 
has been reported previously (Burkala et al., 1998). Both recombinant proteins 
reacted in western blots with JDV and BIV antisera. The Gag protein of JDV has 
been cloned (Desport et al., 2005) as a series of overlapping fragments and when 
analysed by western immunoblotting using JDV and BIV hyperimmune sera, the MA 
and CA were recognised by both sera and the NC did not react with either of the 
sera. This analysis suggested that the N-terminal domain of Gag might contain 
more antigenic epitopes than the C-terminal domain. 
Monoclonal antibodies (MAbs) against JDV have been produced by immunisation of 
mice with whole virus (Kertayadnya et al., 1993) and with recombinant JDV CA 
(Desport et al., 2005). Characterisation of these MAbs by determining their reactivity 
with different truncated Gag proteins of JDV by western immunoblotting (Desport et 
al., 2005) demonstrated that the antibodies produced from recombinant CA reacted 
with different epitopes compared with those produced by immunisation of mice with 
the whole virus. A BIV MAb that recognised epitopes specific to BIV was generated 
(Zheng et al., 2001). This MAb, designated 10H1, was produced using a 
recombinant fusion protein containing the CA of BIV. Based on the immunoreactivity 
of the BIV CA, 3 domains of antigenic importance were identified on the N-terminus 
of the protein and these domains were thought to be BIV-specific (Lu et al., 2002a, 
Zheng et al., 2001). Unfortunately, this region was recognised by JDV-positive sera 
(Desport et al., 2005). 
 
Biological and physiochemical properties of JDV 
The buoyant density of JDV purified from the plasma of infected animas was 1.15 
g/ml in sucrose gradients (Kertayadnya et al., 1993); the diameter of particles at this 
density in the gradients was determined by electron microscopy to be between 96 
and 124 nm (Kertayadnya et al., 1993). The virus in plasma derived from infected 
animals rapidly decline in infectivity at 4
oC but was stable at –70
oC (Kertayadnya et 
al., 1993).  
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Geographic distribution of Jembrana disease  
The population of Bali cattle represents 19% of the total cattle population of 
Indonesia (Talib et al., 2002). The total population of Bali cattle in 2000 in the 5 
major regions has been estimated as 718,000 in South Sulawesi, 443,000 in Nusa 
Tenggara Timur, 377,000 in Nusa Tenggara Barat, 529,000 in Bali and 255,000 in 
Lampung (Talib et al., 2002). There are other provinces with growing population 
such as in Southeast Sulawesi and East Kalimantan (Talib et al., 2002). The unique 
susceptibility of Bali cattle to both sheep-associated malignant catarrhal fever and 
also to Jembrana disease is of concern (Talib et al., 2002). 
Although precise reporting of cases of Jembrana disease is not undertaken in 
Indonesia, it was estimated that there were about 2,000 cases of Jembrana disease 
in Indonesia between 1989 and 1992 (Soeharsono, 1997). However, due to the 
difficulty of recognising and diagnosing the disease even by trained staff, and as 
milder non-fatal cases are unlikely to be reported, this is likely to be a gross 
underestimate. It is only when there are high case fatality rates in association with 
outbreaks that collection of data is likely. In 2000, 168 cases were reported, 331 
cases were reported in 2002 (Peternakan, 2002) and 116 cases were reported in 3 
provinces in 2003: 95 in Bengkulu, 2 in Lampung and 19 in South Sumatra. The 
most recent cases have been identified in the Long Ikis district of East Kalimantan 
(Hartaningsih et al., 2005) (Figure 2.3). 
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Figure 2.3. Distribution of Jembrana disease in Indonesia.  The areas where 
Jembrana disease is endemic include the areas denoted by flags: 1, Bali; 2, 
Banyuwangi; 3, Lampung; 4, Bengkulu; 5, West Sumatra; 6, South Kalimantan; 
7, East Kalimantan. The Data sourced from Soeharsono (1997) and 
Hartaningsih (2005). 
 
Transmission of Jembrana disease  
The mode of transmission of Jembrana disease under field conditions is not known 
but certain assumptions have been made based on the level of virus in blood at 
various stages of the disease process.  During the acute disease the titre of 
infectious virus in peripheral blood is about 10
8 per mL, and virus can also be 
detected in secretions.  During the acute disease, transmission probably occurs by 
2 methods: through direct transmission of virus in secretions between cattle in close 
contact, and through mechanical transmission of virus in the blood by 
haematophagous insects (Soeharsono et al., 1995b).  However, mechanical 
transmission of JDV by arthropods, as seems likely, has not been responsible for 
extensive spread of Jembrana disease from endemic to adjacent areas.  For 
example, the disease has not spread from Bali island to the adjacent islands of 
Nusa Penida and Lombok since the disease initially occurred in Bali in 1964 
(Wilcox, 1997).  Recovered Bali cattle are persistently viraemic but the titre of virus 
in blood by 60 days after recovery from the acute disease was only about 10 
infectious doses per mL, virus could not be detected in secretions during this phase, 
and mechanical transmission of these low levels of virus by haematophagous 
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insects was considered unlikely (Soeharsono et al., 1995b). Persistent infections in 
recovered animals are a potential source of infection but how the virus is transmitted 
from these animals is unknown.   
It has been revealed through epidemiological studies that the risk of transfer was 
intimately related to farming practices, and that an important risk factor was from 
contact transmission associated with JDV present in secretions, including saliva and 
possibly urine, and in lactating animals also in milk, during the acute febrile phase of 
the disease (Soeharsono et al., 1995b). 
 
Diagnosis of JDV infection 
The diagnosis of Jembrana disease has traditionally been based on clinical signs 
and the presence of characteristic pathological lesions in those animals that died, 
although diagnosis was difficult and diagnosis of the disease by these methods was 
often made only reluctantly. Hence the disease in East Java was initially referred to 
as Banuwangi disease, and in Lampung province in Sumatra it was referred to as 
Lampung disease (Soeharsono & Temadja, 1997). The development of an enzyme-
linked immunosorbent assay (ELISA) and western immunoblotting assays  for the 
detection of antibody to JDV in infected cattle (Hartaningsih et al., 1994) using a 
whole viral antigen prepared from the plasma of infected cattle enabled the 
distribution of the virus within Indonesia to be determined and consequent diagnosis 
of the disease in infected areas made with greater confidence.  The use of a 
recombinant JDV CA antigen (Burkala et al., 1998) removed reliance on the use of 
whole virus antigens prepared from infected cattle.  ELISA and western 
immunoblotting assays demonstrated that development of antibody against JDV in 
recently infected cattle was delayed (Hartaningsih et al., 1994, Wareing et al., 
1999).  
A major problem with the JDV serological assays that have been developed is that 
they cannot distinguish between antibody to JDV and BIV (Desport et al., 2005). 
There is a report that it is possible to differentiate antibody to BIV and JDV (Barboni 
et al., 2001) but attempts to confirm this were unsuccessful (Desport et al., 2005).  A 
further problem, investigated in Chapter 6 (this thesis), is that the size and other 
characteristics of the glycosylated envelope proteins have not been determined and 
these glycoproteins have not been identifiable in western immunoblots 
(Hartaningsih et al., 1994).  19 
 
In situ hybridisation (ISH) is commonly used to detect the presence of virus in 
tissues. Chadwick et al. (1998) used ISH with a digoxigenin (DIG)-labelled riboprobe 
to detect viral RNA of JDV in formalin-fixed paraffin-embedded tissue sections, 
concluding that JDV-infected cells were present in many tissues including spleen, 
lymph nodes, lungs, bone marrow, liver and kidney. 
The use of a quantitative PCR for JDV RNA detection in plasma samples has also 
been reported (Stewart et al., 2005). The assay had a detection limit of 4.2 x 10
4 
JDV genome copies per mL of plasma in experimentally infected cattle.  
A monoclonal antibody developed against the CA of JDV (Kertayadnya et al., 1993) 
has been used for the development of specific immunoperoxidase assays on frozen 
and formaldehyde-fixed tissues. 
 
2.2.2 Bovine immunodeficiency virus 
BIV was first isolated in cell cultures from a dairy cow in Louisiana that had 
lymphocytosis, lymphadenopathy, neuropathy, and progressive emaciation (Van der 
Maaten et al., 1972). Based on serological evidence, the virus has since been 
reported from cattle in several countries (Amborski et al., 1989, Forman et al., 1992, 
McNab et al., 1994). Although the virus in these other countries appears to be non-
pathogenic, the genetic relationship between the original BIV isolate and the virus in 
these other countries has not been determined. 
BIV resembles HIV and other lentiviruses in its structural, genetic, antigenic and 
biological properties (Gonda et al., 1987). The mature virions of BIV are bar-shaped 
and 120-130 mm in diameter. The BIV genome contains the obligatory retrovirus 
structural genes in the order gag, pol and env, flanked on the 5’ and 3’ ends by a 
LTR. The core protein of the virus is encoded by gag, which produces a 53 kDa 
precursor Gag protein that is further processed into MA (p17), CA (p26) and NC 
(p15) (Battles et al., 1992, Rasmussen et al., 1990) and 3 small proteins, p2L, p3 
and p2 (Tobin et al., 1994) in the mature virus (Gonda et al., 1994). 
The BIV complete nucleotide sequence consists of 8,482 nucleotides (Garvey et al., 
1990) while JDV has been reported to contain 7,732 nucleotides (Chadwick et al., 
1995b). Apart from the nucleotide number, the difference between the 2 bovine 
lentiviruses consisted of small deletions and insertions located throughout the 
genomes (Chadwick et al., 1995a).  
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2.3 Potential Jembrana disease vaccines  
Effective vaccines against a multitude of viral diseases have been produced by a 
range of methods including whole, live attenuated or inactivated pathogens, 
although the development of effective vaccines against lentiviruses has been 
difficult. Control of Jembrana disease within Indonesia will most likely require the 
development of not only efficacious vaccines but also vaccines of low cost. 
Attenuated viral vaccines are effective in stimulating both humoral and cellular 
immune responses (Young & Ross, 2003). They are usually attenuated in their 
pathogenicity so that they still have ability to replicate but without causing overt 
disease.  Disadvantages of this type of vaccine are that they can potentially revert to 
a virulent strain causing disease and they can be transmitted between individuals. 
Modification of the antigenic properties of live attenuated FIV vaccines improved the 
protection against FIV infection (Broche-Pierre et al., 2005). The close antigenic 
relationship between the non-pathogenic BIV and the pathogenic JDV (Desport et 
al., 2005) suggests that there may be some competitive interaction or cross-
protective immunity between these 2 viruses and prior infection of cattle with BIV 
might protect against subsequent JDV infection. 
Inactivated vaccines are safer than live attenuated vaccines because they cannot 
replicate in the host, although they are frequently less effective in inducing 
protective immunity (Chalmers, 2006, Ellis, 1999). Recently, a vaccine composed of 
inactivated FIV was used and induced high titres of antibody to the Env proteins 
(Hosie et al., 2005).  A whole virus tissue-derived inactivated JDV vaccine has been 
reported to induce a protective immunity against subsequent challenge with JDV but 
this vaccine has several potential disadvantages including high cost that it was 
inactivated with detergent and might therefore be contaminated with adventitious 
infectious agents, and it was not amenable to commercial production methods 
(Hartaningsih et al., 2001).  
During the last decade, recombinant subunit vaccines have emerged as a promising 
vaccine technology. A subunit vaccine can be produced in the form of synthetic 
peptides (Audran et al., 2005, Lopez et al., 2001), recombinant proteins or gene 
fragments (DNA or RNA) encoding the protein immunogens (Wang et al., 2006). By 
using a small and defined part of a pathogen and producing that subunit in a non-
pathogenic host, the safety of vaccines will increase.  
A potential target for a JDV vaccine is the envelope glycoproteins, and in a 
subsequent section of this review the literature examining methods by which such 21 
 
glycosylated proteins might be produced using recombinant DNA technology is 
reviewed.  
 
2.3.1 Recombinant protein vaccines 
The first recombinant subunit vaccine to be produced was licensed in 1986 when 
the Hepatitis B virus surface antigen (HbsAg) was successfully expressed in yeast 
and this then replaced the plasma-derived hepatitis B vaccine used previously 
(Valenzuela et al., 1982). This vaccine was initially tested and produced protective 
antibodies in vaccinated chimpanzees (McAleer et al., 1984). 
Recombinant DNA technology for the production of proteins potentially enables a 
large amount of high value protein, which is often in limited supply due to its low 
natural availability, to be produced. Several host systems are available for 
production of recombinant proteins: eukaryotic cells such as yeasts, filamentous 
fungi, insect cells, plants, mammalian cells and prokaryotes including bacteria such 
as Escherichia coli, Bacillus and Staphylococcus sp. Each host system has its 
advantages and disadvantages. The amount and quality of the produced 
recombinant proteins are influenced by factors such as gene copy number, 
transcription and translation efficiency, mRNA stability, stability and solubility of the 
proteins as well as post-translational modification (Liljeqvist & Stahl, 1999).  
The choice of expression system to be used will often depend on the characteristics 
of the protein required. The heterologous host used may affect the immunogenicity 
and protective efficacy of the protein. In practice, the choice is a combination of the 
ease of growing the host, immunogenic and antigenic characteristics of the protein, 
and yield and ease of purification of the protein. Several issues such as the gene 
construct, solubility of the protein expressed and the nature of the fusion tag that is 
often incorporated into the design of the plasmid, all have to be considered 
(Hockney, 1994). 
Escherichia coli has long been the primary prokaryotic host for heterologous protein 
expression, and there is a lot of information available about the use of this 
bacterium for the production of many different proteins. It has been successfully 
utilised to produce many functional human proteins such as human growth hormone 
(Singh & Panda, 2005), proinsulin (Winter et al., 2001), interferon-gamma 
(Khalilzadeh et al., 2003, Khalilzadeh et al., 2004) and antibody fragments (Santala 
& Lamminmaki, 2004). The advantages of E. coli include its relatively rapid growth, 
its utilisation of inexpensive cultural techniques, its ease of transformation and its 22 
 
ease of maintenance. Nevertheless, the use of E. coli also has major 
disadvantages: it is unable to perform post-translational modifications such as 
glycosylation, phosphorylation and disulfide bond formation, modifications which 
occur in eukaryotic cells; the expression and accumulation of a recombinant protein 
in E. coli  frequently causes the formation of insoluble protein aggregates (Clark, 
2001) and this raises issues concerning methods of subsequent solubilisation of the 
expressed protein. 
Expression in yeast such as Saccharomyces cerevisiae or Pichia pastoris offers 
advantages but also disadvantages in comparison to bacterial systems.  Many 
recombinant proteins have been produced on a large scale using S. cerevisiae, 
including human serum albumin (Kang et al., 2000, Okabayashi et al., 1991), the 
HbcAg (Chen et al., 2004, Yoshida et al., 1991), insulin and hirudin (Mendoza-Vega 
et al., 1994, Vai et al., 2000). Like E. coli, these unicellular eukaryotes grow rapidly 
in relatively inexpensive and simple media and they are easy to transform and 
maintain. Unlike E. coli, yeasts are eukaryotic and therefore express and process 
proteins in a similar way to higher eukaryotes (Cereghino et al., 2002, Cereghino & 
Cregg, 1999). The secretory pathway of yeasts closely resembles that of the 
mammalian cells, thus they are capable of many posttranslational modifications, 
although they are not capable of complex modifications such as prolylhydroxylation 
and amidation, and the glycosylation of proteins in yeast can differ from that of 
higher eukaryotes (Sudbery, 1996).  
The baculovirus expression system is commonly used to express heterologous 
proteins in insect cells (Kost & Condreay, 1999). Since insect cells are eukaryotic, 
proteins expressed will be post-translationally modified in a manner similar to that of 
mammalian cells (Kost & Condreay, 2002, Miller, 1993). Insect cells can be grown 
as suspension cultures, which enable the use of large scale bioreactors for easier 
production scale-up. Another significant advantage of insect cells is that unlike 
mammalian cells, they can be grown in medium that does not need to be 
maintained in CO2 incubators. The most commonly used baculovirus system utilised 
Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) (Jones & 
Morikawa, 1996, Lu et al., 2002b) in a cell line derived from lepidopteran 
Spodoptera frugiperda ovarian (Sf9) cells.  
Mammalian cell systems may be the only way to produce appropriately processed 
and active recombinant proteins. Gene transfer into mammalian cells may be 
performed either by infection with a virus carrying the recombinant gene of interest 
(Makrides, 1999) or by direct transfer of plasmid DNA (Geisse & Kocher, 1999). 23 
 
Recombinant vaccinia virus vectors have been successfully used for the expression 
of recombinant genes (Moss, 1996). Since vaccinia is infectious to humans, safety 
aspects must be taken into considerations. Problems with vaccinia systems include 
their cytopathic nature and dependence on efficient transfection rates (Moss, 1996).  
 
Post-translational modification of viral glycoproteins  
Post-translational modification is a common phenomenon in eukaryotic cells that is 
associated with the chemical modification of one or more aa in a protein chain. 
There are a number of modifications that may occur at the post-translational stage. 
Glycosylation is the most necessary of these modifications as it is important in 
secretion, antigenicity and clearance of glycoproteins (Jenkins et al., 1996). 
Glycosylation during post-translational processing requires the addition of 
carbohydrate structures, forming glycoproteins. The carbohydrate moieties of 
glycoproteins, called oligosaccharides or glycans, are composed of individual sugar 
residues or monosaccharides (Dell & Morris, 2001). Protein glycosylation is 
important for many cellular processes including cell interactions, protein interactions 
and protein folding.  It is especially vital for the proper positioning and function of 
surface receptors; glycosylation of the envelope proteins was shown to be a key 
factor in the ability of HIV to evade recognition by the immune system (Rudd et al., 
2001). The presence of N-linked carbohydrates on the FIV Env is important for the 
interaction of the virus and receptor (Willett et al., 2008). This is similar with both 
HIV and SIV. Mutations in the variable V1/V2 region of HIV SU affect the interaction 
between HIV SU and its receptor and co-receptor and alter the antigenicity of the 
envelope glycoprotein (Kolchinsky et al., 2001, Srivastava et al., 2003). 
There are 2 main classes of glycoproteins, N-linked and O-linked, based on the site 
of attachment of the carbohydrate to the polypeptide chain (Medzihradszky, 2005, 
Peter-Katalinic, 2005). N-linked glycans are attached to the protein only at the aa 
sequences NXS or NXT and are covalently linked to the asparagine (N) residue. In 
contrast, O-linked glycans are linked to any serine (S) or threonine (T) in the 
polypeptide chain. The role of N-linked and O-linked carbohydrates in the function of 
the viral envelope glycoproteins is different but poorly understood (Medzihradszky, 
2005). 
The glycans are monosaccharide residues and while there are approximately 20 
monosaccharide residues (Kobata, 1992), 5 types are common (Table 2.4). Glycans 
consist of one or more monosaccharide residues bonded by glycosidic bonds to 24 
 
form polysaccharide chains. The glycan structure can be linear or branched 
depending on the synthesis pathways (Marquardt & Denecke, 2003), making them 
vary in terms of size, structure and composition. The glycans found on mammalian 
N-linked glycoproteins have a common core composition of Glc3Man9GlcNAc2 (Dell 
& Morris, 2001). 
 
Table 2.4. The monosaccharides and additional residues found in glycoproteins. 
Data sourced from Kobata (1992). 
  Monosaccharide  Monoisotopic mass (Da) 
Hexose (Hex)  Glucose (Glc), Galactose 
(Gal), Mannose (Man) 
162.0528 
N-acetylhexosamine 
(HexNAc) 
N-acetylgalactosamine 
(GalNAc), N-
acetylglucosamine (GlcNAc) 
203.0794 
Deoxyhexose 
(DeoxyHex) 
Fucose (Fuc), Rhamnose 
(Rha) 
146.0579 
Pentose (Pent)  Arabinose (Ara), Xylose (Xyl)  132.0423 
Hexuronic acid (HexA)  Glucuronic acid (GlcA)  176.0321 
Acetyl (Ac)    42.0106 
N-glycolylneuraminic 
acid (NeuGc) 
  307.0903 
N-acetylneuraminic acid 
(NeuAc) 
  291.0954 
Phosphate    79.9663 
Sulfate    79.9568 
2-Keto-3-
deoxynonulosonic acid 
(KDN) 
  250.0689 
Methyl (Me)    14.0157 
 
 
Depending on the nature of the oligosaccharide chain, the glycan can be classified 
as oligomannose, complex or hybrid. Oligomannose glycans contain only mannose 
residues, whereas complex glycans have varied composition and a variable number 
of antennae stemming from the core. Hybrid types have the characteristic of both 
complex and oligomannose glycans (Dell & Morris, 2001). The structures of O-
linked glycans are less defined than that of the N-linked glycans. O-linked glycans 25 
 
are composed of 7 different cores, 4 of them are found in mammalian glycoproteins, 
with varied structures and compositions (Dell & Morris, 2001). 
The analysis of protein glycosylation remains difficult due to the complexity of the 
process and the heterogeneity of the structures that are formed. This heterogeneity 
arises from the variation in the use of the glycosylation sites on the protein and the 
variations in the monosaccharides used. The complexity is increased further as 
different cells, tissues, organs and organisms exhibit different glycosylation patterns 
(Rudd et al., 2001). Therefore, analysis of glycoproteins needs multiple analytical 
methods and requires several analytical steps and a large amount of sample that 
can make it a very expensive process. 
There are a few publicly available glycoprotein analysis tools.  GlycoSuiteDB is one 
of the few glycoprotein databases available on the internet and it has only been 
available since 2001 (Cooper et al., 2001b). It is a database that collates information 
on glycoproteins from the scientific literature only, and consequently there are only a 
small number of entries (Cooper et al., 2003). 
Another publicly available database is O-Glycbase maintained by the Centre for 
Biological Sequencing from the Technical University of Denmark. It is a database of 
O-linked glycoproteins only (Gupta et al., 1999). O-Glycbase is coordinated with 
NetOGlyc, a tool for predicting O-linked glycosylation sites (Julenius et al., 2005). 
Both GlycoSuiteDB and O-Glycbase are extensively cross-linked to various 
nucleotide and protein databases.  
GlycoMod is another tool that predicts possible oligosaccharide structures from their 
experimentally determined masses (Cooper et al., 2001a). 
The identification and characterisation of post-translational modifications has 
become achievable with improvements in mass spectrometry (MS). MS was 
formerly useful in organic chemistry for the analysis of low molecular weight 
molecules but with new methods of ionization of proteins and peptides, MS now 
permits analysis of proteins (Domon & Aebersold, 2006), high molecular weight 
carbohydrates (Mutenda & Matthiesen, 2006), and nucleotides (Banoub et al., 2005, 
Miketova & Schram, 1997) on a routine basis. MS has become the most powerful 
technique to determine the mass of a biomolecules and has several advantages 
over techniques like gel filtration or SDS-PAGE, principallly the high accuracy, high 
sensitivity, and speed (Domon & Aebersold, 2006). The major uses of MS for 
protein analysis were reviewed by (Mann & Pandey, 2001). 26 
 
Two desorption techniques, fast atom bombardment (FAB) (Dell et al., 1981) and 
plasma desorption (PD) (Maugh, 1985) initiated the development of new strategies 
for protein characterization by mass spectrometry. Although these two methods 
were successful, the breakthrough came with the development of matrix-assisted 
laser desorption/ionization (MALDI) (Hillenkamp et al., 1991) and electrospray 
ionisation (ESI) (Andersen et al., 1996, Gaskell, 1997, Ho et al., 2003). The 
techniques are fast, simple, and accurate, and have made mass spectometric 
analysis of biomolecules a routine analytical activity. MALDI has been coupled to 
many different mass analysers but is mostly coupled to a time-of-flight (TOF) 
analyser.  
For the localization of modifications and mutations or for identification by peptide 
mass fingerprinting, the protein needs to be fragmented into smaller peptides. The 
use of in-gel digestion (Huynh et al., 2009, Jimenez et al., 2001) is a good 
alternative for the generation of peptide fragments of a membrane protein. An in-gel 
approach has several advantages. First, only few materials are needed. Second, 
the purity of sample is not critically important because SDS-PAGE separates the 
protein of interest from contaminants. Third, the membrane protein is partially 
unfolded in SDS, providing better accessibility for the protease, whereas the 
denaturant is removed by washing the excised gel. Several examples have been 
published in which the identification of a modification was successful using a 
specific isolation procedure without having a complete peptide map (Lennon & 
Walsh, 1999, Qin & Chait, 1997, Tsur et al., 2005). 
Peptide mass fingerprinting is an identification method first described by James and 
Yates (James et al., 1993, Yates et al., 1993). The peptide mass fingerprinting 
method is based on the idea to divide a whole protein into smaller fragments to 
measure the mass of each fragment and to then use the resulting list of masses, ie. 
a fingerprint, to identify the protein. The analysed protein is then compared with a 
database of proteins, and for characterisation, ie. to detect which variant of an 
identified protein was analysed or if the protein was modified by post-translational 
modification (Cottrell, 1994, Wise et al., 1997). The peptide mass fingerprinting 
method is also widely used to identify and characterise unknown samples (Cottrell, 
1994, Wilkins et al., 1997). 27 
 
 
Selection of appropriate gene constructs for expression of proteins 
Selecting a minimal region of the protein required to elicit a strong immune 
response could reduce the length of the gene to be inserted into the expression 
vector and in some cases the gene needs to be truncated for the purpose of 
facilitating expression (Johne et al., 2004). Promoter sequences may also be altered 
to make production more efficient, especially in the case of toxic proteins (Chevalet 
et al., 2000). The secretion of expressed protein can be intracellular or directed into 
the medium or periplasm; secretion of the protein into the growth medium may 
protect the protein from cytoplasmic proteases and it can simplify the purification 
process. Extracellular production is often preferred to express proteins containing 
transmembrane regions (Sorensen & Mortensen, 2005) or that have a tendency to 
aggregate (Sorensen et al., 2004) as intracellular expression may lead to the 
formation of inclusion bodies, which requires solubilisation and refolding to obtain a 
soluble and active form. 
 
Formation of recombinant proteins within inclusion bodies  
Production of recombinant proteins by bacterial cells is usually the most convenient 
and cost-effective method of recombinant protein production and E. coli has 
become the most extensively used bacterial host.  It is a genetically and 
physiologically well-characterised organism that grows rapidly and requires simple 
medium but its use is also affected by 2 problems: overproduction of recombinant 
proteins leading to the formation of inclusion bodies, and protein degradation 
(Baneyx & Mujacic, 2004, Cabrita & Bottomley, 2004, Markossian & Kurganov, 
2004). Foreign proteins expressed in E. coli can contain regions that are recognised 
by specific host proteases, leading to cleavage and sometimes to subsequent 
degradation (Baneyx & Georgiou, 1990, Rozkov & Enfors, 2004). Inclusion bodies 
are very dense particulate amorphous structures (Bowden et al., 1991) that almost 
exclusively contain over-expressed proteins (Cabanne et al., 2005, Carrio et al., 
1998, Razeghifard, 2004, Rinas & Bailey, 1992, Sakono et al., 2004, Valax & 
Georgiou, 1993). Formation of inclusion bodies can be beneficial if the protein 
product is susceptible to host proteases or is toxic to the cells in its active form; in 
this case, inclusion bodies are advantageous and strategies for increasing inclusion 
body formation have been developed. Although recombinant proteins with 
secondary structure and native-like conformations have been found in inclusion 28 
 
bodies (Khan et al., 1998, Oberg et al., 1994) the proteins aggregated in inclusion 
bodies are normally inactive, unfolded or folded incorrectly and need refolding in the 
functional active format (Buchner & Rudolph, 1991, Misawa & Kumagai, 1999). The 
presence of high concentrations of the protein in inclusion bodies, however, up to 
95% of the mass of the inclusion body, can simplify downstream processing (Han et 
al., 2004, Lilie et al., 1998). Inclusion bodies can be easily removed from host cell 
proteins and debris by low speed or gradient centrifugation (Haelewyn & De Ley, 
1995, Taylor et al., 1986) or an expanded bed adsorption (Cabanne et al., 2005).  
Inclusion bodies form not only with expression of heterologous recombinant proteins  
but also from homologous proteins (Rudolph & Lilie, 1996), indicating that the 
formation is not specific for “foreign proteins“. The formation of Inclusion bodies is 
also not specific for E. coli since they have been found also in Bacillus subtilis 
(Wang et al., 1989), in yeast such as Saccharomyces cerevisiae (Binder et al., 
1991) and in mammalian cells (Broido et al., 1991). They can also form from 
proteins like ß-lactamase secreted into the periplasm (Chalmers et al., 1990). 
Reasons given for the formation of inclusion bodies include the heterologous nature 
of the protein (especially for proteins that require post-translational modifications), 
high protein synthesis rates, proteins with high hydrophobicity that aggregate 
intermolecularly as a result of non-covalent association, and a lack of available 
chaperones (Mukhopadhyay, 1997). Point mutations which change the 
hydrophobicity of a protein can alter the stability and solubility of the protein (Luck et 
al., 1992) and change considerably the amount of protein deposited in inclusion 
bodies (Wetzel et al., 1991). 
To produce a product from inclusion bodies that is similar to the native form, a 
renaturation strategy is required (Clark, 2001, Rudolph & Lilie, 1996). General 
strategies for recovering native proteins from inclusion bodies normally involve 3 
steps: (1) isolation of Inclusion bodies including washing several times to remove 
undesired co-precipitation proteins, (2) solubilisation of inclusion bodies in a strong 
denaturant such as urea or guanidinium chloride to break intermolecular 
interactions, and (3) renaturation of solubilised proteins by dialysis or dilution to 
remove the denaturant. For renaturation of proteins containing disulfide bonds, the 
supplementation of redox systems to the renaturation buffer is needed (Creighton, 
1986). These redox systems provide the appropriate redox potential to allow 
formation and reshuffling of disulfide bonds. 
This strategy to prepare soluble proteins from inclusion bodies is possible only for 
small proteins. Large multi-domain proteins normally fail to fold properly, often 29 
 
leading to kinetically trapped intermediates that aggregate, even in diluted solutions 
and at low temperature (Jaenicke & Bohm, 1998). Moreover, the folding process in 
vitro can take a long time, up to several days. Due to competition between 
aggregation and folding in vitro (Kiefhaber et al., 1991), the protein concentrations 
must be kept low. Thus, to get a given amount of soluble protein, large volumes of 
buffers are needed. The yield of protein refolding can be improved by coupling 
denatured proteins to a matrix (Stempfer et al., 1996), adding low molecular weight 
additives (Rudolph & Lilie, 1996), genetically engineering hydrophobic patches 
(Wetzel, 1994), shifting the temperature rapidly (Betts & King, 1998), or adding 
molecular chaperones (reviewed by (Thomas & Baneyx, 1997)). However, the 
yields are still likely to be modest, especially for large multi-domain proteins. 
Moreover, refolding in vitro is an expensive and time consuming process that 
sometimes is not easy to scale up. To simplify the downstream processing, 
maximisation of the yield of soluble active product during production in vivo is an 
attractive alternative. 
 
Tag protein fusions 
The tags on most fusion proteins are commonly used to optimise the production and 
purification procedures of the target protein but they also can be used for detection 
and immobilisation purposes (Nilsson et al., 1997). The fusion tag can improve the 
solubility (Nallamsetty & Waugh, 2006) or proteolytic stability (Murby et al., 1991, 
Murby et al., 1996) of the overall protein. There are many well-defined affinity tags 
that have been described such as glutathione-S-transferase (GST), polyhistidine 
(His), maltose-binding protein (MBP) and these have been reviewed by (Terpe, 
2003). No single affinity tag is ideal for all expression and purification systems. 
 
2.4  Production of monoclonal and recombinant antibody 
The use of virus-specific antibodies, and in particular the use of MAb, has been of 
considerable value in the development of various assay systems for the detection of 
microbial antigens and diagnosis of disease. 
 
Monoclonal antibodies 
Antibodies are composed of immunoglobulins that are produced by plasma cells. 
There are 5 isotypes of immunoglobulins, namely IgG, IgM, IgA, IgD and IgE. Once 30 
 
a B-lymphocyte has been stimulated by foreign antigen to differentiate into antibody-
producing plasma cells, they may produce only one single type of antibody 
molecule, binding to a particular site (epitope) on the antigen.  The clonal selection 
of individual antibody producing B cells and continued propagation of the cloned 
cells is the basis of producing MAb. 
Attempts to culture single antibody-producing cells in vitro were met with limited 
success until Kohler and Milstein (1975) developed a technique for the reliable long-
term production of cloned antibody producing lymphocytes. Their methods enabled 
the production of individual antibodies of invariant specificity and selectivity, and the 
immortalisation of the antibody-producing cells, ensuring a virtually infinite supply 
(Kohler & Milstein, 1975). The procedure for the production of MAb involves 
immunisation of a mouse or a rat, fusion of the plasma cells from the immunised 
mouse or rat with myeloma cells to create hybridomas, then cloning the fused cells 
and harvesting the antibody product.  
 
Structure and function of antibody molecules 
A schema of a complete antibody molecule is illustrated in Figure 2.4. The basic 
dimeric antibody structure comprises 2 heavy chains (VH) of about 440 aa and 2 
light chains (VL) of about 220 aa residues. These chains fold into 3 domains. Two of 
the domains (Fab domains) are identical and form the arms of the Y-shaped 
molecule. One light chain associates with the amino-terminal region of one heavy 
chain to form an antibody-binding site. The third domain (Fc) forming the base of the 
Y shape is folded together by the carboxy-terminal regions of the 2 heavy chains 
and is responsible for aspects of the immune response. The 4 polypeptide chains 
are held together by disulfide (S-S) bridges and non covalent bonds. The light chain 
can be divided into 2 regions, variable (V) and constant (C) region. The heavy chain 
contains one variable and 3 constant regions. Within the variable regions, 4 
framework regions (F) and 3 hypervariable regions (CDR) can be discriminated. 
These CDRs form the majority of contact residues for the binding of the antibody to 
the antigen (Padlan, 1994).  31 
 
 
 
     
Figure 2.4. Schematic drawings of the organisation of a natural antibody and 
derived recombinant fragment scFv and Fab. The structure of antibody is 
composed of the 2 variable regions of heavy and light chain (VH and VL), which 
include CDR. In recombinant antibodies; a peptide linker connects the 2 antigen 
binding regions of the light and the heavy chain. 
 
 
The repertoire of antibodies is created during B-cell development by DNA 
rearrangement and combinatorial assembly of different genetic segments. The V-, 
D- and J-segments form the heavy chain gene and V- and J-segments form the light 
chain gene (Winter, 1998, Winter et al., 1994).  
 
Recombinant antibodies 
Current molecular techniques enable the construction of recombinant antibody 
fragments that have antigen-binding properties. The general strategy taken is to 
isolate the mRNA from mouse splenocytes or MAb-producing hybridoma cells and 
to reverse transcribe the immunoglobulin encoding mRNA with a single primer, 
which binds either the heavy or light chain antibody gene near the beginning of the 
constant domain. 
Reverse transcription of the mRNA results in the production of immunoglobulin 
variable region cDNA. The cDNA is then amplified by PCR with the original 3' 
constant region primers and the 5' leader signal primers, binding upstream from the 
variable region. The immunoglobulin heavy or light chain cDNA amplified by PCR 
can be cloned into a plasmid or phagemid vector. Once the immunoglobulin genes 
Fab 
COOH  COOH 
NH2  NH2 
V  L 
V  H 
CH1 
CH3 
CH2 
CDR3 
CDR2 
CDR1 
Fab 
CH1 
Fc 
S-S 
ScFv 
NH2  NH2 
COOH  COOH 
V  H  V  L 32 
 
are cloned, they can be sequenced and produced in large scale by simple E. coli 
fermentation methods (Buchner & Rudolph, 1991, Su et al., 2003). 
 
Single chain variable fragment (scFv) antibody 
ScFv is a product resulting from the development of the current biotechnology and 
antibody engineering. The 2 antigen binding variable regions of the heavy (VH) and 
light chain (VL) are artificially connected by a linker peptide, designated as single-
chain variable fragment or single chain antibody (Bird et al., 1988, Orlandi et al., 
1989). This resulting scFv facilitates the equal expression of both variable fragments 
in heterologous micro-organisms, mammalian cells and plants (Schirrmann et al., 
2008). 
The antigen-binding site is made up of the variable domains of light and heavy 
chains of a MAb. The smallest portion containing an antigen binding site is the 
variable fragment (Fv) of an antibody. The Fv fragment has the full intrinsic antigen 
binding affinity of one binding site similar to the binding pattern of the whole parental 
antibody (Takemura et al., 2000). The relative affinity of VH and VL fragments for 
each other depends on the particular sequence of the antibody. Low affinity may 
result in dissociation of the Fv fragment into its components (Horne et al., 1982). 
To stabilise the association of the recombinant Fv fragments, they are joined with a 
short peptide linker and expressed as a single polypeptide chain; linker peptides, of 
12-25 aa do not normally disturb the proper folding of the VH and VL domains (Bird 
et al., 1988, Huston et al., 1988). The most frequently used linker for scFv 
antibodies is (Gly4Ser)3 (a 15 aa peptide of 12 glycines and 3 serines) that bridges 
the ~4.5 nm gap between the C-terminus of one domain and the N-terminus of the 
other and has a flexible structure with enhanced mobility (Freund et al., 1993, 
Huston et al., 1988). This construction facilitates chain pairing and minimises 
refolding and aggregation encountered when the 2 chains are expressed 
individually. Comparison of the unlinked Fv fragment of the antibody McPC603 with 
the corresponding scFv containing a linker (Gly3Ser)4 (VH-linker-VL constructs) has 
shown no perturbation of the folding of the variable domains by the linker (Freund et 
al., 1993). 
There are different forms of scFv; a soluble scFv antibody is the most popular form 
as it shares all the advantages of the MAb (Blazek et al., 2004). The scFv genes 
can also be fused to gene3 protein (g3p) of the phage to form recombinant phage 
display scFv antibody and leads to the expression of scFv on the surface of the 33 
 
phage. An advantage of this form of scFv is that the supernatant of the phage-
infected bacterial culture can be directly used in ELISA (Xu et al., 2004). This is 
useful for screening specific scFv to target antigens from a scFv library through 
multiple rounds of selection. However, this kind of scFv may exhibit some cross-
reactivity (McElhiney et al., 2002). 
Dimeric or mini-antibody is another form of scFv. Such molecules preserve the 
bivalency of native antibody molecules, which is a very effective means of 
increasing the functional affinity (avidity) to the surface of polymeric antigens (Kortt 
et al., 2001, Muller et al., 1998). ScFv fragments can be linked by a small modular 
dimerisation domain in the form of one or 2 amphipathic helices. These mini-
antibodies assemble in dimeric form in E. coli and the avidity of the best of them is 
indistinguishable from a native antibody (Kortt et al., 2001). 
Biotinylated antibodies are commonly used reagents in research and molecular 
diagnostics. The traditional approach to biotinylate antibodies is to conjugate a 
chemically active biotin to scFv antibody. This genetically biotinylated scFv enables 
the production of the antibody conjugate in bacteria, which could decrease costs of 
ELISA reagents (Grimm et al., 2004, Santala & Lamminmaki, 2004). 
The small scFv fragments are considered promising for medical and biological 
applications because of superior tissue penetration, absence of side reactions 
involving the constant domains, as well as easy engineering of fusion proteins, such 
as scFv-coupled toxins, the creation of multivalent or bi-specific proteins (Hudson & 
Kortt, 1999, Leath et al., 2004). 
 
Fab antibody fragments 
The construction of Fab fragments (50 kDa) is similar to that of scFv (30 kDa). The 
difference is that both variable and constant regions of light chain and heavy chain 
still remain in Fab (Figure 2.4). Therefore, a molecule of recombinant Fab fragments 
has the complete antigen binding site and structure of a natural antibody, which may 
result in a relatively higher avidity than that of the same scFv. The thermodynamic 
stability of the corresponding Fab fragments is also higher than that of scFv 
(Rothlisberger et al., 2005). This is due to the 2 interchain disulphide bonds typically 
present in the variable domains (VH and VL) and additional disulphide bonds in the 
constant domains (CH1 and CL). Although Fab fragments have these advantages, 
they are usually produced in the periplasmic space of E. coli at lower functional 
yields and do not have the same advantages of small size, especially in multivalent 34 
 
formats (Skerra & Pluckthun, 1988). Production of functional antibody Fab 
fragments in an oxidising bacterial cytoplasm has overcome those limitations in 
terms of yield, folding and functionality and is economic, rapid and efficient (Venturi 
et al., 2002). A number of Fab fragments have been developed and used in 
immunotherapy and diagnostics (Zhang et al., 2001) and have found some 
applications in clinical toxicology (Flanagan & Jones, 2004). 
 
Generation of scFv antibodies 
Established hybridoma clones are a rich source for generating scFvs. The variable 
domains of the antibodies expressed by the hybridoma cells can be derived 
relatively easily, and cloned into the scFv format. However, a major disadvantage is 
that not all scFv derived from existing antibodies are active. Another disadvantage is 
the non-human origin of most hybridoma clones, which may render the derived 
scFvs immunogenic (Blazek & Celer, 2003, Blazek et al., 2004). 
ScFvs can also be selected from large naïve scFv repertoires or smaller 
“immunised” repertoires. The techniques and methods for such selections include 
phage display that is widely used due to its simplicity and ability to be adapted to 
many specific conditions, including selection on whole cells and tissues (Hust & 
Dubel, 2005) and the system has been extensively reviewed (Kotz et al., 2004, Pini 
& Bracci, 2000), ribosome display that has the capacity to screen libraries of greater 
size as well as facilitating diversity and efficient antibody maturation (He et al., 2004, 
Lee et al., 2004b), bacterial display (Bessette et al., 2004, Su et al., 2003) and yeast 
display (Boder & Wittrup, 2000, Feldhaus & Siegel, 2004, Powers et al., 2001, 
Siegel et al., 2004) that have several advantages over the phage system including 
use of flow-cytometry and sorting techniques to enable finer affinity discrimination of 
selected antibodies. Other techniques are periplasmic expression cytometric sorting 
(PECS) (Chen et al., 2001) and potentially some 2-hybrid systems to screen for 
intracellular antibodies. 
 
Display on phage particles 
The first paper describing phage display (Smith, 1985) described display of a 
fragment of the EcoRI enzyme in the central region of pIII, and showed that the 
recombinant phage could be enriched in a phage pool by panning the pool on 
antibodies recognising EcoRI. The display of an anti-lysozyme scFv on the surface 35 
 
of filamentous phage particles by fusion of the antibody variable genes to one of the 
phage coat proteins paved the way for the generation of antibody repertoires on 
phage (McCafferty et al., 1990). 
Over the years, most of the phage coat proteins have been tested for display of 
antibody fragments, with pIII as the most preferred choice (Ding et al., 2005, Gupta 
et al., 2001, Han et al., 2003, Yang & Shiuan, 2003). The scFv genes are inserted 
directly upstream of the gene for pIII, which results in fusion proteins upon 
expression. The phage particles produced from a phage vector are homogeneous in 
their content of pIII, whereas the phage particles produced from a phagemid vector 
in combination with a helper phage have pIII from both the phagemid (fusion 
proteins) and from the helper phage (non-fusion). The phage vectors offer the 
advantage that all phage particles display scFvs and therefore enable a more 
efficient selection. In contrast, the phage particles produced from phagemid systems 
are monovalent. On average the phage particles displaying a fusion protein display 
only one, whereas the vast majority do not display any (O'Connell et al., 2002); this 
is a clear advantage when high affinity is desired. The other advantage of phagemid 
vectors is their relative high transformation efficiency allowing the generation of 
libraries with higher diversity and the accurate measurement of the antibody library 
size (Hong et al., 2004). 
Antibody repertories can be divided into categories based on the source used for 
their generation (Hoogenboom & Chames, 2000) (Figure 2.5). Natural antibody 
repertoires can be created from B-lymphocyte mRNA obtained from either 
immunised or non-immunised donors. The “immune” repertoires (Duggan et al., 
2001, Okamoto et al., 2004) will be biased by the immune response of the donor 
and will therefore be enriched for antibodies directed against the antigen used for 
immunisation. In addition, several of the antibody genes may contain somatic 
hypermutations, and therefore encode high affinity antibodies (Hoet et al., 2005). 
However, there are several drawbacks: immunisation may not result in an immune 
response, toxic antigens may kill the donor, tolerance may limit or prevent an 
immune response toward self-antigens, ethical concerns may hinder active 
immunisation of humans, and the applicability range of a repertoire is limited to 
selections against the immunising antigen. In contrast, naïve repertoires (reviewed 
by (Winter et al., 1994)) can be applied in the selections against a wide range of 
targets, including those that cannot be used in immunisations. The caveats are the 
diversity requirement and the potential bias by the donors’ immunoglobulin 
repertoire. 36 
 
 
 
Figure 2.5. The source of antibody genes. The model sourced from 
Hoogenboom & Chames (2000). 
 
To extend the repertoire diversity, “synthetic” repertoires have been generated in 
which parts of the natural antibodies are randomised (Sidhu et al., 2004). The 
classic approach is to exchange the CDR3 regions, which are normally created by 
the recombination of the V(D)J gene segments, with synthetic oligonucleotides. This 
strategy can be further extended to cover the other CDR regions (Fellouse et al., 
2004). The synthetic repertoires are not biased, and can generally be applied in 
selections against any antigen, including self-antigens and toxic antigens. The 
synthetic repertoires may contain high fractions of non-active or unfolded antibodies 
(Rubinstein et al., 2003). 
 
Morphology and life cycle of the filamentous bacteriophage Ff 
The filamentous bacteriophage Ff is a rod-shaped particle (Figure 2.6) about 900 
nm in length and 6.5 nm in diameter. It can be propagated by infection of E. coli that 
contain the F conjugative plasmid. The genome of the Ff bacteriophage is a 
covalently closed single-stranded DNA molecule (ssDNA) of about 6,400 
nucleotides, encoding 11 proteins (Table 2.5) that can be grouped according to their 37 
 
functions in the phage morphology or to their roles in the phage lifecycle (Russel, 
1991, Russel et al., 1997). 
 
Table 2.5. F-specific filamentous phage genes/proteins and properties. Data 
sourced from Russel et al. (1991). 
Gene  Protein  Size 
(aa) 
Function  Location  Used for display? 
I  I  348  Assembly  Inner 
membrane 
 
  XI  108  Assembly  Inner 
membrane 
 
II  II  409  Replication (nickase)  Cytoplasm   
  X  111  Replication  Cytoplasm   
III  III  406
a  Virion component  Virion tip 
(end) 
Yes (N-terminus) 
IV  IV  405
a  Assembly (exit channel)  Outer 
membrane 
 
V  V  87  Replication (ssDNA bp)  Cytoplasm   
VI  VI  112  Virion component  Virion tip 
(end) 
Yes (C-terminus) 
VII  VII  33  Virion component  Virion tip 
(start) 
Yes (N-terminus) 
VIII  VIII  50  Virion component  Virion 
filament 
Yes (N- and C- 
termini) 
IX  IX  32  Virion component  Virion tip 
(start) 
Yes (N-terminus) 
a: Mature protein without signal sequence. 
 
 
The phage capsid consists of 5 different proteins of which pVIII (50 aa) is the most 
abundant. pIII, pVI, pVII and pIX (406, 112, 33 and 32 aa, respectively) are all 
present in a few copies at the ends. The actual wall of the rod-like phage particle is 
composed of pVIII (2,700-2,800 copies). All the capsid proteins have hydrophobic 
membrane spanning domains and reside in the inner membrane until they are 
assembled into the mature phage particle (Willats, 2002) (Figure 2.6). 
The infection process is initiated when the phage particle binds to the first of the 2 
bacterial receptors needed for infection, the F-pilus, via an interaction with domain 
N2 of the pIII (Karlsson et al., 2003) as shown in Figure 2.7. Subsequently, domain 
N1 of pIII can interact with the second bacterial receptor, TolA, and complete the 
infection (Click & Webster, 1997, Deng & Perham, 2002, Deprez et al., 2002, 
Lubkowski et al., 1999, Nilsson et al., 2000). 38 
 
 
 
Figure 2.6. Schematic illustration of M13 bacteriophage particle showing the 
organisation of the 5 coat proteins. The approximate number of copies of each 
M13 coat protein is indicated. The model was sourced from Willats (2002). 
 
Three proteins encoded by the phage genome are involved in the replication of 
phage DNA.  pII (410 aa) binds to the double-stranded replicative-form of the phage 
genome and introduces a specific cleavage on the (+) strand at the origin of 
replication. Upon completion of the rolling circle replication, the ssDNA is 
circularised by pII, and a stabilising complex is formed with pV (87 aa). pX (111 aa) 
is the product of an internal initiation of gene II at methionine 300, and probably 
controls DNA replication (Horiuchi, 1997). 
The last 3 proteins encoded by the genome are required for the assembly of the 
phage coat. The pI (348 aa), pXI (108 aa) (Haigh & Webster, 1999) and pIV 
(405[+21] aa) (Marciano et al., 2001) proteins form a channel in the bacterial 
membrane and are required for the phage assembly and release. It has been 
speculated that this channel may set the restrictions on maximum size of proteins 
that can be displayed on phage (Marvin, 1998, Russel, 1991, Russel et al., 1997, 
Stassen et al., 1994). 
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Figure 2.7. Schematic illustration of the bacteriophage infection process via the 2 
E. coli receptors needed: Pilus and TolA. Pilus is usually involved in the conjugal 
transfer of DNA between E. coli. It consists of a protein tube assembled by 
polymerisation of pilin subunits from the bacterial inner membrane. The pilin 
subunits are encoded by the traA operon on the F conjugate plasmid (Manchak et 
al., 2002). Upon interaction with N2 of pIII, pilus retracts and N1 of pIII can interact 
with the TolA leading to completion of infection. The model was sourced from 
Karlsson et al. (2003). 
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Chapter 3 
Solubilisation and purification of insoluble recombinant JDV-
ΔSU present in inclusion bodies 
 
Summary 
Methods were developed to express, solubilise and refold a truncated recombinant 
surface unit (ΔSU) protein of Jembrana disease virus that was expressed as an 
insoluble product in Escherichia coli. The protein was engineered with a glutathione-
s-transferase (GST) tag to facilitate purification and was truncated by deletion of the 
N-terminal region of the protein to eliminate the hydrophobic transmembrane 
domain and cytoplasmic tail of the full-length protein but this truncation of the 
protein failed to increase the solubility of the protein expressed in E. coli and it was 
produced as an insoluble product within inclusion bodies.  To purify the insoluble 
protein present within inclusion bodies, the inclusion bodies were partially purified 
from lysed bacterial cells by an initial washing step to separate the inclusions from 
cellular lipids and membranes. The effect of different buffers on the solubilisation of 
ΔSU inclusion bodies was examined and a denaturing buffer of 2 M Tris-HCl, pH 12, 
containing 2 M urea and 10 mM DTT was selected as an optimal solubilising buffer. 
The solubilised denatured proteins were then refolded by slowly diluting the protein 
solution with 10 volumes of refolding buffer (20 mM Tris pH 8.0 containing 0.1% 
CHAPS, 10 mM DTT and 1 mM PMSF).  Final purification of the ΔSU was achieved 
by affinity column purification of the tagged protein with glutathione-Sepharose 4B 
resin (BioRad) and cleavage of the GST tag with PreScission™ protease (GE 
Healthcare).  The purified solubilised ΔSU protein could be considered for use as a 
vaccine protein or antigen for serological tests. 
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Introduction 
Recombinant proteins are widely used in medicine for production of vaccines and 
therapeutic proteins for human (Green & Gaston, 2006) and animal diseases 
(Weerasinghe et al., 2006). They are also used as antigens for immunological tests 
(Zhang et al., 2006). 
Production of any recombinant protein in a heterologous host cell or organism is a 
complex multi-step process and is often problematic. Protein expression levels can 
be low or the purified protein may be insoluble or unstable. To generate large 
amounts of recombinant proteins, optimal conditions must be determined which 
require selection of an appropriate expression vector and expression host, and the 
ability of the fusion partner to facilitate purification of the expressed protein. 
Glutathione S-transferase (GST) fusion vectors with expression in an Escherichia 
coli vector provide high transformation efficiency, simplicity and low cost of 
production, and are frequently chosen and used for recombinant protein production 
and purification (Terpe, 2006). GST fusion vectors provide GST fusion proteins that 
can be purified by binding to immobilised glutathione followed by competitive elution 
of the immobilised protein with reduced glutathione (Smith & Johnson, 1988). 
However, a significant problem with GST fusion proteins is that they are often 
expressed as insoluble proteins that are difficult to purify by standard procedures 
(Hollenbach et al., 1999, Iwata et al., 2000, Mercado-Pimentel et al., 2002, Terpe, 
2003, Wang et al., 1997). 
Recombinant JDV capsid (CA) and transmembrane (TM ) proteins have been 
expressed in Escherichia coli as a fusion protein with GST (Burkala et al., 1998). 
The soluble fraction of the expressed proteins was purified using affinity 
chromatography with reduced glutathione and then used as an antigen to develop 
serological tests for JDV (Burkala et al., 1998). The majority of the expressed 
protein, however, was present as an insoluble product and yields would have been 
markedly enhanced if the insoluble product had been solubilised.  An effort to 
increase the solubility of the expressed JDV fusion proteins by truncation of the 
protein still resulted in a considerable proportion of the expressed protein being 
present as an insoluble product within inclusion bodies (Burkala et al., 1998). This 
Chapter reports the development of a simple process for solubilisation and 
purification of the insoluble JDV recombinant ΔSU protein present in inclusion 
bodies that considerably enhanced the yield of soluble protein. 
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Material and methods 
Protein expression 
The map of the expression cassette for a fusion of the surface unit protein is shown 
in Figure 3.1. E. coli DH1 (F
-, endA1, hsdR17 (rK-, mK+), supE44, thi-1, λ
-, recA1, 
gyrA96, relA1) transformed with the pGEX-6P-1 plasmid containing JDV nucleotides 
5556 – 6463 (numbering as described by (Chadwick et al., 1995b)) was grown 
overnight with shaking 225 rpm in 5 ml of Luria-Bertani (LB) medium supplemented 
with 100 µg of ampicillin per ml as a selection agent at 37
oC. The overnight culture 
was diluted 1:40 in 200 ml of fresh LB-ampicillin medium, grown again at 37
oC to an 
OD600 of 0.6 – 0.8, when pre-induction samples were taken as controls and protein 
production was induced with 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG) for 
4 h at 37
oC. During incubation, post-induction samples were taken every 1 h. 
Samples were then centrifuged (4,000 g for 10 min at 4
oC) and cell pellets were 
resuspended in reducing SDS-PAGE loading buffer prior to electrophoresis. 
 
 
Figure 3.1. Map of vector pGEX-6P-1 used to produce recombinant ΔSU in E coli 
(from Amersham website http://www4.amershambiosciences.com/pdfs/970004M2-
01.pdf).  
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After 4 h of induction, the bacteria were harvested by centrifugation (4000 g for 10 
min at 4
oC) and the bacterial pellets were suspended in 10 ml of ice cold 
phosphate-buffered saline (PBS; 2 mM KCl, 140 mM NaCl, 10 mM K2HPO4, 2 mM 
KH2PO4, pH 7.4). Lysis of the bacterial cells was achieved by the addition of 
lysozyme (1 mg/ml final concentration) and incubation on ice for 15 min with 
occasional mixing, followed by freeze-thawing using liquid nitrogen, which resulted 
in a dramatic increase in viscosity. The viscosity was then reduced by treatment 
with benzonase (Novogen) (10 µg/ml final concentration) in the presence of 10 mM 
MgCl2. The soluble and insoluble fractions of the E. coli lysate were separated by 
centrifugation (10,000 g for 20 min at 4
oC). The supernatant fractions were collected 
and stored at –20
oC for further analysis and the residual pellets were used for 
solubilisation. 
 
Solubilisation of insoluble proteins in inclusion bodies 
The pelleted inclusion bodies were washed 3 times with washing buffer (50 mM 
Tris-HCl buffer pH 8.0, containing 5 mM EDTA and 1% Triton X-100) by 
centrifugation (10,000 g for 15 min) after each wash step. The pelleted material was 
then washed once with distilled water to remove salt and detergent and centrifuged 
again (10,000 g for 30 min). The pelleted material was then resuspended in 50 mM 
Tris-HCl buffer at pH 8.0. 
To determine the effect of different solubilisation buffers, 100 µl volumes of 
resuspended washed inclusion bodies were placed in microcentrifuge tubes and 
centrifuged (4,000 g for 10 min at 4
oC). The supernatant was discarded and 1 ml of 
the various solubilisation buffers was added to each of the pellets. The suspensions 
were vortexed and left for 1 h at room temperature. The solubilisation buffers tested 
included 100 mM Tris-HCl buffer with or without additional 2% urea at pH 7 to pH 13 
and other solubilisation buffers listed in Table 3.1.  The relative soluble protein 
concentration of the suspensions was determined by centrifugation (10,000 g for 10 
min) of the suspension, followed by filtration of the supernatant through a 0.45 µm 
filter and then determination of the relative protein concentrations by measuring the 
absorbance of the suspensions at 280 nm (A280), where A280 = 1.00 is assumed to 
correspond to 1 mg of protein per ml (Lowry et al., 1951). 
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Table 3.1. Buffers tested for solubilisation of insoluble JDV ΔSU within inclusion 
bodies. 
Buffer 
A. 2 M Tris-HCl pH 12 
B. 2 M Tris-HCl pH 12, plus 2 M urea and 10 mM DTT 
C. 2 M Tris-HCl pH 12, plus 10 mM DTT 
D. 50 mM Tris-HCl pH 8.5, plus1% Sarkosyl 
E. 50 mM Tris-HCl pH 8.5 plus 8 M urea 
F. 50 mM Tris-HCl pH 8.5 plus 6 M guanidine-SCN 
G. 50 mM Tris-HCl pH 8.5 plus 1% SDS 
H. 100 mM Tris-HCl buffer pH 12.5, plus 2 M urea and 10 mM DTT 
 
 
Refolding of solubilised protein 
The solubilised ΔSU-GST was refolded by diluting the protein solution slowly with 
10 volumes of refolding buffer (20 mM Tris pH 8.0 containing 0.1% CHAPS, 10 mM 
DTT and 1 mM phenyl methyl sulfonyl fluoride, a serine protease inhibitor [PMSF]) 
followed by storage overnight at 4
oC.  
 
Cleavage of GST-JDV ΔSU 
After refolding, the fusion protein was applied to a disposable gravity column (Bio-
Rad) containing 2 ml of glutathione-Sepharose 4B resin (Amersham Biosciences) 
equilibrated previously with binding buffer (PBS, pH 7.4) at 4
oC. The column matrix 
was washed twice with the binding buffer and then that buffer was substituted with 
cleavage buffer (50 mM Tris HCl, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, pH 8.0) 
to pre-equilibrate the column, altering the buffer composition required for efficient 
cleavage by PreScission™ protease (GE Healthcare).  PreScission protease™ 
(2 U/100 μg of ΔSU-GST protein) was diluted in cleavage buffer and injected onto 
the column. Following the injection, the column was placed in a closed flow status at 
4
oC overnight. An elution buffer containing reduced glutathione (50 mM Tris-HCl 
and 10 mM reduced glutathione, pH 8.0) was then applied in a one-step gradient 
(100%) to elute the GST and PreScission™ protease. A series of 1 ml eluates were 
collected and stored on ice, then the proteins were precipitated with acetone and 45 
 
ethanol, and stored at -20
oC until subjected to sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). 
 
SDS-polyacrylamide gel electrophoresis 
Fractions collected during the expression and purification procedures were 
subjected to SDS-PAGE in a Mini Protean III cell (Bio-Rad) for 1 h at 200 V by using 
a 4% stacking gel and a 12.5% polyacrylamide separation gel as described by 
Laemmli (1970).  The samples were heated at 95
oC for 10 min before 
electrophoresis. After electrophoresis, gels were stained overnight on a rocking 
platform at room temperature in a solution containing 0.1% (w/v) Coomassie brilliant 
blue R-250 (Bio-Rad) in 40% methanol, 50% water and 10% acetic acid. Excess 
dye was removed by multiple washing in 40% methanol, 50% water and 10% acetic 
acid. 
 
Results 
 
Expression and solubilisation of inclusion body protein 
The recombinant fusion protein ΔSU-GST of ~65 kDa (ΔSU at ~40 kDa plus GST at 
~26 kDa) was detected after induction of the cultures with IPTG and was present in 
the insoluble fraction of the cell lysate, presumably within inclusion bodies. The 
proteins present within the centrifuged and washed pelleted material are shown in 
Figure 3.2 (lane 2). This material contained not only ΔSU-GST but also other 
cellular proteins.  
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Figure 3.2. Coomassie brilliant blue stained SDS-PAGE of fractions collected during 
solubilisation, refolding, and cleavage of GST from to purify recombinant ΔSU-GST 
fusion protein. A: lane 1, MW markers; lane 2, pellet after cell lysis and washing; 
lane 3 and 4, supernatant and pellet after solubilisation in buffer B (2 M Tris pH 12 
supplemented with 2 M urea and 10 mM DTT); lane 5, supernatant after refolding in 
refolding buffer (20 mM Tris pH 8.0 containing 0.1% CHAPS, 10 mM DTT and 1 mM 
PMSF); lane 6, 7 and 8, serial eluates from a glutathione Sepharose 4B column 
loaded with refolded protein (as illustrated in lane 5) and eluted with binding buffer. 
B: lane 1, MW markers in kDa; lanes 2-9, serial eluates from 10 mM reduced 
glutathione column containing bound ΔSU-GST fusion protein after treatment with 
PreScission™ protease.  
 
 
The solubilisation of the insoluble ΔSU-GST product within the inclusion bodies was 
pH dependent in 100 mM Tris-HCl buffer. The solubilisation increased as the pH 
increased, increasing particularly from pH 10 to a maximum at pH 13. The addition 
of 2% urea to the 100 mM Tris-HCl buffer did not significantly affect the 
solubilisation (Figure 3.3).  
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Figure 3.3. Effect of pH (top) and the effect of pH combined with 2% urea 
(bottom) on the solubility of recombinant ΔSU-GST fusion protein in 100 mM 
Tris-HCl buffer. The relative soluble protein concentration was determined by 
A280 (). 
 
Comparison of the solubilisation of the washed inclusion bodies and other insoluble 
cell products with the buffers shown in Table 3.1 is shown in Figure 3.4. The 
greatest solubilisation was achieved with 50 mM Tris-HCl buffer at pH 8.5 
containing 6 M guanidine (Buffer F), followed by 2 M Tris-HCl at pH 12 containing 
2 M urea and 10 mM DTT (Buffer B).  An example of the product solubilised in 2 M 
Tris-HCl at pH 12 containing 2 M urea and 10 mM DTT is shown in Figure 3.2A, 
lane 2. 
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Figure 3.4. Relative yield of soluble recombinant ΔSU-GST protein 
consequent of treatment of washed inclusion bodies with various solubilising 
buffers, determined by measurement of the A280.  A, 2 M Tris-HCl pH 12; B, 
2 M Tris-HCl pH 12 plus 2 M urea and 10mM DTT; C, 2 M Tris-HCl pH12 
plus 10 mM DTT; D, 50 mM Tris-HCl pH 8.5 plus1% sarkosyl; E, 50 mM 
Tris-HCl pH 8.5 plus 8 M urea; F, 50 mM Tris-HCl pH 8.5 plus 6 M 
guanidine; G, 50 mM Tris-HCl pH 8.5 plus 1% SDS; H, 100 mM Tris-HCl pH 
12.5 plus 2 M urea and 10 mM DTT.  
 
As it was deemed that 6M guanidine could not be used for preparation of vaccine 
material (see Discussion), further solubilisation was conducted with Buffer B (2M 
Tris pH 12, 2 M urea and 10 mM DTT). SDS-PAGE of the supernatant and the non-
solubilised pellet resulted in weak bands due to a diluted protein samples used. 
Some impurities from the host cell proteins were detected (Figure 3.2A, lane 3 and 
4). The supernatant was then refolded overnight (Figure 3.2A lane 5) and applied 
directly to a glutathione Sepharose 4B column. Unattached material was eluted with 
binding buffer (PBS, pH 7.4) as shown in Figure 3.2A, lane 6). The buffer applied to 
the column was then changed to the cleavage buffer which provided more stringent 
wash conditions to release the ΔSU-GST fusion proteins, and PreScission™ 
protease to cleaves the GST-tag. After incubation period in a closed flow situation, 
the bound ΔSU-GST was eluted as 2 separate proteins of 40 kDa (ΔSU) and 26 
kDa (GST) as shown in Figure 3.2B. 
 
Discussion 
The expression of recombinant JDV ΔSU-GST in E. coli resulted in mostly insoluble 
protein. Protein insolubility may be caused by a variety of factors including the need 49 
 
for general molecular chaperones, cofactors, or protein partners for proper folding 
(Luo & Hua, 1998, Sun et al., 2005). The properties of proteins, such as the 
hydrophobic and hydrophilic regions of the aa in the protein sequences govern the 
protein structure and folding. In Figure 3.5 the distribution pattern along the aa 
sequences of full length JDV SU shows a highly hydrophobic region in the N-
terminal region. This hydrophobic N-terminal end may be the decisive factor that 
contributes to the formation of full length-SU inclusion bodies. The proteins are 
more predisposed to aggregation due to increased intermolecular interactions of 
regions of the folding polypeptide chain. The truncation of the SU (ΔSU ) protein in 
the current study was designed to eliminate the hydrophobic region near the N-
terminus of the full-length protein but this still did not prevent expression in an 
insoluble form.  
 
 
Figure 3.5. Hydrophobicity analysis of the N-terminus of the 422 aa SU protein 
of JDV. The profile was determined using the Kyte and Doolittle scale; 
hydrophilic residues have a negative score (Kyte & Doolittle, 1982). 
 
 
The formation of protein aggregates within cells is a general cellular response to the 
presence of mis-folded proteins when the proteins are expressed in a concentration 
exceeding the degrading capacity of the cells (Markossian & Kurganov, 2004). The 
expression of recombinant proteins within inclusion bodies in E. coli is affected by 
the specific growth conditions including growth temperature and time of induction 
with inducers, such as IPTG (Kang et al., 2007, Vera et al., 2007, Yeo et al., 2009) 50 
 
but it is difficult to prevent their formation (Peternel et al., 2008). When present, it is 
often necessary to convert the insoluble recombinant proteins and possibly 
improperly folded protein into a soluble and correctly folded product to obtain a 
product that is biologically active (Singh & Panda, 2005). Purification of the inclusion 
bodies containing the protein of interest can assist in the removal of contaminating 
cell debris and host cell proteins from the final recombinant protein; impure inclusion 
body preparations result in a less effective refolding and necessitate further 
purification steps (Clark, 2001). 
In this current study, advantage was taken of the presence of the expressed protein 
in an insoluble form in inclusion bodies to separate the inclusion bodies from 
bacterial cell proteins, resulting in partial purification of the expressed recombinant 
protein. This was easily achieved following disruption of the host cells by washing 
the pelleted inclusion bodies with 50 mM Tris buffer (pH 8) containing 1% Triton X-
100 to remove lipid and E. coli membrane-associated proteins. The success of this 
initial step was illustrated by the presence of a high proportion of ΔSU protein, 
relative to other proteins, in the solubilized inclusion body preparations (Figure 3.2A, 
lane 2).  
A number of methods and strategies have been used previously for converting 
inclusion body proteins into their soluble form (reviewed by Fischer, 1994, and  
Misawa & Kumagai, 1999). The suitability and use of each method has varied.  
Some have resulted in very low yields and some are incompatible with protein 
purification procedures that require the protein to remain in solution as they may 
result in re-aggregation and precipitation of the protein after removal of the 
solubilising agent (Goldberg et al., 1991, Sunitha et al., 2000).  The various 
methods used have included high concentration of chaotropic agents such as urea 
(Cabanne et al., 2005) and guanidine hydrochloride (Tsumoto et al., 2003b), the use 
of detergents such as sodium dodecyl sulphate (SDS) (Lechtzier et al., 2002) and 
sarkosyl (Mercado-Pimentel et al., 2002, Zhuo et al., 2005) with reducing agents like 
dithiothreitol (DTT).   
The need to consider the end use of the protein during the selection of the 
solubilising agents is illustrated by 6M guanidine-hydrochloride.  This is used 
extensively to regenerate active proteins from inclusion bodies, but is not 
acceptable for proteins to be employed as vaccines since guanidine may be 
deleterious to the immunogenicity of the protein, and during attempts to remove the 
guanidine from the protein, either by dialysis (Tsumoto et al., 2003a) or ion-
exchange chromatography (Ejima et al., 1999), significant re-aggregation of the 51 
 
protein may occur.  Meanwhile, urea has been generally favoured over the use of 
guanidine, providing for better refolding and improved yields (Wang et al., 2005a) 
and an improved immune response (Rothel et al., 1997).  Detergents such as SDS 
are highly effective denaturing agents but bind tenaciously to the denatured 
proteins, making its complete removal from the protein problematic (Arakawa et al., 
1994). 
The method chosen for solubilisation of the insoluble SU protein involved the use of 
2 M urea in 2 M Tris buffer pH 12, with the addition of 10 mM DTT.  This provided 
considerable greater solubilisation of the insoluble proteins in inclusion bodies than 
other buffers investigated, with the exception of 6 M guanidine (see Figure 3.4, 
buffer B).  Urea at a concentration of 2 M was less than the 8 M concentration that 
has been used in many previous studies (Tsumoto et al., 2003a, Villaverde & 
Carrio, 2003). The solubilisation of inclusion bodies expressed in E coli by alkaline 
solutions has been previously reported (Jin et al., 1994, Lavallee et al., 1993, 
Suttnar et al., 1994). In the current study a high pH appeared to have a crucial role 
in destabilizing the aggregated proteins in the inclusion bodies. The addition of 
10 mM DTT, a thiol containing reducing agent, allowed reduction of inter-chain 
disulfide bonds by thiol-sulfide exchange and increased solubilisation of the 
aggregated protein. The use of DTT has the advantage that it does not have to be 
removed prior to initiation of the refolding.  
The molecular basis for the denaturation of proteins by urea remains unknown, 
despite its widespread use. Urea may act directly, by binding to the protein, or 
indirectly, by altering the solvent environment. Most versions of the direct interaction 
model (Auton et al., 2007, Dotsch et al., 1995, Zou et al., 1998) postulate that urea 
binds to and then stabilizes the denatured protein, thereby favouring unfolding (Liu 
et al., 1997). Alternatively, urea acts indirectly by altering the solvent environment, 
thereby mitigating the hydrophobic effect and facilitating the exposure of residues in 
the hydrophobic core (Courtenay et al., 2001, Tobi et al., 2003). The mechanism of 
urea-promoted unfolding may depend on the urea concentration (Timasheff & Xie, 
2003). 
A decrease in the concentration of Tris-HCl buffer from 2 M in the solubilisation 
buffer to 20 mM in the refolding buffer, in the presence of 0.1% CHAPS and 10 mM 
DTT, maintained the protein in a soluble format without aggregation. This was 
fortunate as aggregation is a phenomenon common to many refolded proteins 
(Bondos & Bicknell, 2003). The addition of the zwitterionic detergent CHAPS to the 
refolding buffer may have contributed to the continued solubility of the ΔSU protein; 52 
 
this is one of a series of useful kosmotropes (salts that stabilize protein structures), 
chaotropes (salts that destabilize protein structures), aa, sugars, and detergents 
that can contribute to maintaining proteins in a soluble state (Bondos & Bicknell, 
2003).  
An attempt was made to cleave the GST tag from the ΔSU protein in the current 
study.  Sometimes, it is necessary to remove the tag since it can cause unwanted 
immunological responses, inactivate the fused target protein or influence the quality 
of binding properties (Buning et al., 1996, Nilsson et al., 1997). Since GST is a 
relatively large tag (26 kDa), it is preferable to remove it to determine whether the 
truncated SU protein is soluble and properly folded. While several methods have 
been described for site-specific cleavage treatment of the fusion partner, enzymatic 
methods are preferred due to their specificity and milder reaction conditions 
required. The GST vector system (pGEX-6P-1) used in this study allows for 
purification of the GST fusion protein and subsequent cleavage of GST from the 
protein using the PreScission protease, which specifically recognizes the aa 
sequence Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro, cleaving between the Gln and Gly 
residues (Cordingley et al., 1990). Upon removal of the GST-tag with protease, 
SDS-PAGE identified 2 bands (~40 kDa and ~26 kDa), correlated with the ΔSU and 
GST proteins. Further testing of the eluted ΔSU is required as a possible 
complication associated with the use of reduced glutathione for elution is that it can 
affect target proteins containing disulfides (Sassenfeld, 1990) and the proteases 
that cleave after a basic residue such as thrombin and factor Xa, sometimes 
produce non-specific and unwanted products (Jenny et al., 2003). 
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Chapter 4 
Development of monoclonal antibody for the detection of 
recombinant JDV proteins 
 
Summary 
This chapter reports the attempted generation of hybridomas producing monoclonal 
antibodies (MAbs) against the recombinant capsid (CA), truncated SU (ΔSU) and 
Tat proteins of JDV using hybridoma technology. BALB/c mice were immunised 4 
times subcutaneously at 2-week intervals with the proteins excised from SDS-PAGE 
gels. Hybridomas secreting monoclonal antibodies against the proteins were 
developed by fusion of the spleen cells of immunised mouse with SN0 myeloma 
cells and detection of antibody secretion by western immunoblotting. Antibody 
secreting hybridomas were cloned by limiting dilution and the isotypes of the ΔSU 
and Tat MAb were determined as IgM and the CA MAb as IgG.  A CA MAb 
designated LD1 was shown to be an effective reagent for use in a capture ELISA for 
quantitation of viral antigen and for an immunoperoxidase assay for the detection of 
viral antigen in tissue sections.  
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Introduction 
Following the discovery of hybridoma technology (Kohler & Milstein, 1975) and the 
consequent development of monoclonal antibody (MAb) production technology, the 
use of MAbs has been extremely useful in medical and biological research, enabling 
a multitude of tasks such as the detection of viral antigens (Keuser et al., 2004, 
Oldoni et al., 2004), tissue and blood typing (Lee et al., 2004a, Noda et al., 2002), 
the identification of hormones (Fortunati & Frairia, 2003) and the identification of 
tumour antigens (Nustad et al., 2004). 
A range of MAbs against JDV proteins would be extremely valuable for diagnostic 
purposes and particularly to aid in the identification of individual viral proteins.  One 
technique that has been successfully used for the detection of JDV in tissues of 
cattle is immunoperoxidase staining, valuable as it can be conducted using fixed 
tissue sections.  For immunoperoxidase staining, monoclonal antibodies produced 
previously against the 26 kDa CA protein (Kertayadnya et al., 1993) from mice 
immunised with whole viral preparations, have been used but unfortunately the 
hybridomas producing these MAbs were lost due to the difficulty of maintaining 
liquid nitrogen supplies in Indonesia.  Monoclonal antibodies would also be 
extremely useful reagents for the characterisation of JDV proteins.  Although the 
size of the native non-glycosylated proteins can be predicted and therefore 
identified with confidence in western immunoblotted viral preparations, the 
glycosylated native SU and TM proteins have not been characterised with regard to 
size.  Monoclonal antibodies produced against recombinant SU and TM proteins 
would be extremely useful for characterisation of the native viral envelope 
glycoproteins and would then have application for improved diagnostic 
methodology.  The MAbs would also have application during the development of 
Jembrana disease vaccines incorporating individual recombinant viral proteins.  
This Chapter reports the production of MAb against the JDV-CA protein that was 
used for the development of an antigen capture ELISA and for immunoperoxidase 
staining for the detection of JDV antigen in tissues.  It also describes the production 
of MAb against recombinant ΔSU and Tat fusion proteins to assist in the further 
characterisation of these proteins. 
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Material and methods 
Preparation of antigens for immunisation of mice and serological tests 
GST-fusion proteins 
Recombinant glutathione-S-transferase (GST) JDV CA, ΔSU and Tat proteins were 
expressed from JDVTab/87 genes ligated into the pGEX-6-P system (Pharmacia).  
The JDV CA constructs were prepared as previously described (Burkala et al., 
1998) and contained the full-length JDV capsid gene. JDV Tat was prepared as 
previously described from exon 1 of the tat gene (Setiyaningsih, 2006). JDV ΔSU 
was prepared as previously described in Chapter 3. All proteins were purified using 
the methods described in Chapter 3 except that GST was not cleaved from the final 
purified fusion protein (as these studies were undertaken prior to the studies 
reported in Chapter 3).  A summary of the size of the proteins is shown in Table 4.1. 
 
Table 4.1. Recombinant fusion proteins produced and their determined molecular 
weight. 
Fusion protein  Molecular weight (kDa) 
CA-GST  ~ 50  
CA-biotin  ~ 37  
ΔSU-GST  ~ 65  
ΔSU-biotin  ~ 53  
Tat-GST  ~ 38  
Tat-biotin  ~ 27  
GST  ~ 26 
 
 
GST protein 
Preparation of GST for use as a control reagent was as previously described by 
Ditcham (2007).  Escherichia coli transformed with the pGEX plasmid with no insert 
were grown in 2YT supplemented with ampicillin (100 µg/ml) and induced with IPTG 
(final concentration 0.1 mM) at a culture OD600 of 0.6. After 4 h of further growth, the 
bacteria were harvested by centrifugation (18,000 g, 3 min), washed in PBS by 
centrifugation and resuspended in 50 µl of lysis buffer/ml of original culture, and 
lysed by freezing and thawing. After clarification of the lysate by centrifugation, the 56 
 
supernatant was passed 3 times through a column of Glutathione-Sepharose resin 
(0.2 ml volume, equilibrated with PBS). Bound and soluble GST was displaced with 
10 column volumes of 30 mM glutathione in PBS. 
 
Biotinylated fusion proteins 
Biotinylated fusion proteins for immunisation of mice that would be recognised only 
by antibody to the JDV protein and not the GST fusion tag, were produced as 
previously described by Ditcham (2007).  The same genes cloned into a pGEX-6P 
expression vector for the production of GST fusion proteins were ligated into the 
PinPoint Xa-1 T-tailed vector (Promega) for the expression of biotinylated proteins 
in E. coli. Briefly, the recombinant plasmids were transformed by heat-shock into 
JM109 competent E. coli. The transformed cells were then plated onto LB agar 
plates supplemented with 100 µg/ml ampicillin and incubated (37ºC, overnight). The 
colonies were screened for transformants with inserts in the correct orientation by 
directional PCR with standard thermocycling conditions and a Tm of 50ºC. Positive 
clones were verified by sequencing. Protein expression was induced by the addition 
of IPTG to a final concentration of 0.1 mM in LB broth, supplemented with 100 µg/ml 
ampicillin and biotin at a concentration of 2 µM. The expression of the proteins was 
monitored by SDS-PAGE and western immunoblotting using an alkaline 
phosphatase labelled streptavidin probe and western Blue chromogenic substrate 
(Promega). 
For immunisation of mice, fusion proteins were first separated by SDS-PAGE (30% 
acrylamide, 0.3% bisacrylamide) and extracted from gels as described by Prussack 
(1989), with slight modification. Briefly, after SDS-PAGE, gels were placed in ice-
cold 0.25 M KCl for 20 min to identify the protein bands. The bands of the 
appropriate size were then excised and eluted from the gel slices in 700 µl of elution 
buffer (0.01% SDS, 20 mM Tris-HCl pH 7.9, 1 mM CaCl2) overnight at 37
oC. The 
eluate was then centrifuged and unbound SDS was precipitated by the addition of 
KCl to a final concentration of 50 mM on ice for 10 min.  The mixtures were 
centrifuged (10,000 g for 5 min) and the supernatant containing recombinant 
proteins were stored at -20
oC until required. 
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Production of fragments of Gag protein 
Biotin tagged truncated gag fusion proteins as shown schematically in Figure 4.1 
were produced in E. coli JM109 following the procedure described by (Desport et 
al., 2005). Briefly, early log phase cultures were induced by the addition of IPTG 
and recombinant fusion proteins were harvested by pelleting the cultures by 
centrifugation. Pelleted cells were resuspended in cold lysis buffer, sonicated and 
centrifuged again. The biotinylated proteins were purified in batch by mixing the cell 
lysates with equilibrated Steptavidin Softlink resin (Promega).  The bound proteins 
were washed with cold lysis buffer and then eluted from the resin by the addition of 
5mM biotin in cold lysis buffer. Total and purified protein concentrations were 
determined using an assay based on the Bradford method (BioRad) with bovine 
serum albumin standards. 
 
 
Figure 4.1. Schematic representation of primer combinations used to amplify 
JDV gag sequences for cloning in-frame into Pinpoint Xa-1 for protein 
expression. The picture sourced from Desport et al. (2005).  
 
Generation of MAb-producing hybridomas 
Immunisation of mice 
A 500 µl volume of each biotinylated CA, ΔSU, and Tat recombinant protein 
extracted from SDS-PAGE gels was homogenised with an equal volume of 
incomplete Freund’s adjuvant (Sigma) and 200 µl of the suspension was injected 
subcutaneously into 8-week old female BALB/c mice. Further injections with freshly 
prepared emulsions were given at 2-week intervals. Four days after the fourth 
injection the mice were bled, the blood was allowed to clot at 4
oC, the serum was 
removed from the clot following centrifugation (10,000 g for 10 min) and specific 58 
 
antibody was detected by ELISA. If antibody was detected, the mice required for 
fusions were re-injected with a further 200 µl of freshly prepared protein emulsion 
and used for fusions 4-7 days later. 
 
Preparation of spleen cells 
When required for fusions, immunised mice were euthanised and the heart was 
punctured to obtain about 300 µl of blood, which was subsequently examined for 
antibody. In a laminar flow hood, the skin of the mouse was swabbed with 70% 
alcohol, the abdominal skin cut and resected, and the peritoneal cavity was opened 
and the spleen was removed and placed in a plastic 50 mm cell culture dish (Nunc) 
containing 10 ml Dulbecco’s modified Eagle’s medium (DMEM).  The spleen was 
cut into several pieces and disrupted using small gauge needles on sterile 10 ml 
disposable syringes. After removal of the connective tissue and other large pieces 
of cellular debris, the cell suspension containing an estimated 10
8 splenocytes was 
placed in a centrifuge tube. An aliquot of the suspension was stained with 0.4% 
trypan blue and counted in a haemocytometer to ensure at least 90% viability. The 
spleen suspension was gently centrifuged (500 g for 5 min) to pellet the cells and 
the cells were then resuspended in 10 ml of DMEM and incubated at 37
oC for 15 
min. For the preparation of feeder cells (splenocytes), spleens from normal BALB/c 
mice were processed as described above. 
 
Preparation of myeloma cells 
Two weeks prior to fusion, a vial of NS0 myeloma cells was recovered from liquid 
nitrogen and thawed in a 37°C water bath. The thawed cells were immediately 
transferred into 10 ml of DMEM (serum free) before centrifugation (500 g for 5 min) 
to gently pellet the cells. The cells were resuspended in growth medium (DMEM 
supplemented with 10% FCS, 0.58 mg/ml L-glutamine, 0.22 mg/ml sodium 
pyruvate, 1 ml/L fungizone, 200 IU/ml penicillin and 200 μg/ml streptomycin).  The 
cells were then distributed into culture flasks and incubated in a 5% CO2-in-air 
atmosphere at 37°C.  To ensure the cells were in active growth phase for cell 
fusion; the cells were subcultured daily for 3 days prior to fusion. The concentration 
of viable cells at the time of fusion was determined by counting the cells with a 
haemocytometer following staining with 0.4% trypan blue.   
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Fusions 
Cell fusions were performed by techniques similar to those described by Chan & 
Mitchison (1982). The mouse spleen cell suspension (above) containing an 
estimated 10
8 cells was mixed with the NS0 cell suspension (above) containing an 
estimated 2 x 10
7 cells in a 50 ml round bottom sterile centrifuge tube and gently 
centrifuged (100 g for 5 min). The supernatant was discarded and the cell pellets 
were disrupted by gently tapping the side of the tube. One ml of 43% PEG (MW. 
1300-1600; Sigma) solution was added drop-wise over a 1 min period, at the same 
time shaking the tube in water bath at 37
oC. The cell suspension was then 
incubated at 37°C for 1 min, then 1 ml of serum-free DMEM was added over a 1 min 
period, and the suspension was shaken gently for a further 1 min. Subsequently, 10 
ml of serum-free DMEM was added over 1 min. The fused cells were gently 
centrifuged (100 g for 5 min) and the cell pellet gently resuspended in 50 ml of 
DMEM-HAT medium (DMEM supplemented with 20% FCS, 100 µM hypozanthine, 
0.4 µM aminopterin, 16 µM thymidine, 0.58 mg/ml glutamine, 0.22 mg/ml sodium 
pyruvate, 200 IU/ml penicillin and 200 µg/ml streptomycin). An estimated 10
6 
splenocytes from another freshly killed normal mouse were added to the cell 
suspension as feeder cells, mixed gently, and distributed into 96-well flat bottomed 
cell culture microplates (Nunc) in 100 μl/well volumes (resulting in about 5 plates per 
fusion). Trays were placed in a 5% CO2 incubator at 37°C. 
Four days after fusion, an additional 2 drops of HAT medium containing 10
6 feeder 
cells (spleen cells from a normal mouse)
 was added to each well with a sterile 
Pasteur pipette, followed 2 days later by a further 2 drops of feeder cells in HT 
medium (HAT medium without aminopterin). After 7 days, plates were examined 
daily for evidence of hybridoma formation. Ten to 15 days after fusion, the medium 
from wells containing hybridomas was screened by western immunoblotting for 
antigen-specific antibodies.  
 
Cloning hybridoma cells by limiting dilution 
To assure monoclonality, antibody-producing hybridoma clones were subcloned 3 
times by a limiting dilution method. The cells in antibody-positive wells were diluted 
in 50 µl of cell suspension and mixed with 50 µl of DMEM-HT. The cells were 
serially diluted (2-fold) in DMEM-HT in wells of a 96-well plate. Wells were 
supplemented with an equal volume of feeder spleen cells and any positive wells 
containing single hybridomas were checked for antibody production by western 60 
 
immunoblotting. Any positive wells containing single hybridomas were re-cloned by 
the same method. Cloned hybridomas were expanded in number by first cultivating 
them in 24-well and then in 6-well plates (Nunc) and finally in 25 cm
2 culture flasks 
(Nunc). 
 
Storage and recovery of hybridoma cells 
Hybridomas were stored in liquid nitrogen when not required. Approximately 10
6 
cells from a 25 cm
2 flask were centrifuged (500 g for 5 min) and then resuspended 
in a mixture of 90% (v/v) FCS and 10% dimethylsulfoxide (DMSO). The cells were 
pipetted into 2 ml cryogenic vials and frozen slowly overnight by placing them in an 
insulated container at -80
oC, and they were then transferred into liquid nitrogen. 
When required, the frozen cells were removed from the liquid nitrogen and thawed 
rapidly in a 37°C water bath, and then immediately transferred aseptically into 10 ml 
of DMEM before centrifugation (500 g for 5 min) to gently pellet the cells. The 
pelleted cells were resuspended in growth medium (DMEM-HAT) supplemented 
with feeder spleen cells. The cells were then distributed into wells and cultured in a 
5% CO2 incubator at 37°C. 
 
Western immunoblot analysis for antibodies 
Fifteen days after fusion, the supernatants of the wells that contained large 
hybridomas (that covered minimal 50% of the bottom of the wells) were screened 
for protein-specific antibody by western immunoblotting using GST-ΔSU, CA and 
Tat proteins produced using the pGEX expression system. The proteins were 
fractionated by SDS-PAGE and then transferred to nitrocellulose membranes 
overnight at 4ºC. Non-specific binding of antibodies to the membrane was blocked 
by incubating the membranes in TBS (200 mM NaCl, 50 mM Tris-HCl, pH 8.0) 
containing 0.05% (v/v) Tween-20 (TBST) and 5% (w/v) commercial skim milk 
powder for 1 h at room temperature.  After washing 3 times with PBST (PBS 
containing 0.05% Tween-20), membranes were incubated with 100 µl of the 
medium (diluted 1:10) from wells containing hybridomas for 3 h at room 
temperature. The membranes were washed again 3 times with TBST and then 
incubated with 1:2,000 dilution of anti-mouse IgG horseradish peroxidise (HRP) 
conjugate for 1 h at room temperature. After 3 additional washings, HRP colour 
development reagent (Bio-Rad) was added until the colour developed. The reaction 
was stopped by washing the membranes in deionised water. 61 
 
Determination of Ig isotype 
The Ig subclass of MAb was determined with a Mouse Typer Sub-Isotyping Kit 
(BioRad) according to the manufacturer’s instructions. One hundred µl of antigen 
(GST-ΔSU, GST-Tat and GST–CA) diluted in a carbonate buffer (pH 9.6) was 
added to each well of the 96-well cell culture microplates. After incubation overnight 
at 4
oC, the solution was discarded and the plate was washed 4 times with PBST 
(PBS containing 0.05% Tween-20). The wells were dried by tapping them hard onto 
tissue paper. Two hundred µl of blocking solution (5% skim milk powder in PBS) 
was then added to all the wells and the plates incubated at room temperature for 1 
h.  The blocking solution was then discarded, the wells were washed and dried as 
before, and 100 µl of hybridoma supernatant was added (ΔSU and Tat supernatants 
were diluted 1:10 and CA supernatants were diluted 1:250 in PBST) and incubated 
for 1 h at room temperature. The wells were washed and dried again and 100 µl of 
the appropriate rabbit anti-mouse panel reagent was added for 1 h at room 
temperature.  The wells were then washed and dried and 100 µl of goat anti-rabbit 
horseradish peroxidase conjugate was added and incubated for 1 h. After washing 
the plate, 100 µl of ABTS substrate solution was added and incubated for 15 min at 
room temperature when the colour development reaction was stopped by the 
addition of 100 µl of 2% oxalic acid.   
 
ELISA for detection of antibody 
To obtain an optimum combination of CA antigen and CA MAb for ELISA, a 
checkerboard titration of antigen and antibody was performed by indirect ELISA 
using a Jgag6 antigen (a full length capsid protein; Figure 4.1) at concentrations 
ranging from 8.8 to 87.5 ng/well and a MAb dilution ranging from 1:100 and 1:3,000. 
The optimum combination was selected on the basis of the antigen: MAb 
combination producing the highest absorbance above 0.5.  
The 96-well cell culture microplates were coated with 100 µl/well of 2-fold dilutions 
of Jgag6 protein in a carbonate buffer (pH 9.6) and allowed to stand at 4
oC 
overnight. The plates were then washed 4 times with PBST to remove the non-
adsorbed antigen. Sites not coated with the proteins were blocked with 200 µl/well 
of 5% (w/v) skim milk in PBST. After incubation at room temperature for 1 h, the 
plates were washed and dried as described previously. Then 100 µl/well of 2-fold 
dilutions of MAb (diluted with PBST) was added to the plate, which was then 
reacted at room temperature for 1 h and washed and dried. One hundred µl/well of 62 
 
goat anti-mouse IgG conjugated to horseradish peroxidase diluted 1:4,000 with 
PBST was added to each well and the plates were incubated at room temperature 
for 1 h. The plates were then washed and 100 µl/well of a substrate solution (TMB; 
tetramethylbenzidine, Bio-Rad) was added to each well. After colour development at 
room temperature, the reaction was stopped by the addition of 100 µl/well of 2% 
oxalic acid and the absorbance read at a wavelength of 405 nm. 
 
Antigen capture ELISA for quantitation of viral antigen 
An antigen capture ELISA was performed as previously described (Stewart et al., 
2005). Briefly, 96-well flat bottom cell culture microplates were coated with either a 
1:200 dilution of the produced MAb or with a 1:1,000 dilution of the previously 
produced BC10 CA MAb (Kertayadnya et al., 1993) in 100 µl carbonate buffer pH 
9.6 per well, then incubated at room temperature for 1 h. The microplates were 
washed 3 times with PBST and blocked with 200 µl of blocking solution (2% casein 
and 1-5% skimmed milk powder in PBST) and incubated at room temperature for 
1h. After the plates were washed 3 times with PBST, 100 µl of Jgag6 protein (100 
ng/ml) in PBST containing 1% skim milk powder was added. The plates were again 
washed 3 times with PBST and 100 µl of a 1:4,000 dilution of polyclonal rabbit anti-
JDV CA (from J. Brownlie) was added. After another 3 washes with PBST, 100 µl of 
goat anti-rabbit HRP conjugate (ICN, Australia) (1:4,000) was added to each well 
and incubated at room temperature for another 1 h. After another wash with PBST, 
100 µl of TMB colour development reagent was added to each well, the microplates 
were incubated at room temperature until colour development and the absorbance 
of the colour reaction was determined at 450 nm.  
 
Immunoperoxidase staining of virus in fixed tissue sections 
The CA MAb was analysed by immunoperoxidase staining of formaldehyde-fixed 
paraffin-embedded issue sections from JDV-infected and control animals. The 
antigen retrieval was performed by microwave treatment of 6 µM tissue sections for 
2 x 4 min treatments at high wattage (805 watt), followed by 2 x 4 min treatments at 
low wattage (230 watt).  The sections were then left to cool in distilled water. The 
tissue sections were rinsed in PBS, blocked in 3% H2O2 for 5 min to remove 
endogenous peroxidases and then rinsed again before incubation for 1.5 h  at room 
temperature with anti-CA (MAb LD1 or MAb BC10) diluted 1:50, 1:100 and 1:200 in 
PBS. The sections were then washed in PBS before the addition of secondary 63 
 
antibody (HRP-conjugated goat anti-mouse IgG) (EnVision) for 30 min at room 
temperature. After washing, the bound antibodies were visualised as a brown 
insoluble precipitate by the addition of 3,3’-diaminobenzidine (DAB; DAKO) solution 
for 5-10 min at room temperature. The slides were counterstained with Harris 
haematoxylin and dehydrated before they were mounted with DePex (BDH 
Chemicals).  
 
Results 
Production of MAb-secreting hybridomas 
BALB/c mice immunised 4 times with biotinylated ∆SU, CA and Tat extracted from 
acrylamide gels developed serum antibody that was detectable by western blot 
utilising the homologous GST-fused protein as an antigen. 
One week after fusion, hybridoma cell growth was visible microscopically in the 
96-well microplates and at about day 14, the number of hybridoma cells increased 
and grew large enough to where they occupied one half or more of the surface of 
each well (Figure 4.2).  
 
 
 
Figure 4.2. Microscopic image of hybridoma cells 
14 days after fusion. Magnification X400. 
 
From the mice immunised with the biotin-tagged ΔSU, western immunoblotting 
detected antibody production in 68 wells containing hybridomas from 5 plates. Many 64 
 
of the these supernatants reacted with more than one band, and to achieve mono-
specificity, the hybridoma cells from all the positive wells were then cloned by 
limiting dilution and after 3 cloning procedures, 7 of the 68 hybridomas produced 
MAb reactive with a single band of about 65 kDa in western immunoblots (Figure 
4.3). The MAbs were all of IgM subclass and had kappa light chains.  
 
 
 
 
Fusion of spleen cells obtained from BALB/c mice immunised with biotinylated-CA 
recombinant proteins resulted in 74 wells containing hybridomas, which detected a 
mixture of antibodies by western immunoblotting.  After cloning by a series of 3 
limiting dilutions, the supernatant from one hybridoma was selected that reacted 
with one protein only of ~ 50 kDa (Figure 4.4). Cells from one well were expanded in 
25 cm
2 culture flasks. This cloned hybridoma was selected for further analysis and 
designated as LD1. 
 
 
 
 
Figure 4.3. The supernatant from hybridoma-containing wells which reacted with 
recombinant ΔSU-GST proteins in western immunoblots.  After cloning, 7 of the 
hybridomas produced MAb that reacted to a ~65 kDa protein only (positive lanes 
indicated by arrows).  The control molecular weight markers and their size are 
shown on the left. 
MW 
75 
50 
37 
25 65 
 
 
 
 
Figure 4.4. The supernatant from hybridoma-containing wells was screened 
against recombinant CA-GST fusion proteins by western immunoblotting. The 
positive hybridomas were cloned 3 times by a limiting dilution method and the 
supernatant from several clones that reacted with one protein only of ~ 50 kDa. 
The control molecular weight markers and their size are shown on the left. 
 
Following fusion of spleen cells obtained from BALB/c mice immunised with 
biotinylated-Tat recombinant proteins, 34 wells containing hybridomas were 
produced but only one was detected that contained antibody against Tat. This 
positive hybridoma was re-cloned 3 times (Figure 4.5).  The MAb against 
recombinant Tat protein was of IgM isotype and possessed kappa light chains. 
 
 
 
Figure 4.5. The supernatant from hybridoma containing wells was screened 
against recombinant Tat-GST fusion protein by western immunoblotting. The 
positive wells were cloned by a limiting dilution method and one of the cloned 
hybridomas produced antibody reactive with the recombinant protein. The gel 
depicts the reactivity of multiple wells containing the same cloned hybridoma. The 
control molecular weight markers and their size are shown on the left. 
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Determination of optimal antibody and antigen dilution 
A checkerboard titration was conducted to determine the optimal working dilution of 
the LD1 CA MAb and the optimal concentration of Jgag6 protein for maximum 
sensitivity. The optimum conditions were selected on the basis of the highest 
absorbance above 0.5.  The optimal antigen concentration was 87.5 ng/well of 
Jgag6 and the optimal LD1 CA MAb dilution was 1:500 (Figure 4.6). 
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Figure 4.6. A checkerboard titration to determine the reactivity of various dilutions 
of the LD1 CA MAb with varying dilutions of the Jgag6 protein by ELISA. 
 
Analysis of reactivity of LD1 with different proteins 
The MAb LD1 CA was reacted in western immunoblots against ΔSU, CA and Tat 
fusion protein products that were produced (Figure 4.7).  The MAb LD1 reacted with 
CA-GST and CA-His (a gift from William Ditcham) but not with the ΔSU and Tat 
proteins. 67 
 
 
Figure 4.7. Reactivity by western blotting of the anti-CA MAb LD1 with various 
recombinant proteins. Lane 1, GST; lane 2, Tat-GST; lane 3, biotinylated-ΔSU; 
lane 4, CA-GST; lane 5, biotinylated Tat; lane 6, Tat-His; lane 7, CA-His; lane 8, 
ΔSU-GST.  The control molecular weight markers and their sizes are shown on the 
left. 
 
The CA MAb LD1 was reacted in western immunoblots against the 9 overlapping 
fragments of Gag proteins (Figure 4.1) and the results are shown in Figures 4.8 and 
4.9. The MAb LD1 recognised Jgag2, Jgag3, Jgag4, Jgag5, Jgag6, and Jgag11 but 
not Jgag1 (MA protein) and Jgag 7 confirming its specific reactivity to the CA 
protein. 
 This reactive epitope for this MAb was a region of CA that was encoded by a region 
of the JDV genome between nucleotides 604 and 810. The reactivity of LD1 
monoclonal antibody was different to the hyperimmune sera when tested against 
the same truncated Gag proteins (Figure 4.9); the hyperimmune serum did not 
recognise the Jgag11 product whereas it was recognised by the MAb LD1, 
indicating a difference in reactivity between native and recombinant CA protein 
epitopes. 
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Figure 4.8. Schematic diagram of recombinant Gag fragments expressed in 
E. coli and reacted in western immunoblots with truncated proteins 
encompassing regions of the MA, CA and NC. The top (multi-coloured) bar 
represents the full length of the region covered by the individual peptides that 
were produced. Numbers below the bar show nucleotide numbers of the 
regions of gag encoding the truncated fragments Jgag1 to Jgag13.  Those 
fragments shown in red were reactive to the LD1 anti-CA MAb, those in black 
were non-reactive. The schematic was adapted from Desport et al. (2005). 
 
   
Figure 4.9. Reactivity of different truncated Gag proteins detected by 
hyperimmune sera (A) and anti-CA LD1 (B). Lane 1, Jgag1; lane 2, Jgag2; lane 
3, Jgag4; lane 4, Jgag4; lane 5, Jgag5; lane 6, Jgag6; lane 7, Jgag7; lane 8, 
Jgag11; lane 9, Jgag13. 
 
Comparison LD1 and BC10 
To determine if the MAb LD1 was suitable for the antigen capture ELISA to 
quantitate virus, the reactivity of MAb LD1 was compared with the MAb BC10; as 
whole virus was unavailable for this, the Jgag6 peptide was used instead.  The MAb 
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LD1 (at 1:200 dilution) was able to detect 1,750 ng/ml Jgag6 whereas the MAb 
BC10 (at 1:1,000 dilution) detected 875 ng/ml Jgag6 (Figure 4.10). Evaluation with 
different concentration of blocking solutions showed that the results were not 
significantly different, and 5% skim milk powder in PBS was arbitrarily selected for 
use in all serological assays. 
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Figure 4.10. Comparison of antigen capture ELISA with MAb BC10 at 1:1,000 
dilution (top) and MAb LD1 at a 1:200 dilution using Jgag6 protein as antigen 
and with various blocking agents including casein and skim milk (SM) powder 
(bottom). 
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Immunoperoxidase staining of tissue sections 
The IHC procedure was conducted with spleen tissue from uninfected control cattle 
and from cattle on the 2
nd day of fever after experimental infection with JDVTab/87. 
The staining pattern was observed with 1:50, 1:100, and 1:200 dilutions of the CA 
MAb LD1. Granular brown staining in the cytoplasm was detected with all dilutions; 
however, the 1:200 dilution resulted in less background staining than the other 
dilutions. Comparison of the CA MAb LD1 with the MAb CA BC10 for 
immunoperoxidase staining of virus in formaldehyde-fixed paraffin-embedded 
sections showed that while both were effective reagents for the detection of virus 
antigen, the MAb BC10 provided more intense brown staining of tissues than did the 
MAb LD1 (Figure 4.11). 
 
   
 
 
Figure 4.11. Immunoperoxidase staining using MAb CA LD1 (B) and MAb CA 
BC10 (C) of formaldehyde-fixed paraffin-embedded spleen tissue section from 
uninfected cattle (A) and JDV-infected cattle (B and C).  Magnification X20. 
 
Discussion 
Only one MAb was produced against each of the 3 proteins that were selected. 
While further investigation may have resulted in a greater range of MAbs covering 
multiple epitopes, the aim of this project was to quickly produce a single MAb 
(A)  (B) 
(C) 71 
 
against each of the 3 proteins, that could then be used to identify each of the 
proteins and expand the range of diagnostic reagents available for Jembrana 
disease. As the immunising protein was in a denatured state it was not expected 
that MAb would be produced against all epitopes on native proteins.  
As the proteins used for this study were fusion proteins, to facilitate the process of 
selection of specific antibodies the fusion tag on the immunising protein was 
different to the fusion protein used as antigen in the serological test used for 
screening for MAbs. western immunoblotting was used as a screening assay and 
while it was possibly less sensitive than ELISA, it had the advantage of identifying 
the reactivity of the antibodies with proteins of the appropriate size. Additionally, 
certain antigens that bind to ELISA plates may also not be accessible for the 
antibodies due to steaic hindrance (Mohammad & Esen, 1989). It would have been 
appropriate to test the MAbs against native protein antigens but these were not 
available.  
The anti-CA MAb LD1 was shown to react specifically with the CA as it reacted to 
the CA-specific construct Jgag11. Desport et al. (2005) suggested that the Jgag11 
region must contain a reactive epitope since it was recognised by the hyperimmune 
JDV sera and to a lesser extent hyperimmune BIV sera. In the previous 
investigation reported by Desport et al. (2005) the CA-specific MAb BC10 was 
reactive with the Jgag13 construct as was the MAb LD1. However, some CA-
specific MAbs investigated by Desport et al. (2005), which included BC1 and BC10 
that were produced by Kertayadnya et al. (1993), did not react with Jgag11 whereas 
the MAb produced in this study (LD1) reacted with Jgag11 indicating it was different 
to the other MAbs previously available for JDV research (Kertayadnya et al., 1993).   
The potential application of the MAbs produced, particularly the anti-CA MAb LD1, 
was illustrated by its ability to be used as an alternative to MAb BC10 for the 
quantitation of virus (Stewart et al., 2005) and the staining of JDV in paraffin-
embedded tissue sections.  This was facilitated as this MAb was of IgG type. The 
MAbs against the SU and Tat proteins also have the potential to provide diagnostic 
and research reagents for the detection and characterisation of these 2 proteins but 
unfortunately, these MAbs were of IgM type and this will limit their usefulness; most 
commercially available labelled secondary immunoglobulins are directed against 
IgG. 72 
 
 Chapter 5 
Production of single chain fragment antibody (scFv) against 
recombinant ΔSU and CA proteins of Jembrana disease virus 
 
Summary 
Single chain fragment antibody (scFv) that specifically bound to recombinant 
truncated SU (∆SU)-GST fusion protein and capsid (CA) proteins from Tomlinson I 
and J phage display antibody libraries were produced. Two different methods of 
panning, a colony lift assay (CLA) and microtiter plate technique, were used to 
screen and identify the scFv: the CLA was used to detect scFv against the less 
soluble ΔSU protein and the microplate technique was used for the more soluble CA 
proteins. The phage-positive clones from both methods were transformed into 
E. coli HB2151 and the expression of soluble scFv was induced by the addition of 
IPTG. The scFv were then identified by ELISA. Comparison of scFv binding 
affinities assessed by indirect and capture ELISA tests indicated that the scFv 
produced against the SU was reactive not with the ∆SU component but the GST 
component of the ∆SU-GST fusion protein. The microplate panning generated 
colonies reactive with a truncated CA protein (Jgag6) and recombinant CA-Tat 
polyproteins. Four Jgag6 clones with the highest affinity were expressed as soluble 
scFv in the cell periplasmic area. 73 
 
Introduction 
The technology for the large scale production of highly specific antibody reagents 
has developed significantly with recent advances in recombinant antibody 
technology that may overcome many of the problems associated with the production 
of monoclonal antibodies (MAb) by conventional hybridoma technology (see 
Chapter 4). Phage display antibody technology provides an in vitro selection 
technique in which antibody fragments are genetically fused to the coat protein of a 
filamentous bacteriophage, resulting in display of antibody fragments on the exterior 
surface of the phage virion. The DNA encoding the fusion product resides within the 
virion. Once cloned, it is possible to improve the affinity and specificity of antigen 
binding by mimicking somatic hypermutation during an immune response (Gram 
et al., 1992). The method was introduced for the first time by Smith (1985) who 
fused a portion of the gene encoding the EcoRI endonuclease to the minor CA 
protein pIII present on the surface of bacteriophage M13. For reviews of the 
technique see Hoogenboom et al. (1998) and Winter et al. (1994). 
The use of phage display technology has many applications, including the isolation 
of antigen-specific antibody fragments either as fragment-antigen-binding (Fab) or 
single-chain antibody fragments (scFv). Recent reports of these applications include 
the production of scFv against the SARS-associated coronavirus (Liu et al., 2005b), 
human fibrin clots (Yan et al., 2004) and the capsid (CA) protein and 
transmembrane (TM) glycoprotein (gp46) of Maedi-visna virus (Blazek et al., 2004, 
Celer et al., 2003).  ScFvs have also been expressed intracellularly to inhibit the 
function of intracellular proteins (Lobato & Rabbitts, 2004). These intracellular 
antibodies or intrabodies have been applied to engineer a human MAb F240, which 
recognised the disulfide loop-bonded immunodominant epitope of HIV-1 gp41 (Liu 
et al., 2005a) and human MAb F102, which recognised the conserved CD4-binding 
region of HIV-1 gp120 (Wang et al., 2005b). These results suggested that the 
constructed scFv F240 and scFv F102 may inhibit viral replication and may be 
useful for gene therapy. Other research has demonstrated that these intrabodies 
can be directed to multiple HIV-1 target proteins that are present in cells, including 
the major CA p24 protein (de Haard et al., 1998), Gag p17 protein (Tewari et al., 
1998), Vif (Goncalves et al., 2002) and Vpr (Krichevsky et al., 2003).  
There are different methods of panning to isolate high affinity scFv against a wide 
variety of target antigens. Immunotube-based selection has resulted in production of 
scFV with high affinity for the target antigen but it requires a high volume of purified 74 
 
antigen (Mi et al., 2005). Similar techniques have been described that use 
microplates or tagged antigens that can be isolated using magnetic beads (Siegel et 
al., 1997). However, those techniques may not be suitable for antigens with poor 
solubility or that tend to aggregate. An improved method for phage display panning 
was developed employing whole cells that produced specific phage after several 
rounds of panning (Radosevic et al., 2003, Siva et al., 2008, Sui et al., 2004). 
Storage of hybridomas for conventional MAb production has always been a problem 
within Indonesia because of difficulties in maintaining liquid nitrogen storage 
facilities due to supply problems. To overcome the limitation represented by the 
storage of hybridomas producing MAb against JDV proteins prepared by 
conventional methods as described in Chapter 4, antibody phage display was 
attempted to produce specific scFv directed towards the recombinant truncated SU 
(ΔSU) and CA proteins of JDV. Due to the nature of the recombinant proteins used 
in this study, 2 methods of panning were employed for each of the 2 proteins. For 
the insoluble ΔSU protein, a colony lift assay (CLA) was used.  This method is 
based on the production of scFv by phage-infected bacteria plated on IPTG-
containing agar plates (Siegel et al., 1997). The scFv diffuse through the bacterial 
membrane and bind to the antigen-coated membrane that is placed under the 
bacterial membrane. The scFv that bind to the antigen-coated membrane are 
detected using antibodies specific for the tag fused to the scFv. An alternative 
microplate technique was also used, where phages are absorbed onto ELISA plates 
coated with CA that are subsequently eluted with trypsin. The eluted phages are 
used to infect E. coli of the TG1 genotype to produce scFv-phages, followed by 
soluble scFv expression in E. coli of the HB2151 genotype. The synthetic phagemid 
library, the human single-fold scFv libraries I+J (Tomlinson I+J), used for the 
generation of scFv antibodies directed against recombinant JDV SU and CA is 
described.  
 
Material and methods 
Tomlinson I and J phage antibody libraries 
Two phage-display antibody libraries generated at the MRC Centre for protein 
engineering (Cambridge, UK) were used. Both libraries were based on a single 
human framework for VH(V3-23/DP-47 and JH4b) and VK(012/02/DPK9 and JK1), 
with side chain diversity (either NKK or DVT encoded library J and I, respectively) 
incorporated at positions in the antigen binding site that make contact with antigen 75 
 
and are highly diverse in the mature repertoire (Rubinstein et al., 2003). The vector 
used for the expression of scFv antibody fragments is depicted in Figure 5.1. 
Phagemid vector pIT2 contains a lac promoter and a pelB leader sequence up-
stream of the scFv insert, which is then followed by hexa-histidine and myc tags, an 
amber stop codon and the gene encoding the pIII phage coat protein. After helper 
phage KM13 infection, scFv up-stream of the amber stop codon is displayed on the 
phage particle with the use of a suppressor strain such as TG1. However, scFv with 
a His6-myc tag is secreted into the periplasmic space with the use of a non-
suppressor strain such as HB2151. 
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Figure 5.1. Schematic representation of the scFv expression vectors: amp, 
ampicillin resistance encoding gene; colE1 ori, origin of DNA replication; pelB, 
signal peptide sequence of bacterial pectate lyase; myc tag, sequence 
encoding an epitope recognised by the MAb 9E10.  Adapted from the 
Tomlinson I+J protocol, http://www.geneservice.co.uk/products/proteomic/ 
scFv_tomlinsonIJ.jsp. 
 
 
In conjunction with the phage display antibody library, the E. coli strain TG1 (K12, 
∆(lac-pro), supE, thi, hsd∆5/F’traD36, proA
+B
+, lac I
q, lacZ∆M15) used for the phage 
rescue and the non-suppressor E. coli strain HB2151 (K12, ara, ∆(lac-pro), 
thi/F’proA
+B
+, lacI
qZ∆M15) used for the preparation of single-chain Fv fragments 
were supplied by I. M. Tomlinson, Laboratory of Molecular Biology (MRC, 
Cambridge). 
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Preparation of phage library stocks 
Tomlinson I and J libraries were delivered as glycerol stocks. One hundred µl of the 
E. coli (TG1 genotype) glycerol stock was inoculated into 200 ml of pre-warmed 2YT 
broth containing 1% glucose and 100 µg/ml of ampicillin and incubated with shaking 
at 37
oC to an optical density at 600 nm (OD600) of 0.4. KM13 helper phage (2 x 10
11 
pfu) was added to 50 ml of each culture and incubated without shaking in a 37
oC 
water bath for 30 min. The remaining 150 ml of each culture was incubated for a 
further 2 h with shaking at 37
oC and used to make secondary bacterial stocks. After 
incubation, the phage-infected culture was centrifuged (3,000 g for 10 min) and the 
resulting pellet was resuspended in 100 ml of 2YT broth containing 100 µg/ml of 
ampicillin, 50 µg/ml of kanamycin and 0.1% glucose and re-incubated overnight at 
30
oC. The resulting culture was clarified by centrifugation (3,000 g for 30 min) and 
phage particles were concentrated from the supernatant by precipitation with 20 ml 
of PEG/NaCl (20% [w/v] polyethylene glycol 6,000 in 2.5 M NaCl) for 1 h on ice.  
The suspension was then centrifuged (3,000 g for 30 min), the supernatant was 
discarded and the pellet resuspended in 4 ml PBS and re-centrifuged (3,000 g for 
30 min) and the supernatant containing phage was kept at 4
oC for short term 
storage or at –70
oC in PBS with 15% glycerol for longer storage.  
To titrate the phage, 10-fold serial dilutions of the phage suspension were prepared 
in PBS. To 100 µl of each dilution, 900 µl of TG1 cells at an OD600 of 0.4 was added 
and the tubes then incubated at 37
oC in a water bath for 30 min. Ten µl of each 
dilution was then spotted on a 2YT agar plate containing 1% glucose and 100 µg/ml 
ampicillin.  
 
Protein preparations 
A ΔSU-GST protein was prepared as previously described (Chapter 3). A 
biotinylated CA fragment (Jgag6) was expressed and solubilised as described 
previously (Chapter 4). A recombinant CA-Tat fused polyprotein (Lewis, 2008) was 
kindly provided by Dr Joshua Lewis (this laboratory). Ubiquitin (Sigma) was used as 
a control antigen for assessment of the quality of the panning process. 
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Preparation of scFV by panning using CLA 
The detection of ΔSU scFv was attempted using CLA; the principle of the assay 
utilised is demonstrated in Figure 5.2 (Radosevic et al., 2003). 
 
 
Figure 5.2. Schematic representation of the colony lift assay. YTAG denotes 
2YT agar containing 100 µg/ml ampicillin and 1% glucose. YTAI denotes 2YT 
agar containing 100 µg/ml ampicillin and 1 mM IPTG. Diagram sourced from 
Radosevic et al. (2003). 
 
Selection of ΔSU phage 
Solubilised ΔSU was separated by SDS-PAGE and electro-transferred to a 
nitrocellulose membrane. The membrane was stained with Ponceau red and after 
washing, non-reactive sites on the membrane were blocked by immersing it in 5% 
skimmed milk powder in TBST for 1 h at 4
oC. The membrane was washed with 
TBST and the band that corresponded to ΔSU was excised. The excised ΔSU 
protein was then incubated with ~10
12 phage in 1 ml of 5% skimmed milk powder in 78 
 
TBST at 4
oC for overnight. After 3 washes with TBST the bound phages were eluted 
by adding 500 µl of trypsin-PBS (50 µl of 10 mg/ml trypsin stock in 450 µl PBS) for 
10 min and propagated in fresh TG1 cells by adding 250 µl of the eluted phage 
particles to 1.75 ml of exponentially growing TG1 cells at an OD600 of 0.4 and 
incubating them for 30 min at 37
oC in a water bath without shaking. A sample was 
removed and the phage titrated. The remaining TG1 culture was centrifuged 
(microcentrifuge for 5 min) to pellet the cells and the pellet resuspended in 50 µl of 
2YT and plated on a 100 mm 2YT agar plate containing 100 µg/ml ampicillin and 
1% glucose. The plates were then incubated overnight at 37
oC. After overnight 
growth, 2 ml of 2YT medium was added to the plate and the bacteria were collected 
by scraping with a glass spreader.  Fifty µl of the scraped bacteria suspension was 
added to 50 ml of 2YT containing 100 µg/ml ampicillin and 1% glucose and grown at 
37
oC while shaking until the OD600 was 0.4. Then 5 x 10
10 helper phage was added 
to 10 ml of this culture and incubated at 37
oC for 30 min without shaking. The 
bacteria were centrifuged (3,000 g for 10 min) and the pellet resuspended in 50 ml 
of 2YT medium containing 100 µg/ml ampicillin, 50 µg/ml kanamycin and 0.1% 
glucose and incubated with shaking at 30
oC overnight. The overnight culture was 
centrifuged (15 min at 3,300 g at 4
oC) and 40 ml of the phage-containing 
supernatant was transferred to a new tube and precipitated with 10 ml of ice-cold 
PEG/NaCl (20% polyethylene glycol 6,000, 2.5 M NaCl) for 1 h. The phage 
suspension was centrifuged (3,300 g for 30 min) and the pellet resuspended in 2 ml 
PBS and centrifuged (~11,000 g for 10 min in a micro centrifuge) to remove 
bacterial debris.  
The phage selection protocol was repeated a further 3 times (a total of 4 times) and 
the enrichment of specific phages in each round of the selection was assessed by 
polyclonal phage ELISA. 
 
Coating ΔSU proteins onto nitrocellulose membranes 
Two ml of ΔSU-GST protein (100 µg/ml) was further diluted in 4 ml of PBS and 
poured onto the surface of a nitrocellulose membrane (pore size 0.45 µm; Bio-Rad) 
in a culture dish and left overnight at 37
oC. The excess suspension was then 
removed and the ΔSU-coated membrane was rinsed with PBS. Non-reactive sites 
on the membrane were then blocked by immersing it in 10 ml of PBS containing 3% 
(w/v) skimmed milk powder for 1 h at room temperature. The blocked membrane 
was rinsed twice with PBS and then air-dried. 79 
 
Panning for ΔSU scFV 
The phage rescued from each round of selection (as described above) were used to 
infect E. coli HB2151 cells (non-suppressor strain) for the attempted expression of a 
soluble scFv antibody. The bacteria were grown in 2YT culture medium at 37
oC until 
OD600 of 0.4 was achieved. Two hundred ml of the culture was infected with 10 µl of 
phage from each round of panning (above) and then incubated at 37
oC for 30 min 
without shaking. Serial 10-fold dilutions of the phage-infected HB2151 bacteria were 
plated on YTAG plates (2YT agar containing 100 µg/ml ampicillin and 1% glucose) 
and grown overnight at 37
oC. The dilution which resulted in isolated bacterial 
colonies was used for the CLA (further referred to the original bacterial plate). 
The nitrocellulose ΔSU-coated membrane (prepared as described above) was 
soaked in 2YT medium containing 100 µg/ml ampicillin and 1 mM IPTG and then 
placed, coated side upwards, onto the surface of an YTAI agar plate (2YT agar 
containing 100 µg/ml ampicillin and 1 mM IPTG). Another non-coated membrane 
was placed on top of the original bacterial plate (referred to as the master 
membrane). The master membrane was removed from the original bacterial plate 
and placed, colony side up, on the antigen-coated membrane on the YTAI agar 
plate. The YTAI agar plate was then incubated overnight at 30
oC. Both membranes 
were marked simultaneously by stabbing them with a needle for orientation 
purposes. 
The master membrane was removed and placed, colony side up, onto a fresh 
YTAG agar plate. The plate together with the master membrane was stored at 4
oC 
and later used for picking selected clones. The ΔSU-coated membrane was 
removed from the YTAI plate, washed 3 times with 10 ml PBST (PBS containing 
0.05% Tween-20) for 10 min with gentle shaking, blocked with PBS/3% dried 
skimmed milk powder for 1 h at room temperature and rinsed twice with PBS/0.05% 
Tween-20. The membrane was incubated with 10 ml mouse anti-His antibody 
(Sigma) (recognising the His-tag fused to scFv) diluted 1:2,000 in PBS/1% dried 
skimmed milk powder, for 1 h at room temperature. After incubation, the filter was 
washed 3 times with 10 ml PBST for 10 min each time, with shaking, followed by 
incubation with 10 ml of 1:3,000 dilution of goat anti-mouse Ig-HRP (ICN) in 
PBS/1% dried skimmed milk powder for 1 h at room temperature. The membrane 
was washed 3 times with 10 ml PBST for 10 min each time with gentle shaking and 
then rinsed twice with PBS. The membrane was then treated with 10 ml of HRP 
colour development solution (Bio-Rad) until spots were visible when the membrane 
was rinsed with water to stop the reaction. The spots from the ΔSU-coated 80 
 
membrane were used to identify the corresponding colonies responsible for the 
production of specific scFv on the master membrane and the original plate. 
 
Preparation of soluble ΔSU scFv  
Individual colonies were picked from each positive agar plates and resuspended in 
100 µl 2YT medium containing 100 µg/ml ampicillin and 1% glucose in 96-well 
microplates and incubated overnight at 37
oC with shaking. The overnight cultures 
were then diluted 1:20 and added to wells of another 96-well microplate containing 
200 µl fresh 2YT medium supplemented with 100 µg/ml ampicillin and 0.1% glucose 
and grown at 37
oC with shaking until the OD600 was about 0.9. IPTG was added to a 
final concentration of 1 mM and the cultures were incubated with shaking overnight 
at 28
oC. Bacteria were pelleted by centrifugation (1,800 g at 4
oC for 15 min) and 50 
µl of the supernatant was used for ELISA.  
 
ELISA 
To evaluate the specificity of the scFv against the ΔSU protein, 2 kinds of ELISA 
were used: an indirect phage ELISA and a capture phage ELISA. 
Indirect ELISA. ELISA microplates (Maxisorp, Nunc) were coated overnight at 4
oC 
with 100µl/well of 10 µg/ml ΔSU-GST fusion protein and GST alone in 100 mM 
carbonate buffer (pH 9.6). After 3 washes with PBST, the plates were subsequently 
blocked with 200 µl/well of 5% skimmed milk powder in PBS for 2 h at room 
temperature. The plates were washed 3 times with PBST and then 75 µl/well of the 
scFv supernatants were added to the plates and they were incubated at room 
temperature for 2 h. PBS was used as negative control. After 3 washes with PBST, 
the plates were incubated for 1 h with 100 µl/well of a 1:5,000 dilution of HRP-
conjugated protein L (Sigma) in PBS. The plates were washed a further 3 times with 
PBST and once with PBS before they were reacted with 50 µl/well of TMB (3,3’,5,5’-
tetramethylbenzidine) colour development reagent for 5-15 min at room 
temperature. The colour development was stopped with 50 µl/well of 1 M H2SO4 and 
the absorbance was determined at 450 nm and 650 nm. 
Capture ELISA. ELISA microplates (Maxisorp, Nunc) were coated overnight at 4
oC 
with 100 µl/well of goat anti-GST antibody (diluted 1:5,000 in 100 mM carbonate 
buffer pH 9.6). After 3 washes with PBST the plates were subsequently blocked with 
100 µl/well of goat anti-GST antibody (diluted 1:5,000 in 100 mM carbonate buffer 81 
 
pH 9.6). After 3 washes with PBST the plates were subsequently blocked with 200 
µl/well of 5% skimmed milk powder in PBS for 1 h at room temperature. The plates 
were then washed 3 times with PBST and 100 µl/well of 10 µg/ml ΔSU-GST or GST 
only were added to the wells and incubated for 1 h at room temperature, then PBS 
was added to blank wells as a negative control. After 3 washes with PBST, 75 
µl/well of the scFv-containing supernatant was added to the plates for 2 h at room 
temperature. After washing as described above, the plates were further incubated 
for 1 h with 100 µl/well of a 1:5,000 dilution in PBS of HRP-conjugated protein L 
(Sigma). The plates were washed a further 3 times with PBST and once with PBS 
before the addition of 50 µl/well of substrate solution containing TMB for 5-15 
minute at room temperature. The colour development was stopped with 50 µl/well of 
1 M H2SO4 and the absorbance determined at 450 nm and 650 nm. 
 
Preparation of CA scFV by panning with microplate method 
Selection of CA scFv-phage 
The panning procedure was conducted using 96-well microplates. One hundred µl 
of Jgag6 (10 µg/ml), CA-Tat polyprotein (10 µg/ml) or ubiquitin (100 µg/ml) was 
added to wells of a 96-well microplate (Nunc). The plates were incubated for 3 h at 
room temperature and then the non-reactive sites were blocked by the addition of 
with 2% skimmed milk powder in PBS. The plates were then washed 3 times with 
PBS and 100 µl of the supernatant containing the phage library stocks was added to 
each well. Plates were incubated at room temperature for 2 h and washed 10 times 
with PBST. To the wells containing bound phage, 100 µl of 10 mg/ml trypsin in PBS 
was added and incubated at room temperature for 10 min. The eluted phage were 
used to infect 1 ml of log-phase TG1 cells at an OD600 of 0.4 in 2YT medium and 
grown at 37°C for 1 h. Ampicillin was added to a final concentration of 100 µg/ml 
and glucose to a final concentration of 1% (w/v). Helper phage (5x10
10 cfu) was 
then added to the TG1 cell suspension and the culture was incubated at 37°C for 30 
min then centrifuged (3,000 g for 10 min at room temperature) to pellet the bacteria. 
The bacterial cells were then resuspended in 1 ml 2YT containing 100 µg/ml 
ampicillin, 50 µg/ml kanamycin and 0.1% glucose and cultured overnight at 28°C. 
The phage panning protocol was repeated a further 3 times. 
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Preparation of scFv-phage for monoclonal ELISA 
Serial dilutions (10
-1, 10
-2,  10
-4 and 10
-6) of E. coli TG1 infected with eluted scFv-
phages from each round of selection were plated on 2YT agar with 1% glucose and 
100 µg/ml ampicillin to enable the selection of individual separated colonies. These 
individual colonies were picked and inoculated into individual wells of a microplate 
with 100 µl of 2YT, 1% glucose and 100 µg/ml ampicillin and cultured at 37
oC 
overnight with shaking (250 rpm). Then, 2 µl of the overnight cultures from each well 
was transferred into a new plate with 200 µl of 2YT, 1% glucose and 100 µg/ml 
ampicillin per well and incubated for 2 h at 37
oC with shaking. The remainder of the 
bacterial culture from the overnight plate was stored frozen after the addition of 15% 
glycerol.  Next, 10
9 pfu of the helper phage KM13 was added per well and shaken 
for 60 min. This was centrifuged (1,800 g for10 min) and samples of the supernatant 
and the pellet were cultured in 200 µl of 2YT, 50 µg/ml kanamycin and 100 µg/ml 
ampicillin and cultured at 28
oC overnight with shaking. The overnight culture was 
centrifuged (1,800 g for 10 min) and 75 µl of the phage containing supernatant was 
used in monoclonal phage ELISA. 
 
Production of soluble scFv 
The selected scFv-phage from each round of selection was inoculated into the 
E. coli HB2151 non-suppressor strain to produce soluble scFv antibody.  HB2151 
cells were grown in 2YT media at 37
oC until the OD600 was 0.4. Two hundred µl of 
this culture was infected with 10 µl of scFv-phage, incubated at 37
oC for 30 min 
without shaking and plated on 2YT agar with 100 μg/ml ampicillin. From this plate, a 
single colony was picked and inoculated into 5 ml 2YT, 1% glucose and 100 μg/ml 
ampicillin, and cultured at 37
oC overnight with shaking (250 rpm). The overnight 
cultures were then diluted 1:20 in fresh 2YT medium containing 100 µg/ml ampicillin 
and 0.1% glucose and grown at 37
oC with shaking until the OD600 was 0.9. The 
culture was then induced by the addition of isopropyl β-D-thiogalactopyranoside 
(IPTG), to a final concentration of 1 mM. The culture was incubated at 28
oC 
overnight with shaking (250 rpm). The cells were centrifuged (3,300 g for 30 min) 
and the soluble scFv were recovered from the pellet by osmotic shock. The pellet 
was resuspended in ice-cold osmotic shock buffer [20% sucrose, 200 mM Tris-HCl 
pH 7.6 and 1 mM EDTA] and incubated on ice for 5 min. The suspension was 
pelleted by centrifugation in microcentrifuge (14,000 g for 5 min): the supernatant 
was collected and stored (sucrose fraction), the pellet was resuspended in ice-cold 83 
 
water, incubated on ice for 5 min, centrifuged in a microcentrifuge (14,000 g, 5 min) 
and the resulting supernatant containing the periplasmic fraction was collected. All 
osmotic shock fractions were either stored at 4
oC and analysed immediately by 
ELISA or frozen at -20
oC and analysed later. 
 
Polyclonal and monoclonal scFv-phage ELISA  
Wells of a 96-well microplate were coated with 50 µg/ml of ubiquitin, 10 µg/ml of 
Jgag6 or 10 µg/ml of CA-Tat polyprotein diluted in carbonate buffer (pH 9.6), 100 µl 
per well, and left at 4
oC overnight. The plate was washed with PBS and blocked with 
200 µl of PBS/2% skimmed milk powder for 60 min at room temperature, washed 
with PBS, then 100 µl of scFv-phage (about 2x10
12 pfu) of either amplified 
polyclonal (polyclonal ELISA) collected after each round of selection or MAb 
(monoclonal ELISA) in PBS/2% skimmed milk was added and incubated at room 
temperature for 60 min. PBS was used as negative control. Bound scFv-phage was 
detected with the monoclonal anti-M13gp8 conjugated to HRP (Pharmacia) diluted 
1:5,000 in PBS, 100 µl per well, and incubated for 60 min at room temperature. After 
each incubation step, the microplates were washed 3 times with PBST and finally 
with PBS. The ELISA was developed with 100 µl ABTS (BioRad) per well, and the 
absorbance was read after 5 min incubation at 405 nm with a microplate reader 
(BioRad). 
 
SDS-PAGE and western blotting of soluble scFv 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting were 
performed as described previously (Chapter 3). Briefly, 20 µl of all fractions of scFv 
were separated by 12.5 % SDS-PAGE, and then transferred electrophoretically to 
nitrocellulose membrane. The membrane was blocked with PBST containing 5% 
skimmed milk powder for 1 h before washing with PBST. The membrane was then 
incubated with 1:5,000 diluted HRP-conjugated anti-His antibody in 10 ml of PBST 
containing 2% skimmed milk powder for 1 h at room temperature. Bound anti-His 
was detected by the addition of HRP colour development reagent (Bio-Rad). 
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Results 
Screening for ΔSU scFv by CLA 
The panning procedure with ΔSU-GST proteins bound to a nitrocellulose membrane 
was used to selectively capture ΔSU-positive recombinant phage from 2 phage 
antibody display libraries (I and J). During 4 panning cycles, the number of ΔSU-
GST specific phage increased significantly from the third round (Figure 5.3). 
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Figure 5.3. ELISA results demonstrating enrichment of ΔSU-GST scFv during 
panning. Four rounds of panning were conducted against ΔSU-GST proteins 
immobilised on nitrocellulose membranes. The bound phage from Library I 
(blue bars) and Library J (violet bars) after each round of selections were eluted 
with trypsin and were titrated. An increase in number of eluted phages could be 
seen as the panning progressed. 
 
HB2151 bacteria that were infected with phage recovered after the third and fourth 
panning rounds were plated on individual YTAG agar plates in different dilutions and 
screened by CLA using nitrocellulose membranes coated with ΔSU-GST fusion 
protein (Figure 5.2). This screening resulted in isolated colonies at a 10
-4 dilution. 
These single bacterial colonies were tested for their ability to bind to ΔSU-GST 
immobilised on nitrocellulose membranes and a number of scFv-positive-colonies 
from both phage libraries were identified (Figure 5.4). 
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Figure 5.4. Screening of diffused scFv antibodies secreted by the bacterial 
colonies grown on master filter to the membrane coated with recombinant 
protein ΔSU-GST. The scFv-antibodies were detected by anti-His antibody. (A) 
Antibodies identified after third round of selection and (B) antibodies identified 
after the fourth round of selection. 
 
Forty single colonies obtained using CLA from the third and the fourth panning 
round of libraries I and J were selected and subcultured on YTAG plates and then 
tested for the production of antibody by CLA. Multiple scFv-binding spots, 
corresponding to colonies, were visualised on the membrane and an example of the 
results obtained during the third selection round of Library J is shown in Figure 5.5. 
A few positive single colonies were also obtained using Library I.  
 
   
 
Figure 5.5. Bacteria colonies expressing potential antibody fragments (scFv). 
Forty selected colonies were tested for antibody production by CLA. Antibody 
fragments that diffused from master filter (A) and bound to the ΔSU-GST 
coated filter (B) could be detected by an enzyme colorimetric reaction. The 
corresponding positive colonies could be identified from the master filter (A). 
A  B 
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Four positive colonies derived from the third round of panning using the J-library 
and 8 positive colonies from the fourth round of panning (4 using the J-library and 4 
using the I-library) that showed a strong band on western immunoblotting, were 
further subcultured and re-screened by CLA for positive scFv antibody reactions 
and the results are shown in Table 5.1.  Numerous positive colonies were identified 
although 2 of the 12 parental clones produced a failed to react when retested after 
subculture. 
 
Table 5.1. Results of screening of parental clones with colony lift assay (CLA). 
Plate  Number of colonies  Number of positive colonies 
determined by CLA 
Percentage 
positive 
3J-1  200  98  49 
3J-1A  196  49  25 
3J-1B  192  57  30 
3J-9  140  43  31 
4J-1  158  17  11 
4J-2  154  Negative  N/A 
4J-6  260  10  4 
4J-7  132  Negative  N/A 
4I-1  180  75  42 
4I-2  284  43  15 
4I-3  115  24  21 
4I-4  240  24  10 
 
 
Five isolated colonies from each positive plate were subcultured and 10 colonies 
from each subculture (total of 50) were used to express soluble scFv antibody, 
determined by indirect and capture ELISA against ΔSU-GST and GST proteins. 
Most of the 50 colonies produced scFv that reacted with both ΔSU-GST and GST 
by both ELISA methods (Figure 5.6) but scFv produced by 2 colonies (referred to as 
clones 32 and 34) showed a relatively stronger affinity to antigen. However, there 
was a strong reactivity to both the ΔSU-GST and GST indicating that the selected 
scFv had affinity to the GST and not ΔSU protein. 
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Figure. 5.6. Results of indirect (A) and capture (B) ELISA of scFv from 
individual colonies against ΔSU-GST and GST proteins. The scFv were 
produced from individual colonies after detection by CLA. Fifty colonies from 
the 10 positive plates were analysed by indirect and capture ELISA and the 
bound scFv was detected with protein L-HRP. The absorbance readings shown 
were the average of 3 replicate reactions. 
 
Screening for CA scFv by microplate method 
Four rounds of panning were undertaken on ubiquitin, Jgag6 and CA-Tat proteins 
bound to microplates. After each round of panning, the titre of the eluted phage was 
measured to monitor the efficiency of the selection process (Figure 5.7). After the 
third round, phage recovery increased almost 100-fold compared to the second 
round of panning, indicating the library was already enriched in each protein binder. 
However, during the fourth round the recovery decreased slightly in comparison to 
the third round. 
A 
B 89 
 
binders in each panning round (Figure 5.8). The enrichment with Library J was 
greater than with Library I for all 3 proteins, including ubiquitin. 
To identify individual specific scFv-phage binders, the eluted scFv-phage after the 
third round of selection were used for infection of TG1, which were then cultured to 
obtain single colonies. Twenty colonies from each library were selected and tested 
for their ability to bind to ubiquitin, Jgag6 and CA-Tat proteins with the monoclonal 
scFv-phage ELISA. When the value of absorbance of all colony samples for each 
binding protein was averaged, the average absorbance of scFv-phage clones for 
ubiquitin, Jgag6 and the CA-Tat polyprotein were 2.6049, 2.1529 and 1.4442 for 
library I and 2.4628, 2.3820 and 1.7622 for library J (Figure 5.9). Based on these 
average values, colonies producing absorbance values that exceeded the average 
absorbance were selected as potentially protein-specific scFv-phages (Table 5.2). 
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Twenty selected clones reacted better to the truncated CA protein Jgag6 than the 
CA-Tat polyprotein (Figure 5.9) even though the CA-Tat polyprotein contained the 
full-length JDV CA, plus Tat encoded by exon 1 of the tat1 gene (Lewis, 2008). 
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Figure 5.9. The binding of 20 clones detected by a monoclonal phage ELISA to 
ubiquitin, Jgag6 and CA-Tat proteins. The 20 colonies (clones) from library I 
(top) and library J (bottom) were selected from the third round of panning. 
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In order to obtain specific scFv against the CA protein, 4 colonies of Jgag6 scFv-
phage, 2 each from each library, designated as IF3, JG8, JB1 and ID6 were 
selected and used to infect non-suppressor strain E. coli HB2151 for expression of 
soluble scFv. The culture was grown overnight with shaking at 28
oC and expression 
was induced with IPTG when the absorbance was 0.9. The distribution of the 
soluble scFv in the bacterial periplasm and in the culture supernatant was evaluated 
in 12.5% SDS-PAGE gels stained with Coomassie Blue and in western 
immunoblots reacted with anti-His antibody (Figure 5.10). western immunoblotting 
indicated that in the supernatant, the sucrose fraction, the periplasmic fraction, a 
distinct band of 30 kDa within the expected molecular weight range of soluble scFv 
was present and was of stronger reactivity in the sucrose and periplasmic fractions. 
The results indicated that most of soluble scFv was secreted into the periplasm but 
that a substantial amount of soluble scFv was also released into the medium (Figure 
5.10). A major band of about 30 kDa corresponding to the monomeric form of the 
scFv was also detected in the pellet fraction of JB1 scFv by Coomassie Blue 
staining and western immunoblotting with anti-His antibody.  
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Figure 5.10. 12.5% SDS-PAGE (A and B) and western blot analysis (C and D) 
of scFv in the supernatant, sucrose fraction, periplasmic fraction and pellet of E. 
coli HB2151 after induction of expression with IPTG. The gels were stained with 
Coomassie Brilliant Blue and scFv were detected using His antibody. Lane 1, 
IF3 supernatant; lane 2, JG8 supernatant; lane 3, JB1 supernatant; lane 4, ID6 
supernatant; lane 5, IF3 sucrose fraction; lane 6, JG8 sucrose fraction; lane 7, 
JB1 sucrose fraction; lane 8, ID6 sucrose fraction; lane 9, IF3 periplasmic 
fraction; lane 10, JG8 periplasmic fraction; lane 11, JB1 periplasmic fraction; 
lane 12, ID6 periplasmic fraction; lane 13, IF3 pellet; lane 14, JG8 pellet; lane 
15, JB1 pellet; lane 16, ID6 pellet. 
 
 
Discussion 
Recombinant antibody can be produced in E. coli or other expression systems from 
cloned cDNA and due to the stability of the DNA constructs and ease of production 
compared with conventional monoclonal antibody technique, unlimited supplies of 
specific antibodies can be produced at a reasonable cost (Foord et al., 2007) 
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without the need for long term storage of hybridomas. The technique does have the 
disadvantage of producing only a monovalent product that may have a fast off-rate 
and poor retention time on the target (Cheng et al., 2005).  In addition, there are 
challenges to overcome when isolating antibodies from the phage display library. 
Isolation of phage displayed antibodies is dependent on a number of parameters 
including the size of the library, phage preparation, conditions and time of 
incubation, blocking and washing during selection, and the method of elution of 
bound scFv (Chen et al., 2009). 
In this current study, phage display technology was used to facilitate the selection of 
the scFv against recombinant ΔSU and CA proteins of JDV using the synthetic 
phagemid Tomlinson I and J libraries.  Protein-specific scFv would have application 
in methods for the detection of protein either by ELISA or western immunoblotting 
and could have many applications in the development of diagnostic methods. This 
phage display technology has not been used previously to produce antibody against 
JDV proteins. The selection of the 2 JDV proteins ΔSU-GST and CA for which it 
was attempted was based on the premise that they would be useful proteins to 
explore as vaccines against Jembrana disease. They also have a role during the 
production and purification of these proteins and could be targets of immunological 
tests for the detection of virus during routine diagnosis.  
Technical problems associated with the technology included problems associated 
with the selection of methods used for screening. Proteins have different tendencies 
of adsorption to nitrocellulose membrane and polystyrene. According to the 
manufacturer’s specification for the polystyrene microplate used in this work (Nunc 
MaxiSorp) the microplates have hydrophilic binding groups that attract hydrophilic 
regions on molecules. Since the recombinant CA proteins used were hydrophilic 
(soluble in water) they were likely to be well adsorbed onto the surface of the plate. 
In contrast, the solubilised ΔSU protein was more insoluble and probably has few 
hydrophilic aa residues exposed as a consequence it was likely to attach poorly to 
the surface of microplates whereas the presence of hydrophobic interactions and 
weak hydrogen bonds would allow its adsorption to the surface of nitrocellulose 
membranes (Ahmad et al., 2009). For that reason, in this study the microtitre plate 
method was used for panning and screening the phage antibody library using CA 
proteins and nitrocellulose membrane was used with the ΔSU protein.  The nature 
of the solid binding surface, however, is not the only factor in selection of an 
appropriate matrix for protein binding, and the protein structure, size of a molecule, 95 
 
charge, density and distribution in the protein molecule, and conformational 
rearrangements all must be considered (Kamyshny et al., 1999). 
The production of scFv that reacted specifically with CA proteins appeared to be 
successful although additional studies will be required to optimise their expression 
and demonstrate their value for diagnostic purposes and in protein identification and 
purification. At least 4 clones were produced that expressed soluble scFv in E. coli 
and reacted with the Jgag6 ΔCA protein. western immunoblotting results indicated 
the soluble scFv were expressed into the bacterial periplasm, under the culture 
conditions used, although some leakage of scFv fragments to the extracellular 
medium did occur. Antibody fragments expressed under the control of the lac 
promoter are known to be released to the extracellular medium after several hours 
of induction, even though signal sequences have directed them to the periplasm 
(Shibui & Nagahari, 1992, Takkinen et al., 1991). Control of leakage would be 
required to produce a single location for scFv fragments, which will improve 
downstream processing for recovery. One of the Jgag6-scFv clones, JB1, did not 
remain exclusively in the periplasmic space and was not released into the culture 
medium: a small proportion of the JB1-scFv was also present in the pellet as 
insoluble scFv. Possibly this may have been the result of a high concentration of 
scFv produced in the bacterial periplasmic space where the accumulation of scFv 
may then form insoluble aggregates. If this were the case, this insoluble scFv could 
be solubilised with urea and refolded (as described in Chapter 3) using a buffer 
containing aa, which destabilizes wrongly folded structures (Huston et al., 1994), or 
its solubility could be influenced by the mutation within the framework regions of the 
scFv (Duenas et al., 1995). 
The expression of the scFv reactive with the JDV CA was limited and further 
optimisation of expression is required. It was, however, expressed into the 
periplasm which is preferred for large-scale preparation because this is of smaller 
volume than the extracellular fraction. Specific release of scFv using a technique 
such as osmotic shock, which would not rupture the inner cell membranes, could 
offer an attractive option for purification. If, however, it was instead chosen to 
promote extracellular scFv production, this might avoid the need for cell disruption.  
Attempts to produce clones that would express scFv against the ΔSU protein with 
the phage display library were unsuccessful. The CLA method used in this 
experiment did result in the production of clones that expressed scFv that reacted 
with the ΔSU-GST but analysis of the results suggested they reacted against the 
GST component of the ΔSU-GST and not the ΔSU. The 26 kDa GST tag is 220 aa, 96 
 
larger than other tags such as myc- or FLAG. This large size of GST may potentially 
influence the panning or may render it more immunogenic than the target protein 
ΔSU. Zhang et al. (2001) also described selection of false positives when GST 
fusion proteins were used for selection of antibodies specific to viral movement 
protein. A similar phenomenon was also reported by Murthy et al. (1999) during 
attempts to identify a consensus motif specific for the PDZ2 domain of a cytosolic 
protein tyrosine phosphatase by peptide phage display. 
In conclusion, the results presented demonstrate successful production of a scFv 
with the capacity to bind to CA antigens of JDV. Further development of this scFv 
antibody could enable it to be used for immunodiagnosis of JDV infections and for 
identification of CA proteins during future attempts to produce Jembrana disease 
vaccines.  97 
 
Chapter 6 
Identification and preliminary analysis of JDV envelope 
glycoproteins by MALDI-TOF mass spectrometry 
 
Summary 
Matrix-assisted laser desorption/ionisation–time of flight (MALDI-TOF) mass 
spectrometry of the proteins of JDV derived from infected cattle was conducted to 
determine the size and potential glycosylation sites in the SU and TM glycoproteins. 
Virus extracted from the plasma of JDV-infected cattle was purified and subjected to 
SDS-PAGE and 2 proteins of 60 and 75 kDa were identified as potential 
glycosylated proteins by staining with a Gelcode® Glycoprotein Staining Kit (Pierce 
Biotechnology). MALDI-TOF/MS examination of 77 tryptic peptide fragments of the 
75 kDa protein and 80 peptide fragments of the 60 kDa protein revealed significant 
identity of the aa sequence of these proteins to the predicted aa sequence of JDV 
SU and TM. Further analysis identified glycosylation sites in the fragments of the 2 
proteins: 2 potential sites of N-linked glycosylation in the 75 kDa band and 3 
fragments with 6 potential O-linked glycosylation sites in the 60 kDa protein. This 
study has confirmed the identity of the 75kDa and 60kDa as SU and TM 
glycoproteins, respectively. 
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Introduction 
Although the predicted sizes of the non-glycosylated forms of the Env polyprotein 
and the SU and TM have been determined as 88.8, 47.8 and 41.1 kDa, 
respectively, and a number of potential glycosylation sites have been predicted from 
analysis of the sequence (Chadwick et al., 1995b), information about the size or the 
degree of glycosylation of the native forms of these proteins has not been reported. 
Membrane glycoproteins are responsible for many important functional properties of 
not only eukaryotic cell surfaces but also virus-cell interactions (Parekh, 1991) and 
their post-translational modification by glycosylation is critical to their function. This 
glycosylation is a complex process varying in different cell types and cannot be 
easily predicted by simple rules. Two types of carbohydrate-protein linkages are 
known: O-linked and N-linked (Medzihradszky, 2005, Peter-Katalinic, 2005).  
Although some characteristics of glycosylation can be obtained by metabolic 
labeling with radioactive saccharides or affinity chromatography with lectins such as 
concanavalin A (Bundy & Fenselau, 1999, Bundy & Fenselau, 2001), mass 
spectrometry (MS) offers several advantages and it has been used widely to 
characterise biomolecules such as carbohydrates (Siemiiatkoski & Lyubarskaya, 
2005), peptides and proteins (Stutz, 2005, Wysocki et al., 2005), DNA (Mauger et 
al., 2006), metabolites (Xu et al., 2006), phospholipids (Pulfer & Murphy, 2003) and 
also whole cells (Easterling et al., 1998). It provides a rapid method for identification 
of biomolecules based upon molecular weight and offers better resolution and 
accuracy than other techniques such as SDS-PAGE. In recent years, matrix-
assisted layer desorption/ionisation (MALDI) MS has been used to characterise 
glycoproteins (Ayers et al., 2002, Barrientos et al., 2004, Kim et al., 2001, 
Serebryakova et al., 2006). MS procedures offer the opportunity for peptide mass 
fingerprinting and de novo sequencing. Peptide mass fingerprinting is a useful 
technique used to identify proteins whose aa sequences are known or have been 
predicted from DNA analysis of the encoding gene (Thiede et al., 2005). MALDI MS 
in combination with proteolytic assays has been used to identify the functional 
epitope on envelope glycoprotein gp41 of HIV-1 (Parker et al., 2001).  
To provide information about the size of the native glycosylated proteins of JDV an 
attempt was made to identify the proteins present in native viral preparations 
obtained from the plasma of JDV-infected cattle by utilising matrix-assisted laser 
desorption/ionisation–time of flight (MALDI-TOF) MS. The data generated was also 99 
 
used to identify glycosylation sites (both N- and O-linked) as well as the types of 
glycans attached to the glycosylated proteins.  
 
Material and methods 
Identification of potential glycoproteins in SDS-PAGE preparations of JDV 
A plasma-derived preparation of JDV (30 µl) from JDV infected cattle was a kind gift 
from Dr. Nining Hartaningsih (Indonesia). The plasma was prepared as described 
by (Hartaningsih et al., 1994). Briefly, plasma collected from JDV-infected cattle and 
containing an estimated 10
8 infectious virions per mL of plasma was clarified by low 
speed centrifugation.  The virus was then pelleted by centrifugation and the 
resuspended pellet subjected to sucrose gradient centrifugation.  Visible bands in 
the sucrose gradient were harvested and resuspended in Tris-HCl buffer to 1% of 
the original plasma volume. The partially purified virus sample obtained was 
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) as described previously (Hartaningsih et al., 1994) but using a 4% stacking 
gel and 14% resolving gel. The protein bands were detected by staining with 
Coomassie Blue R20 in 40% methanol and 10% acetic acid or with a GelCode® 
Glycoprotein Staining Kit (Pierce Biotechnology) according to the manufacturer’s 
instructions. This glycoprotein detection system selectively stains glycoproteins in 
polyacrylamide gels using a modified Periodic Acid-Schiff (PAS) staining method 
(Zacharius et al., 1969). Staining of sugar moieties of the glycoproteins yields 
magenta bands with a light pink background. The Periodic Acid-Schiff reagent 
stains vicinal diol groups found mainly on peripheral sugars and sialic acids and is 
used as a general glycoprotein stain (Thornton et al., 1994). 
 
Preparation of potential glycoproteins for MALDI-TOF MS analysis 
Two protein bands of 75 kDa and 60 kDa visualised with both Coomassie Blue and 
the Glycoprotein Staining Kit were excised using a sterile scalpel blade and placed 
in separate Eppendorf tubes. Each gel segment was washed by covering it with 500 
µl of PBS at 4
oC for 30 min, then discarding the PBS and repeating the washing 
step. The gel pieces were then washed a further 2 times with 500 µl of 100 mM 
NH4HCO3 / acetonitrile (1:1, v/v) for 15 minute and dehydrated the gel in 200 µl of 
100% acetonitrile. Digestion of the proteins was conducted by the addition of 200 µl 
of 50 mM NH4HCO3 containing 4 ng/µl of trypsin to fully immerse the gel pieces and 100 
 
incubated for 30 min at room temperature before the tubes were incubated 
overnight at 37
oC. The tubes were spun down for 10 s. The gels were washed with 
200 µl  of 25 mM NH4HCO3/acetonitrile and the peptides were extracted with 50 µl 
of 5% formic acid (HCOOH)/acetonitrile by sonicating the gel in a ultrasonic bath for 
2 min and then incubated for 30 min at room temperature. The supernatant was 
transferred to a clean Eppendorf tube and dried in a speedvac. The dried peptides 
were reconstituted in 20 µl of 0.5% HCOOH in 65% methanol.  
 
MALDI-TOF MS analysis of tryptic peptides 
One µl of each peptide solution was mixed with an equal volume of a saturated 
solution of α-cyano-4-hydroxycinnamic acid in 0.5% HCOOH/65% methanol, and 
dried at room temperature. The molecular masses of the tryptic peptides were then 
determined by MALDI-TOF MS (Voyager, Applied Biosystems) with the assistance 
of Proteomics International Inc. at Murdoch University. MALDI spectra were 
calibrated using a peptide mixture provided by the manufacturer.  Monoisotopic 
peptide masses obtained from mass spectra were searched against the NCBI non-
redundant protein database (NCBInr) and MSDB databases using the MASCOT 
protein identification system (Matrix Science Ltd. London, UK, 
http://www.matrixscience.com). The same monoisotopic peptide masses were also 
subjected to FindPept (http://au.expasy.org/tools/findpept.html) and GlycoMod 
(http://au.expasy.org/tools/glycomod/) tools to predict the theoretical peptides and 
the glycosylation sites, respectively. The data was also compared to the predicted 
aa sequence of the JDV genomic sequence (GenBank accession no. U21603.1 gi: 
733067) and the JDV Env precursor protein sequence (accession number gi: 
733070). This Env precursor is assumed to be post-translationally processed to 
produce the SU and TM proteins (Chadwick et al., 1995b). 
 
Results 
Identification of glycoproteins in SDS-PAGE gels 
When the native JDV proteins were separated by SDS-PAGE and stained with 
Coomassie Blue, 4 relatively abundant proteins with a MW of >41.1 kDa, the 
predicted size of the smallest non-glycosylated envelope protein (Chadwick et al., 
1995), were identified with a MW of approximately ~250, ~75, ~60 and ~50 kDa 
(Figure 6.1). When stained with the GelCode® Glycoprotein Staining Kit (Pierce 101 
 
Biotechnology), magenta bands with a light pink background indicated 3 of these 
proteins were glycosylated. The protein with a predicted mass of ~75 kDa was the 
most abundant while the 2 bands at ~250 kDa and ~60 kDa stained weakly. 
 
 
 
Figure 6.1. Coomassie Blue (RHS) and GelCode® Glycoprotein Staining (LHS) 
of JDV proteins in 14% SDS-PAGE gels. The protein markers and their size are 
shown in the extreme LHS of the gel. 
 
 
MALDI-TOF/MS analysis 
Two potentially glycosylated protein bands of MW 75 and 60 kDa (Figure 6.1) were 
excised from the SDS-PAGE gel and subjected to in-gel digestion with trypsin, 
which cleaves after lysine and arginine residues, and the peptide digests were then 
analysed by MALDI-TOF MS. The m/z spectra of the mixture of peptides resulting 
from tryptic digestion of the 75 kDa proteins and the 60 kDa protein are shown in 
Figures 6.2 and 6.3.  
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Figure 6.2. Single MALDI-TOF/MS spectrum of the peptide mixture obtained 
from a tryptic digests of the 75 kDa protein. The labels associated with the 
peaks indicate the measured mass for the tryptic peptides. The ordinate axis 
represents the intensity of the detection signal of peptide detected by the MS at 
a specific mass to charge (m/z). 
 
 
Figure 6.3. MALDI-TOF/MS spectra of a tryptic digests of 60 kDa protein 
excised from a preparative PAGE gel. The peak labels indicate the measured 
mass (m/z) for all the tryptic peptides that contribute to the whole protein. 
 103 
 
The sequence of the monoisotopic peptide masses were examined for sequence 
similarity to proteins in the MSDB and NCBInr databases using the MASCOT 
search program. With this program, the protein hits were scored using a probability 
based Mowse (molecular weight search) score. The ion score is –10*Log (P), where 
P is the probability that the observed match is a random event. Individual ions that 
scored more than 51 indicated identity or extensive homology (p<0.05).  The scores 
obtained ranged from 24 to 40, so that neither protein was identified as having a 
significant match to any protein in the MSDB database. However, the proteins with 
greatest identity to the 75 kDa peptides in the NCBInr database were envelope 
glycoproteins of HIV-1, Saimiriine herpesvirus-2 and the envelope glycoprotein of 
Caprine arthritis-encephalitis virus (Table 6.1). Proteins of greatest identity with the 
60 kDa protein in the NCBInr database were of Porcine reproductive and respiratory 
syndrome virus, the envelope glycoprotein of HIV-1 and Hepatitis C virus (Table 
6.2). The databases did not contain data for any bovine lentivirus protein.   
 
Table 6.1. Comparison of peptides found in tryptic digests of the 75 kDa protein with 
proteins in the NCBInr database using the MASCOT search program. Only Mowse 
scores of more than 51 indicate identity or extensive homology. 
 
Mowse 
score 
Protein   Virus  Molecular 
weight 
Peptide sequence 
30  Envelope 
glycoprotein 
gp120 
HIV-1  826.42  QPVSKLR 
28  Envelope 
glycoprotein 
gp120 
HIV-1  1035.53  KLSDQFGNK 
26  Envelope 
glycoprotein 
gp120 
HIV-1  939.41  KSINIGPGR 
25  Glycoprotein  Saimiriine 
herpesvirus-
2 
1414.78  VITSSLQTTSSYK 
24  Glycoprotein 
120 
HIV-1  516.51  VGLTK 
24  Surface 
glycoprotein 
Caprine 
arthritis-
encephalitis 
virus 
516.51  VIGTK 104 
 
Table 6.2. Comparison of peptides found in tryptic digests of the 60 kDa protein with 
proteins in the NCBInr database using the MASCOT search program. Only Mowse 
scores of more than 51 indicate identity or extensive homology. 
 
Mowse 
score 
Protein name  Species  Molecular 
Weight 
Peptide 
Sequence 
40  Polypeptide 
precursor 
NSP1 – NSP8 
Porcine 
reproductive 
and 
respiratory 
syndrome 
virus 
821.50  VAAEIYR 
34  Envelope 
glycoprotein, 
V3-V5 region 
HIV-1  913.50  DPITLPCR 
29  Reverse 
transcriptase 
HIV-1  1069.53  WGFYTPDGK 
29  Polyprotein  Hepatitis C 
virus 
989.54  TRVTGGSSAR 
 
 
The peptide mass fingerprinting data obtained by MALDI-TOF MS were compared 
with the theoretical peptides calculated by Findpept software program. The 
FindPept program deduced the theoretical peptides that would be obtained by 
trypsin digestion of the aa sequence of the envelope proteins of JDV derived from 
the DNA sequence and then calculated the theoretical masses of the fragments. 
The 75 kDa peptide mass fingerprinting data generated by MALDI-TOF/MS resulted 
in masses for 77 peptides, 66 of which matched the theoretical peptide masses of 
JDV SU (aa 1-422) calculated by the FindPept program and 11 were unmatched 
and assumed to be glycosylated (Figure 6.4 and Table 6.3). The 60 kDa peptide 
mass fingerprinting data generated by MALDI-TOF/MS resulted in a mass for 94 
peptides, 80 of which had high sequence identity to the deduced masses of the 
peptides of JDV TM (Env aa 423-781) calculated by the FindPept program and 14 
were unmatched (Figure 6.5 and Table 6.4) and were assumed to be glycosylated. 
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Table 6.3. Comparison between the masses of experimentally observed with the 
theoretical masses and assignment of the tryptic peptide mass fingerprint MALDI-
TOF/MS of the 75 kDa protein. 
 
Peptide 
m/z  
(detected) 
m/z 
(calculated) 
Residue 
position 
Peptide sequence 
P1  1649.77  1648.72  1-13  MMEEGRKEEPEER 
P2  1192.58  1191.60  13-22  RGEKSTMRDL 
P3  1589.73  1588.84  17-30  STMRDLLQRAVDKG 
P4  2095.10  2094.11  25-42  RAVDKGHLTAREALDRWT 
P5  2338.37  2337.16  43-63  LEDHGEIHPWIILFCFAGAIG 
P6  1739.02  1737.95  59-76  AGAIGVIGGWGLRGELNV 
P7  2556.33  2555.44  71-93  RGELNVCMLIVLVVLVPIYWGIG 
P8  2247.07  2246.20  94-111  EAARNIDSLDWKWIRKVF 
P9  1445.65  1444.75  98-108  NIDSLDWKWIR 
P10  2440.29  2439.38  111-133  FIVIIFVLVGLLGGCSAQRQHVA 
P11  1595.89  1594.88  134-148  MLLSPPGIRLPSTVD 
P12  1633.82  1632.83  142-155  RLPSTVDIPWFCIS 
P13  2408.21  2397.12  152-172  FCISNAPIPDCVHWTVQKPDQ 
P14  2094.22  2093.02  169-185  KPDQKHQQIENVMELQE 
P15  1036.55  1035.49  184-192  QEVLDNATF 
P16  1038.55  1037.51  190-198  ATFFEVPDL 
P17  1266.59  1265.63  196-205  PDLFDRVYLE 
P18  2220.03  2219.19  206-227  LARLDANSTGVPVNIPPTGISQ 
P19  2435.29  2434.28  208-231  RLDANSTGVPVNIPPTGISQVKGD 
P20  2398.20  2397.09  227-249  QVKGDCSTGDIQGMNETLSTRGT 
P21  1034.54  1033.54  243-252  TLSTRGTLGE 
P22  1475.85  1474.77  251-263  GERTFLSIRPGGW 
P23  1783.92  1782.80  262-275  GWFTNTTVWFCVHW 
P24  1665.77  1664.80  269-281  VWFCVHWPFGFIQ 
P25  1019.53  1018.50  282-290  RKENLSEGS 
P26  2511.26  2510.25  285-307  NLSEGSAQVRNCLDPINVTEPRV 
P27  1412.69  1411.67  301-312  NVTEPRVANYSY 
P28  1634.81  1633.78  307-320  VANYSYCPLEYKGK 
P29  1635.81  1634.86  321-335  NYINKGLKCVGGRVD 
P30  1226.58  1225.56  334-344  VDLSSNPEQHT 
P31  2408.03  2407.02  345-365  DLLACGTFCQNFRNCDMVSRD 
P32  1635.76  1634.75  358-371  NCDMVSRDILIGYH 
P33  1485.80  1484.72  369-380  GYHPSQQKQHIY 
P34  1052.54  1051.56  376-383  KQHIYINH 
P35  1635.82  1634.81  384-396  TFWEQANTQWILV 
P36  1855.92  1855.00  392-407  QWILVQVPNYGFVPVP 
P37  2527.38  2526.36  401-422  YGFVPVPDTERPWKGGKPRGKR 
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         160          170          180          190          200 
WFCIS NAPIP  DCVHW TVQKP  DQKHQ QIENV  MELQE VLDNA  TFFEV PDLFD 
 
 
 
 
         210          220          230          240          250 
RVYLE LARLD  ANSTG VPVNI  PPTGI SQVKG  DCSTG DIQGM  NETLS TRGTL 
 
 
 
         260          270          280          290          300 
GERTF LSIRP  GGWFT NTTVW  FCVHW PFGFI  QRKEN LSEGS  AQVRN CLDPI 
 
 
                                         
         310          320          330          340          350 
NVTEP RVANY  SYCPL EYKGK  NYINK GLKCV  GGRVD LSSNP  EQHTD LLACG 
 
 
 
         360          370          380          390          400 
TFCQN FRNCD  MVSRD ILIGY  HPSQQ KQHIY  INHTF WEQAN  TQWIL VQVPN 
 
                            
 
         410          420       
YGFVP VPDTE  RPWKG GKPRG  KR  
 
 
 
 
 Figure 6.4Interpretation of the MALDI peptide mass fingerprint results of the 75 
kDa protein. The arrows indicate the tryptic peptide fragment (P1 – P37) 
produced by MALDI-TOF/MS. 
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Table 6.4. Comparison of the masses of the experimentally produced peptides of 
the 60 kDa protein generated by MALDI-TOF/MS with the theoretical masses of the 
tryptic peptide mass fingerprint generated by FindPept software. 
 
Peptide 
m/z 
(detected) 
m/z 
(calculated) 
Residue 
position  Peptide sequence 
P1  1358.77  1357.84  423-435  AVGMVIFLLVLAI 
P2  1479.85  1478.82  429-442  FLLVLAIMAMTASV 
P3  1036.60  1035.53  438-448  MTASVTAAATL 
P4  1209.69  1208.69  442-453  VTAAATLVKQHA 
P5  1567.81  1566.85  452-466  HATAQVVGRLSTNLT 
P6  1194.67  1193.67  463-472  TNLTYITKIQ 
P7  1283.75  1282.69  467-476  YITKIQNQYL 
P8  1355.83  1354.71  477-487  HLFQNLNTRVN 
P9  1266.66  1265.66  487-496  NNLHHRVTYL 
P10  927.53  926.49  492-498  RVTYLEF 
P11  1855.11  1853.95  498-514  FLAEVHEVQTGLGCVPR 
P12  1249.70  1248.58  512-521  VPRGRYCHFD 
P13  2435.29  2434.08  518-537  CHFDWRPEEVGLNMTLWNST 
P14  1567.70  1566.69  533-544  LWNSTTWQQWMS 
P15  1490.77  1489.62  540-550  QQWMSYYDQIE 
P16  804.31  803.34  550-555  EENIWN 
P17  1423.60  1422.69  554-564  WNLKYNWSEAL 
P18  1789.96  1788.84  561-577  SEALEKGKSNTDGLEPD 
P19  1311.71  1310.61  571-581  TDGLEPDVFRY 
P20  1469.68  1468.72  576-588  PDVFRYLADLSSS 
P21  2045.11  2044.01  587-603  SSFTWGSWVDKLVWLAY 
P22  1866.15  1865.05  594-608  WVDKLVWLAYILLAY 
P23  2393.46  2392.27  600-619  WLAYILLAYFAFKVLQCIMS 
P24  1597.90  1596.78  616-629  CIMSNLGAQTRYQL 
P25  1633.89  1632.77  626-639  RYQLLNAQEDTDPA 
P26  832.34  831.32  633-640  QEDTDPAG 
P27  1471.58  1470.56  640-653  GDGDQPDDHRSGDT 
P28  1398.73  1397.63  646-658  DDHRSGDTPRSGV 
P29  833.34  832.37  656-664  SGVPSGGWS 
P30  1247.73  1246.67  662-672  GWSQKLSEGKK 
P31  1732.98  1731.93  668-682  SEGKKIGCLILRTEW 
P32  1019.56  1018.46  680-686  TEWQNWR 
P33  1800.10  1799.00  685-698  WRNDLRTLRWLTLG 
P34  1640.01  1639.03  689-711  LRTLRWLTLGGKIL 
P35  1293.79  1292.84  699-710  GKILQLPLSLLV 
P36  1485.88  1484.98  710-722  VLLVRILLHILSP 
P37  1220.66  1219.57  721-730  SPTFQNQRGW 
P38  1644.83  1643.82  731-746  TVGRKGTGGDDRELSP 
P39  1097.52  1096.51  747-755  ELEYLSWTG 
P40  1926.03  1924.87  753-768  WTGSSQEMVEMRDLKE 
P41  993.61  987.44  766-774  KEEDIPEE 
P42  1059.55  1058.51  773-781  EEGIRPVEM 
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                 430         440          450 
***** *****  ***** *****  **AVG MVIFL  LVLAI MAMTA  SVTAA ATLVK 
 
 
 
        460          470          480          490          500 
QHATA QVVGR  LSTNL TYITK  IQNQY LHLFQ  NLNTR VNNLH  HRVTY LEFLA 
 
 
 
        510          520          530          540          550 
EVHEV QTGLG  CVPRG RYCHF  DWRPE EVGLN  MTLWN STTWQ  QWMSY YDQIE 
 
 
 
        560          570          580          590          600 
ENIWN LKYNW  SEALE KGKSN  TDGLE PDVFR  YLADL SSSFT  WGSWV DKLVW 
 
 
 
        610          620          630          640          650 
LAYIL LAYFA  FKVLQ CIMSN  LGAQT RYQLL  NAQED TDPAG  DGDQP DDHRS 
 
 
                         
        660          670          680          690          700 
GDTPR SGVPS  GGWSQ KLSEG  KKIGC LILRT  EWQNW RNDLR  TLRWL TLGGK 
 
 
 
        710          720          730          740          750 
ILQLP LSLLV  LLVRI LLHIL  SPTFQ NQRGW  TVGRK GTGGD  DRELS PELEY 
 
 
 
        760          770          780 
LSWTG SSQEM  VEMRD LKEED  IPEEG IRPVE  M 
 
 
 
 
 
Figure 6.5. Interpretation of the MALDI peptide mass fingerprint results of the 
60 kDa protein. The arrows indicate the tryptic peptide fragment (P1 – P42) 
produced by MALDI-TOF/MS. 
 
 
Glycoprotein analysis 
The GlycoMod program was used to predict the mass of the glycopeptides and the 
numbers of glycosylation sites obtaining from the tryptic digest of the 75 and 60 kDa 
proteins. Analysis of the 11 unmatched masses of the 75 kDa protein predicted 
there was one glycosylated peptide of 2013.98 Da with 2 potential sites of N-linked 
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glycosylation at asparagine (N) residues at aa 285 and 301 (Table 6.5). Analysis of 
the 14 unmatched masses of the 60 kDa protein predicted there were 3 
glycosylated peptides (1596.01 Da, 1802.11 Da and 1894.13 Da) and 6 potential 
sites of O-linked glycosylation at serine residues at aa positions 650, 668 and 707, 
and at threonine (T) residues at aa positions 653, 737 and 691 (Table 6.6).  
 
 
Table 6.5. Prediction of unmatched masses of 75 kDa protein containing the motif 
'N-X-S/T/C (X not P)'. Coloured (red) letters indicates the predicted position of 
glycosylated aa. 
 
Peptide mass 
(exp.observed) 
Peptide sequence  Peptide 
mass 
(calc.) 
Δm or 
predicted 
residual 
carbohydrate 
mass 
Predicted 
carbohydrate 
side chain 
structure 
2013.98  284-294 
ENLSEGSAQVR 
1188.57  825.41  1. (Hex)1 
(NeuAc)2 
(Sulph)1 
2. (Hex)1 
(NeuAc)2 
(Phos)1 
  295-306 
NCLDPINVTEPR 
1369.67  644.31  (Hex)1 
(HexNAc)1 
(Deoxyhexose)1 
(Pent)1 
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Table 6.6. Predictions of unmatched masses of 60kDa protein containing S or T. 
Coloured (red) letters indicate the predicted position of glycosylated amino acids. 
 
Peptide mass 
(exp.observed) 
Peptide sequence  Peptide 
mass 
(calc.) 
Δm or predicted 
residual 
carbohydrate 
mass 
Predicted carbohydrate side 
chain structure 
1596.01  650-655  
SGDTPR 
631.29  964.72  (Pent)1 (Sulph)6 (HexA)2 
  736-742 
GTGGDDR 
676.28  919.73  (NeuGc)1 (Pent)1 (Sulph)6 
1802.11  650-655  
SGDTPR 
631.29  1170.82  1. (Pent)2 (Sulph)6 (KDN)1 
(HexA)1 
2. (Hex)1 (Deoxyhexose)1 
(Pent)1 (Sulph)6 (KDN)1 
3. (Pent)2 (Phos)6 (KDN)1 
(HexA)1 
  667-671  
LSEGK 
532.29  1269.82  1. (Deoxyhexose)1 (NeuAc)1 
(Sulph)6 (HexA)2 
2. (HexNAc)1 
(Deoxyhexose)1 (Pent)2 
(Sulph)6 (HexA)1 
  701-714 
ILQLPLSLLVLLVR 
1589.06  213.05  1. (Pent)1 (Sulph)1 
2. (Pent)1 (Phos)1 
  736-742  
GTGGDDR 
676.28  1125.83  1. (Hex)1 (NeuGc)1 (Sulph)6 
(HexA)1 
2. (Hex)1 (NeuGc)1 (Phos)6 
(HexA)1 
1894.13  650-655  
SGDTPR 
631.29  1262.84  (HexNAc)1 (NeuGc)1 (Sulph)5 
(HexA)2 
  667-671  
LSEGK 
532.29  1361.84  (Hex)2 (NeuGc)1 (Sulph)6 
(KDN)1 
  691-693  
TLR 
388.24  1505.89  1. (NeuAc)1 (Pent)1 (Sulph)6 
(KDN)1 (HexA)2 
2. (Deoxyhexose)2 (NeuGc)1 
(Sulph)6 (KDN)1 (HexA)1 
3. (Hex)1 (Deoxyhexose)1 
(NeuAc)1 (Sulph)6 (KDN)1 
(HexA)1 
4. (Hex)2 (HexNAc)1 
(Deoxyhexose)1 (Sulph)6 
(HexA)2 
5. (Deoxyhexose)1 (NeuGc)1 
(Pent)3 (Sulph)6 (HexA)1 
6. (HexNAc)1 
(Deoxyhexose)1 (Sulph)6 
(KDN)2 (HexA)1 
7. (Hex)1 (NeuAc)1 (Pent)3 
(Sulph)6 (HexA)1 
8. (HexNAc)1 (Pent)3 (Sulph)6 
(KDN)1 (HexA)1 
9. (NeuAc)1 (Pent)1 (Phos)6 
(KDN)1 (HexA)2 
Carbohydrate symbols used are: Hex, hexose; Pent, Pentose; Sulph, sulphate; HexA, β-
hexosaminidase A; NeuAc, N-acetylneuraminic acid; NAc, N-acetyl; NeuGc, N-
glycolylneuraminic acid; KDN, 2-keto-3-deoxy-nonulosonic acid. 111 
 
Discussion 
The HIV envelope glycoproteins have a central role in the induction of the host 
immune response and are targets for protective immunity (Bukrinskaya, 2004, Chan 
& Kim, 1998, Gummuluru & Emerman, 2002) and it is assumed that this would also 
be true for JDV.  Some preliminary study of the role of the JDV envelope proteins as 
potential vaccine immunogens has been undertaken utilizing recombinant SU and 
TM expressed in a bacterial expression system, and hence with non-glycosylated 
forms of these proteins (Ditcham, 2007), with minimal effect.  Further work with 
these proteins as potential vaccines requires an improved understanding of the 
comparative structure of the non-glycosylated recombinant JDV proteins and the 
structure and glycosylation characteristics of the native proteins. While the size of 
the JDV Env polyprotein has been predicted (781 aa), this is considerably smaller 
than that of the other lentivirus envelope glycoproteins including the other bovine 
lentivirus BIV (904 aa) (Garvey et al., 1990), HIV (856 aa) (Martoglio et al., 1997), 
SIV (854 aa) (Fomsgaard et al., 1991), FIV (856 aa) (Olmsted et al., 1989) and 
EIAV (859 aa) (Rushlow et al., 1986) and the predicted structure of those envelope 
proteins is varied and it is possible that these differences could be even greater for 
JDV.   
The use of peptide mass fingerprinting with the MALDI-TOF system, whereby the 
proteins were digested into smaller peptide fragments and then the resulting 
peptides were compared to those in protein databases, enabled identification of 2 
native JDV proteins, one of 75 kDa and the other of 60 kDa, as the SU and TM 
proteins, respectively. Analysis of peptide mass fingerprinting data enabled 66 of 77 
peptides of the 75 kDa protein to be matched to the JDV Env aa positions 1-422 
(SU region) and 80 of 94 peptides of the 60 kDa protein matched to the JDV Env aa 
positions 423-781 (TM region). A search of the NCBInr database using Mascot 
software also revealed similarities of both proteins to other viral envelope 
glycoproteins, particularly lentiviral proteins, but there were no definitive matches as 
the scores obtained were less than 51. However, none of the other databases 
searched contained data for JDV proteins. 
Further analyses of the 2 proteins using GelCode® Glycoprotein Staining Kit 
suggested that the 75 and the 60 kDa proteins were glycosylated and the 
glycosylation of these 2 proteins was confirmed by analysis of the MALDI-TOF data.  
One peptide fragment of the JDV 75 kDa SU was identified that had 2 potential sites 
of N-linked glycosylation.  Three peptide fragments the 60 kDa TM protein were 112 
 
identified with a total of 6 potential O-linked glycosylation sites. A lower number of 
potential glycosylation sites in the JDV Env than in other lentiviruses was predicted 
by examination of the sequence data (Chadwick et al., 1995b) and the low number 
of glycosylation sites identified by MALDI-TOF analysis was consistent with this 
analysis. The position and number of potential N- and O-glycosylation sites in the 
JDV 75kDa and 60 kDa proteins seems quite different to that in the envelope 
glycoprotein of the other lentiviruses. The envelope proteins of HIV-1 contain 
approximately 30-38 potential asparagine-linked (Asn-X-Ser/Thr) glycosylation sites 
(Ratner, 1992). HIV-1 Env gp120 contains 18 to 33 potential N-glycosylation sites 
(Korber et al., 2001) and is among the most heavily glycosylated envelope proteins 
of any retrovirus. HIV-1 has also 3-6 potential N-glycosylation sites in the TM 
protein, the number varying in different strains of the virus (Dedera et al., 1992). 
Potential O-glycosylation sites in different strains of HIV-1, HIV-2, and SIV were 
examined by Hansen et al. (1998) and demonstrated that SIV Env (gp110) 
contained more O-glycosylated (4–18 sites) than HIV-1 or HIV-2 (less than 5 sites). 
FIV has 20 potential N-linked glycosylation sites present in the deduced Env aa 
sequence (Olmsted et al., 1989). 
The probable structures of the carbohydrate side chain at the glycosylation site 
predicted with the GlycoMod program used for the analysis were heterogeneous 
and possibly complex. It might be possible to use the molecular mass of 
carbohydrate side chain to search for their probable glycan structures, thus 
providing useful information towards the structural characterization of JDV 
glycoproteins. Other analytical methods such as complete cleavage of the 
oligosaccharide chains from the glycoproteins and mass spectrometry analysis of 
each purified oligosaccharide after separation of the carbohydrate mixture by high 
performance liquid chromatography would be required for the complete 
characterisation of the glycan structure.  113 
 
Chapter 7 
General discussion 
 
Jembrana disease is a disease specific to the Indonesian archipelago and there are 
2 major reasons for this: the geographic isolation of Indonesia and limited trade in 
live cattle from Indonesia to other countries, and the specificity of the disease for 
Bali cattle. One consequence of this is that research on the disease, especially 
studies involving the use of live animals, has been restricted to Indonesia and a 
small research group only. While our understanding of Jembrana disease and has 
improved markedly since the recognition that a lentivirus was the aetiological agent 
(Chadwick et al., 1995a), progress has been restricted by infrastructure and funding 
restraints. 
Attempts to control the disease by limiting the movement of Bali cattle from Bali 
have slowed the spread of the disease from Bali to other islands but despite these 
restrictions it has also occurred on the islands of Java, Sumatra and Indonesian 
Borneo (Kalimantan). How this occurred is not fully understood and documented but 
it may well have, at least in the case of Java and Sumatra, involved the illegal 
movement of virus-infected Bali cattle from Bali. Future control of Jembrana disease 
will likely require more than quarantine, and will need the development of improved 
diagnostic and immunosurveillance procedures to monitor the distribution of the 
disease and provide rapid diagnosis, and the development of an effective vaccine.  
To support the development of improved diagnostics and vaccines, an improved 
understanding of native JDV proteins and their production using recombinant 
techniques is required.  The studies reported in this thesis have helped to improve 
our knowledge in this area.  In this current study, only selected proteins were 
examined: the CA, the major and immunodominant protein of JDV that is likely to be 
a key protein in the development of diagnostics, and the 2 envelope proteins SU 
and TM involved in attachment and entry of virus into cells. There is remarkably little 
information available about the envelope glycoproteins of JDV, not even 
fundamental characteristics of the size of the native proteins and the degree and 
type of glycosylation.  The studies reported in this thesis have added to our 
understanding of these glycoproteins and will facilitate their future use as antigens 
and vaccines. 114 
 
For many years in this laboratory, recombinant JDV proteins and including CA and 
the envelope proteins SU and TM have been produced as fusions to GST in E. coli 
under the control of the tac promoter and used as antigens for ELISA and western 
blotting procedure for detection of antibody (Burkala et al., 1999, Burkala et al., 
1998, Desport et al., 2005). Cloning and expression of recombinant protein in E. coli 
has been favoured because this bacterium has relatively simple genetics, a rapid 
growth rate and it is well characterised. The methodology needed for cloning and 
expression of proteins is relatively simple compared to many other expression 
systems, requiring only basic equipment, enabling it to be used in Indonesia. Most 
JDV recombinant proteins were expressed, however, in the form of insoluble 
proteins within inclusion bodies which has limited their use in serological assays and 
in experimental vaccines.  
One of the aims of this thesis was to establish a simple method to solubilise the 
inclusion body proteins while retaining their antigenicity. The studies reported in 
Chapter 3 showed that SU-GST could be reliably and efficiently expressed in E. coli 
as inclusion bodies with good yields. The solubilisation of the SU-GST inclusion 
bodies was achieved with a combination of a low concentration of urea in an 
alkaline solution, with the addition of the reducing agent dithiothreitol (DTT) and the 
serine protease inhibitor phenylmethanesulfonyl fluoride, providing an acceptable 
yield of denatured protein for purification. The solubilised SU-GST protein was 
refolded by slow 10-fold dilution in 20 mM Tris pH 8.0 containing CHAPS and DTT 
and the refolded protein reacted in western immunoblots with bovine antisera. The 
technique developed for solubilisation of the proteins present in inclusion bodies is 
simple and the technology has been successfully used in Indonesia for the 
solubilisation not only of recombinant SU but also for the solubilisation of other JDV 
proteins present in inclusion bodies, including CA, Tat and TM.  These solubilised 
proteins have been used successfully for the development of serological antigens 
and experimental vaccines (Ditcham, 2007, Lewis, 2008). The technique is a 
significant advance in the preparation of antigens and vaccines for JDV and 
removes the dependency on the need for expression of soluble proteins, which is 
always difficult using such bacterial expression systems. 
The addition of the reducing agent DTT seemed to be important in the solubilisation 
process, probably because of the presence of disulfide bonds in the proteins. The 
SU protein of JDV contains 13 cysteine residues predicted to form 5 disulfide bonds 
(Chapter 6) and supposing that the aggregation of the protein is mainly caused by 
the creation of the intra- and interchain disulfide bridges, resulting in formation of 115 
 
disulfide bonded aggregates. The addition of DTT probably prevented aggregation 
by inhibiting the formation of non-native disulfide bonds and dissolve disulfide 
bonded aggregates (Rothel et al., 1997). 
During western immunoblotting procedures for the detection of antibody against 
JDV, reliance has been placed on the detection of the immunodominant 26 kDa CA 
protein as many of the other proteins that are observed with whole JDV 
preparations have not been identified (Hartaningsih et al., 1994, Kertayadnya et al., 
1993).  In Chapter 6, a study utilising a specific glycoprotein staining method and 
MALDI-TOF mass spectrometric analysis identified the 2 JDV envelope 
glycoproteins SU and TM in SDS-PAGE gels as being of 75 and 60 kDa, 
respectively. Identification of the size of these glycosylated proteins in SDS-PAGE 
gels will permit their use for better interpretation of western immunoblotting results 
with sera from JDV-infected cattle. 
The MALDI-TOF mass spectrometric analysis of the glycosylated Env proteins SU 
and TM (Chapter 6) also provided information on the secondary glycan structure of 
these glycoproteins. MALDI-TOF mass spectrometry has proven to be a method of 
choice for glycoprotein analysis because it is one of the most sensitive methods for 
the analysis of glycoproteins (de Laurentiis et al., 2006). The GlycoMod method of 
determining the mass value from MALDI-TOF/MS data provided initial 
characterisation of the sugar moiety decorating at least 2 putative N-glycosylation 
site of the JDV-SU and 6 putative O-glycosylation sites of the JDV-TM. 
To assist in the characterisation of JDV proteins and to provide methods for the long 
term production of MAbs in Indonesia, their production by conventional and 
recombinant techniques was investigated in Chapters 4 and 5 of this thesis. 
Monoclonal antibodies have been used widely for diagnostic purposes for many 
conditions and infections and for many years a JDV CA MAb BC10 (Kertayadnya et 
al., 1993) produced in Indonesia provided an invaluable reagent in 
immunoperoxidase assays for the detection of JDV in tissues and as a control 
reagent in western immunoblotting. Unfortunately, the hybridoma secreting this MAb 
was lost when liquid nitrogen supplies in which it was maintained were lost. During 
the current study, an alternative hybridoma was produced (Chapter 4) against the 
JDV CA which was of IgG2 isotype and this was identified as binding to the aa 
encoded by nucleotides 604-810 of the JDV capsid gene.This MAb was 
successfully used to identify JDV in formalin-fixed paraffin embedded tissue 
sections. Attempts were made to also produce a monoclonal against a recombinant 
SU but these attempts were unsuccessful.  The attempts to produce a SU MAb 116 
 
were undertaken prior to the identification of the whole virus SU and additional 
attempts using the glycosylated whole virus SU may have been worthwhile. 
To overcome the problem of storage of hybridomas in liquid nitrogen in Indonesia, 
the use of recombinant antibody fragments was investigated as a means of 
providing a solution to the problem of long-term storage. These attempts to produce 
recombinant MAb (Chapter 5) utilised the phage display antibody method because 
the technique has been previously used for generating recombinant antibodies 
against the TM glycoprotein gp46 of Maedi visna virus (Blazek et al., 2004) and CA 
(Celer et al., 2003). Recombinant antibody fragments, scFv, with specificity for the 
CA protein of JDV were generated using the Tomlinson I and J phage display 
antibody libraries. Attempts were also made to produce scFv against a ΔSU with a 
GST fusion tag but the only scFv detected were against the GST component. Using 
an E. coli expression system, soluble scFv against the CA was expressed in the 
bacterial periplasm but it was produced in small quantities only. While clones are 
now available as a consequence of these studies that will allow the expression of 
CA scFv, further work is now required to optimise this system and obtain adequate 
stocks for further investigation, perhaps by modifying the bacterial growth conditions 
or modifying the method of expression.  The success with the method shows that it 
does offer the potential for the production not only of CA scFv but also those against 
other viral proteins.  The main difficulty and most time consuming part of attempts to 
produce scFv with the Tomlinson I and J libraries was the panning process. It is 
likely that with experience, greater efficiency of the phage technique could be 
obtained.  Another problem was an apparent low affinity of the scFv to the JDV ΔSU 
and CA proteins and this is a noticeable characteristic of scFv isolated from this 
library (Kjaer et al., 2001, Wang et al., 2004) that can be improved by introducing 
diversity to the V genes of the original antibody. Diversity can be introduced by 
random mutations either by error-prone PCR (Meyer et al., 2002) or by applying 
bacterial mutator strains (Coia et al., 2001). 
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